<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">90189</article-id><article-id pub-id-type="doi">10.7554/eLife.90189</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Normal and dysregulated crosstalk between iron metabolism and erythropoiesis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-115569"><name><surname>Ginzburg</surname><given-names>Yelena</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3496-3783</contrib-id><email>yelena.ginzburg@mssm.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-59146"><name><surname>An</surname><given-names>Xuili</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-230738"><name><surname>Rivella</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-115146"><name><surname>Goldfarb</surname><given-names>Adam</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01xvcf081</institution-id><institution>LFKRI, New York Blood Center</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01z7r7q48</institution-id><institution>Department of Pediatrics, Division of Hematology, The Children’s Hospital of Philadelphia</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Cell and Molecular Biology affinity group (CAMB), University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01z7r7q48</institution-id><institution>Raymond G. Perelman Center for Cellular and Molecular Therapeutics at the Children’s Hospital of Philadelphia</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01z7r7q48</institution-id><institution>Penn Center for Musculoskeletal Disorders at the Children’s Hospital of Philadelphia</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Perelman School of Medicine, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Institute for Regenerative Medicine at University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>RNA Institute at University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0153tk833</institution-id><institution>Department of Pathology, University of Virginia</institution></institution-wrap><addr-line><named-content content-type="city">Charlottesville</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Isales</surname><given-names>Carlos</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012mef835</institution-id><institution>Augusta University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Isales</surname><given-names>Carlos</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012mef835</institution-id><institution>Augusta University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>14</day><month>08</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e90189</elocation-id><history><date date-type="received" iso-8601-date="2023-06-16"><day>16</day><month>06</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-08-06"><day>06</day><month>08</month><year>2023</year></date></history><permissions><copyright-statement>© 2023, Ginzburg et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Ginzburg et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-90189-v1.pdf"/><abstract><p>Erythroblasts possess unique characteristics as they undergo differentiation from hematopoietic stem cells. During terminal erythropoiesis, these cells incorporate large amounts of iron in order to generate hemoglobin and ultimately undergo enucleation to become mature red blood cells, ultimately delivering oxygen in the circulation. Thus, erythropoiesis is a finely tuned, multifaceted process requiring numerous properly timed physiological events to maintain efficient production of 2 million red blood cells per second in steady state. Iron is required for normal functioning in all human cells, the erythropoietic compartment consuming the majority in light of the high iron requirements for hemoglobin synthesis. Recent evidence regarding the crosstalk between erythropoiesis and iron metabolism sheds light on the regulation of iron availability by erythroblasts and the consequences of insufficient as well as excess iron on erythroid lineage proliferation and differentiation. In addition, significant progress has been made in our understanding of dysregulated iron metabolism in various congenital and acquired malignant and non-malignant diseases. Finally, we report several actual as well as theoretical opportunities for translating the recently acquired robust mechanistic understanding of iron metabolism regulation to improve management of patients with disordered erythropoiesis, such as anemia of chronic inflammation, β-thalassemia, polycythemia vera, and myelodysplastic syndromes.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>erythropoiesis</kwd><kwd>iron deficiency</kwd><kwd>anemia</kwd><kwd>polycythemia</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>DK079924</award-id><principal-award-recipient><name><surname>Goldfarb</surname><given-names>Adam</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>DK101550</award-id><principal-award-recipient><name><surname>Goldfarb</surname><given-names>Adam</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL165202</award-id><principal-award-recipient><name><surname>An</surname><given-names>Xuili</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL149626</award-id><principal-award-recipient><name><surname>An</surname><given-names>Xuili</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL140625</award-id><principal-award-recipient><name><surname>An</surname><given-names>Xuili</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>DK133475</award-id><principal-award-recipient><name><surname>Rivella</surname><given-names>Stefano</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>DK095112</award-id><principal-award-recipient><name><surname>Rivella</surname><given-names>Stefano</given-names></name><name><surname>Ginzburg</surname><given-names>Yelena</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007929</institution-id><institution>Institute for Translational Medicine and Therapeutics</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rivella</surname><given-names>Stefano</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>DK107670</award-id><principal-award-recipient><name><surname>Ginzburg</surname><given-names>Yelena</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>DK132146</award-id><principal-award-recipient><name><surname>Ginzburg</surname><given-names>Yelena</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The expansion of our understanding about the regulation of iron metabolism, erythropoiesis, and the crosstalk between them has enabled delineating the pathophysiology of multiple diseases and provided rationale for novel therapeutic interventions.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Iron is an essential element for almost every organism on earth. Iron can donate and accept electrons from various substrates due to its unique oxidation-reduction properties, making it an important cofactor in mammalian cells. Despite its abundance in the Earth’s crust, high oxygen availability in the atmosphere leads to iron oxidation and the formation of poorly soluble ferric iron. As a consequence, iron-dependent organisms like mammals have evolved complex mechanisms to conserve and recycle iron, preventing its loss and enabling its enhanced absorption during a deficit or in times of increased demand. The physiological status of iron in biological systems can be delineated into three categories: iron coordinated by protein side chains, iron complexed within the porphyrin ring of heme, and iron within iron-sulfur clusters. Outside of these contexts, iron displays promiscuous reactivity that can damage cells and tissues poorly equipped for handling what is termed ‘labile iron.’ Extensive coordination is also required in multicellular organisms for movement of iron between organs, in and out of cells, and between compartments within cells to effectively avoid inadequate iron supply that may limit systemic functioning and excess iron that may be toxic to cells and tissues. Thus, dysregulated iron homeostasis can manifest as total body iron deficit (iron deficiency) or excess (iron overload), as well as iron maldistribution among tissues in which individual organs may be iron-deficient while other iron-overloaded. Such iron disorders may be caused by genetic lesions that directly impair iron regulation or conditions that impact iron regulation indirectly.</p><p>Although all cells in mammalian systems require small amounts of iron, systemic iron homeostasis is mainly regulated by the specific compartments involved in iron absorption, transport, storage and recycling, and high-level utilization. These include duodenal enterocytes; serum transferrin-bound iron; hepatocytes and macrophages in the liver and spleen; and erythroid precursors in the bone marrow, respectively. The largest of these compartments is the erythron, comprising the majority of total body iron in adult humans, mainly contained within hemoglobin inside erythroblasts and ultimately red blood cells (RBCs). Said another way, erythropoiesis, even at steady state, consumes most of the transferrin bound iron in circulation. Furthermore, stimulation of increased erythropoiesis (e.g. via exogenous erythropoietin [EPO], bleeding, phlebotomy, or hypoxia) requires enhanced iron availability to keep pace with acutely increased hemoglobin synthesis within erythroblasts in the bone marrow. A large body of observational work amassed in the last &gt;50 y suggested the presence of a direct ‘erythroid regulator’ of iron metabolism to enable this crosstalk. The last few decades have provided a series of substantial advances, enabling significant progress in our understanding of iron metabolism regulation; normal, stress, and ineffective erythropoiesis; and the crosstalk between them. In addition, the development of novel tools, both experimental methods and models of disease, has furthered and provided additional opportunities to better understand these pathways, robustly confirming and extending previously held assumptions and conjectures. This article aims to bring together our collective understanding of what has been learned and developed to study iron metabolism and erythropoiesis in health and disease.</p></sec><sec id="s2"><title>Normal erythropoiesis</title><p>Erythropoiesis is a continuous process required for making new RBCs in order to replace the senescent RBCs lost at the end of their lifecycle. To determine how many RBCs are required, the bone marrow relies on the kidney in which interstitial fibroblasts in the renal medulla sense hypoxia, leading to the hypoxia-inducible factor 2 (HIF-2) mediated production and excretion of EPO. EPO binding to EPO receptor on erythroid precursors in the bone marrow in turn induces their survival, cell division, and differentiation to ultimately enucleate, producing reticulocytes that mature to RBCs in the circulation. Hemoglobin synthesis in the developing erythroblasts requires iron-containing heme.</p><p>The first wave of erythropoiesis starts as early as embryonic day 7.5 (E7.5) in mouse (<xref ref-type="bibr" rid="bib181">Palis et al., 1999</xref>; <xref ref-type="bibr" rid="bib182">Palis and Yoder, 2001</xref>; <xref ref-type="bibr" rid="bib17">Baron et al., 2013</xref>) and 3 wk in human (<xref ref-type="bibr" rid="bib182">Palis and Yoder, 2001</xref>; <xref ref-type="bibr" rid="bib54">Dzierzak and Philipsen, 2013</xref>) in the yolk sac and produces large nucleated erythroid cells from hemangioblasts (<xref ref-type="bibr" rid="bib54">Dzierzak and Philipsen, 2013</xref>; <xref ref-type="bibr" rid="bib183">Palis, 2008</xref>; <xref ref-type="bibr" rid="bib17">Baron et al., 2013</xref>). Due to its transient nature, it is termed ‘primitive’ erythropoiesis to distinguish it from ‘definitive’ erythropoiesis that gradually replaces primitive erythropoiesis in the fetal liver and bone marrow, persisting thereafter throughout life. Definitive erythropoiesis produces erythroid progenitor cells from hematopoietic stem cells (HSCs) that seed and differentiate within the fetal liver by ~E14.5 in the mouse (<xref ref-type="bibr" rid="bib181">Palis et al., 1999</xref>; <xref ref-type="bibr" rid="bib182">Palis and Yoder, 2001</xref>; <xref ref-type="bibr" rid="bib17">Baron et al., 2013</xref>) and 7–8 wk in the human embryo (<xref ref-type="bibr" rid="bib182">Palis and Yoder, 2001</xref>; <xref ref-type="bibr" rid="bib54">Dzierzak and Philipsen, 2013</xref>). After birth, sites of erythropoiesis transition from liver to spleen and eventually bone marrow and enable robust RBC production needed to reach and sustain steady-state adult erythropoiesis levels by age 7 wk in the mouse (<xref ref-type="bibr" rid="bib41">Chen et al., 2021</xref>).</p><p>Definitive erythropoiesis is a multi-step, complex process that can be divided into three maturational stages, namely early-stage erythropoiesis, terminal erythroid differentiation, and reticulocyte maturation (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Early-stage erythropoiesis consists of two erythroid progenitor stages, burst-forming unit-erythroid (BFU-E) and colony-forming unit-erythroid (CFU-E). BFU-E and CFU-E were initially defined by their ability to form distinct types of colonies of erythroid cells in semisolid media (<xref ref-type="bibr" rid="bib110">Iscove and Sieber, 1975</xref>; <xref ref-type="bibr" rid="bib94">Gregory and Eaves, 1977</xref>). With the development of flow cytometry technology in conjunction with the identification of surface markers, both murine and human BFU-E and CFU-E cells can now be identified and isolated by fluorescence-activated cell sorting (FACS) for subsequent cellular and molecular studies (<xref ref-type="bibr" rid="bib72">Flygare et al., 2011</xref>; <xref ref-type="bibr" rid="bib143">Li et al., 2014</xref>; <xref ref-type="bibr" rid="bib267">Zhang et al., 2021</xref>). Furthermore, a recent study showed that human erythroid progenitor (EP) populations can be further subdivided into four subpopulations with EP1 representing predominantly BFU-E with EP2, EP3, and EP4 representing increasingly mature CFU-E populations with reduced proliferative responsiveness to stem cell factor (SCF), indicating heterogeneity of previously identified CFU-E population (<xref ref-type="bibr" rid="bib261">Yan et al., 2021</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Definitive erythropoiesis.</title><p>Definitive erythropoiesis in the adult organism is derived from hematopoietic stem cells (HSCs) with progressive movement of cells through three compartments: progenitors, erythroblast precursors, and erythrocytes. Erythroid progenitors (burst-forming unit-erythroid [BFU-E], colony-forming unit-erythroid [CFU-E]) are defined by their capacity to form colonies of maturing erythroid cells in vitro. Erythroid precursors are defined as pro-erythroblasts (ProE), basophilic erythroblasts (BasoE), polychromatophilic erythroblasts (PolyE), and orthochromatic erythroblasts (OrthoE) based on morphology and progressive change in the expression of surface markers. OrthoE enucleate to form a pyrenocyte, which contains the condensed nucleus, and a reticulocyte, which goes on to mature into an erythrocyte in the peripheral circulation. Erythroblast precursors undergo differentiation in contact with a macrophage within the erythroblastic island (EBI).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90189-fig1-v1.tif"/></fig><p>Terminal erythroid differentiation is a process by which proerythroblasts (Pro) differentiate sequentially to basophilic (Baso), polychromatic (Poly), and orthochromatic (Ortho) erythroblasts that expel their nuclei to become reticulocytes (<xref ref-type="fig" rid="fig1">Figure 1</xref>). During terminal erythroid differentiation, several notable changes occur, enabling one to selectively identify erythroblasts at distinct developmental stages based on morphological features. These changes include decreasing cell size, hemoglobin accumulation, chromatin condensation, and enucleation. Previously, Giemsa staining and morphological assessment by light microscopy were the only means for identifying at these terminally differentiating erythroblast stages. Currently, isolating and purifying both murine and human erythroblasts at distinct stages can be accomplished using surface markers and FACS analysis (<xref ref-type="bibr" rid="bib39">Chen et al., 2009</xref>; <xref ref-type="bibr" rid="bib148">Liu et al., 2013</xref>; <xref ref-type="bibr" rid="bib108">Hu et al., 2013</xref>). These novel methods for isolating erythroid lineage cells at each stage have not only enabled the study of normal and disordered erythropoiesis in a stage-specific manner (<xref ref-type="bibr" rid="bib148">Liu et al., 2013</xref>; <xref ref-type="bibr" rid="bib108">Hu et al., 2013</xref>) but have also facilitated global molecular characterization of erythropoiesis. Various global omics analyses have been performed using purified erythroid cell populations (<xref ref-type="bibr" rid="bib143">Li et al., 2014</xref>; <xref ref-type="bibr" rid="bib4">An et al., 2014</xref>; <xref ref-type="bibr" rid="bib56">Edwards et al., 2016</xref>; <xref ref-type="bibr" rid="bib214">Schulz et al., 2019</xref>). Transcriptome analyses of human and murine erythroblasts reveal significant stage- and species-specific differences across stages of terminal erythroid differentiation (<xref ref-type="bibr" rid="bib4">An et al., 2014</xref>). The epigenetic landscape of human erythropoiesis reveals that erythroid cells exhibit chromatin accessibility patterns distinct from other cell types. It also reveals stage-specific patterns of gene regulation (<xref ref-type="bibr" rid="bib214">Schulz et al., 2019</xref>). Global omics analyses have also been performed on primitive erythroblasts during embryogenesis that revealed molecular similarities and differences between primitive and definitive erythropoiesis (<xref ref-type="bibr" rid="bib173">Nemkov et al., 2022</xref>). The omic databases generated during the last decade not only contribute novel understanding of normal erythropoiesis regulation but also provide insight into disease pathophysiology and serve as rich resources for future studies.</p><p>Enucleation is a distinctive feature of mammalian erythropoiesis. Given the physiological significance of enucleation in generating highly deformable RBCs for effective oxygen delivery, understanding the mechanistic basis of enucleation has been an active area of investigation. Cytoskeleton proteins such as actin (<xref ref-type="bibr" rid="bib232">Takano-Ohmuro et al., 1996</xref>; <xref ref-type="bibr" rid="bib114">Ji et al., 2008</xref>; <xref ref-type="bibr" rid="bib253">Watanabe et al., 2013</xref>; <xref ref-type="bibr" rid="bib242">Ubukawa et al., 2020</xref>; <xref ref-type="bibr" rid="bib149">Liu et al., 2021</xref>), tubulin (<xref ref-type="bibr" rid="bib38">Chasis et al., 1989</xref>; <xref ref-type="bibr" rid="bib250">Wang et al., 2012</xref>), myosin (<xref ref-type="bibr" rid="bib232">Takano-Ohmuro et al., 1996</xref>; <xref ref-type="bibr" rid="bib241">Ubukawa et al., 2012</xref>), tropomodulin (<xref ref-type="bibr" rid="bib229">Sui et al., 2014</xref>), and chromatin condensation and lipid rafts (<xref ref-type="bibr" rid="bib115">Ji et al., 2010</xref>; <xref ref-type="bibr" rid="bib127">Konstantinidis et al., 2012</xref>; <xref ref-type="bibr" rid="bib156">Malik et al., 2017</xref>; <xref ref-type="bibr" rid="bib268">Zhao et al., 2019</xref>; <xref ref-type="bibr" rid="bib252">Wang et al., 2021</xref>; <xref ref-type="bibr" rid="bib112">Jeffery et al., 2021</xref>) are essential for normal enucleation. Although the function of actin and tubulin in enucleation suggests that erythroblast enucleation is a form of asymmetric cytokinesis, evidence documents that vesicle trafficking rather than cytokinesis is required for enucleation (<xref ref-type="bibr" rid="bib121">Keerthivasan et al., 2010</xref>). This conclusion is supported by a recent finding that vesicle formation regulated by ERK/MAPK pathway mediates human erythroblast enucleation (<xref ref-type="bibr" rid="bib5">An et al., 2021</xref>). Furthermore, although some evidence suggests that actin forms a contractile ring to help expel the nucleus (<xref ref-type="bibr" rid="bib114">Ji et al., 2008</xref>), other data demonstrates that a dedicated cytoskeletal assembly in the cytoplasm, the ‘enucleosome,’ located contralateral to the site of enucleation, that is, at the rear of the nucleus, is most likely the driver of nuclear expulsion (<xref ref-type="bibr" rid="bib176">Nowak et al., 2017</xref>). These findings indicate that despite relatively extensive studies on enucleation, the relevant mechanisms remain incompletely understood, somewhat controversial, and would benefit from further investigation.</p><p>Reticulocyte maturation is the final step of erythropoiesis. During this process, a series of major changes occur. These include membrane surface area loss via membrane vesiculation (<xref ref-type="bibr" rid="bib254">Waugh et al., 1997</xref>), organelle (mitochondria and ribosome) clearance via autophagy (<xref ref-type="bibr" rid="bib95">Gronowicz et al., 1984</xref>; <xref ref-type="bibr" rid="bib133">Kundu et al., 2008</xref>; <xref ref-type="bibr" rid="bib265">Zhang et al., 2009b</xref>), and membrane skeleton reorganization (<xref ref-type="bibr" rid="bib38">Chasis et al., 1989</xref>; <xref ref-type="bibr" rid="bib146">Liu et al., 2010</xref>; <xref ref-type="bibr" rid="bib147">Liu et al., 2011</xref>). These changes together lead to fully functional mature RBCs with maximum hemoglobin carrying capacity and flexible yet stable membranes.</p><p>Erythropoiesis is tightly regulated by multiple soluble factors. To determine how many RBCs are required, the bone marrow relies on the kidney in which interstitial fibroblasts in the renal medulla sense hypoxia, leading to the HIF-2-mediated production and excretion of EPO. Very recent preliminary data using single-cell RNA and transposase-accessible chromatic (ATAC) sequencing to molecularly identify EPO-producing cells indicate that a distinct population of renal stromal cells, termed Norn cells, are the main source of EPO production in mice and humans (<xref ref-type="bibr" rid="bib128">Kragesteen et al., 2023</xref>). EPO binding to EPO receptor (EPOR) on erythroid precursors in the bone marrow in turn induces their survival, cell division, and differentiation to ultimately produce RBCs. EPO and EPOR are indispensable for definitive erythropoiesis. Deletion of EPO or EPOR leads to embryonic lethality at approximately E13 due to severe anemia associated with defects in deﬁnitive erythropoiesis in mice (<xref ref-type="bibr" rid="bib259">Wu et al., 1995</xref>). Other cytokines, growth factors, and hormones such as stem cell factor, interleukin-3, insulin-like growth factor 1, and glucocorticoids, although not essential for erythropoiesis, also promote proliferation of erythroid progenitors (<xref ref-type="bibr" rid="bib224">Sonoda et al., 1988</xref>; <xref ref-type="bibr" rid="bib225">Sonoda et al., 1994</xref>; <xref ref-type="bibr" rid="bib126">Kolbus et al., 2003</xref>; <xref ref-type="bibr" rid="bib190">Perry et al., 2007</xref>; <xref ref-type="bibr" rid="bib72">Flygare et al., 2011</xref>). At the transcriptional level, red cell development is regulated by multiple transcription factors (<xref ref-type="bibr" rid="bib54">Dzierzak and Philipsen, 2013</xref>; <xref ref-type="bibr" rid="bib8">Andrieu-Soler and Soler, 2022</xref>), two of which, GATA1 and KLF1, are considered master regulators, indispensable for normal erythropoiesis (<xref ref-type="bibr" rid="bib191">Pevny et al., 1995</xref>; <xref ref-type="bibr" rid="bib219">Siatecka and Bieker, 2011</xref>).</p><p>Similar to EPO, iron is also essential for erythropoiesis. Hemoglobin synthesis in the developing erythroblasts requires iron-containing heme. While EPO allows survival of erythroid progenitors and early-stage erythroblasts by activating transcription of anti-apoptotic genes via the EPO/EPOR/JAK2/STAT5 signaling pathway (<xref ref-type="bibr" rid="bib258">Witthuhn et al., 1993</xref>), iron modulates EPO responsiveness (<xref ref-type="bibr" rid="bib123">Khalil et al., 2018</xref>) and is also essential for differentiation of early- to late-stage erythroblasts, during which time iron incorporation into the protoporphyrin ring is required as the last step in heme synthesis. EPO can thus be regarded as a ‘driver’ of erythropoiesis, while iron acts as a ‘modulator’ and also serves as the fuel for the production of RBCs. In addition, recent data demonstrates that iron may be involved in the modulation of EPO responsiveness via the regulatory function of monoferric transferrin.</p></sec><sec id="s3"><title>Physiological regulation and dysregulation of iron metabolism</title><sec id="s3-1"><title>Systemic regulation of iron metabolism</title><p>Because of its low bioavailability, complex living organisms have developed sophisticated mechanisms to obtain, distribute, and sequester iron that have also enabled competition for iron with pathogens and prevention of iron excess. In a seminal discovery more than two decades ago, the peptide hormone hepcidin, secreted primarily by hepatocytes, has been shown to be the principal regulator of iron homeostasis (<xref ref-type="bibr" rid="bib130">Krause et al., 2000</xref>; <xref ref-type="bibr" rid="bib186">Park et al., 2001</xref>; <xref ref-type="bibr" rid="bib78">Ganz, 2005</xref>), modulating dietary iron absorption, iron recycling by macrophages, and the release of iron from hepatic stores (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Hepcidin is a negative regulator of iron flows with high hepcidin concentration typically resulting in the blockade of iron absorption and sequestration of cellular iron. Hepcidin downregulates iron release into plasma by binding to and functionally downregulating ferroportin 1, the sole exporter of intracellular iron (<xref ref-type="bibr" rid="bib170">Nemeth et al., 2004</xref>; <xref ref-type="bibr" rid="bib51">Donovan et al., 2005</xref>; <xref ref-type="fig" rid="fig2">Figure 2B</xref>). Ferroportin is evolutionarily conserved and is found in microbes, invertebrates, plants, and animals (<xref ref-type="bibr" rid="bib234">Taniguchi et al., 2015</xref>). In humans, ferroportin is found in duodenal enterocytes, macrophages, and hepatocytes, all cells involved in iron transport (<xref ref-type="fig" rid="fig3">Figure 3</xref>). In addition, erythroid progenitors and precursors in the bone marrow as well as circulating RBCs also express ferroportin (<xref ref-type="bibr" rid="bib266">Zhang et al., 2018</xref>; <xref ref-type="fig" rid="fig3">Figure 3C</xref>), an interesting finding that remains incompletely understood.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Hepcidin is central to the regulation of iron metabolism.</title><p>(<bold>A</bold>) Systemically, hepcidin is a negative regulator of iron flows such that increased hepcidin synthesis (which mainly occurs in the liver) leads to hypoferremia by decreasing iron absorption in the duodenum, iron recycling from splenic macrophages, and iron release from hepatocyte stores. (<bold>B</bold>) The mechanism of action of hepcidin involves binding to and occluding ferroportin, induction of ferroportin ubiquitination, followed by endocytosis and lysosomal degradation of the ferroportin:hepcidin complex. Fe-Tf, transferrin-bound iron; FPN1, ferroportin1; Ub, ubiquitination.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90189-fig2-v1.tif"/></fig><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Cellular iron metabolism.</title><p>Intracellular iron homeostasis is balanced by coordinated iron uptake, utilization, storage, and export. The three main cells of interest include duodenal enterocytes (involved in systemic iron absorption), reticuloendothelial macrophages (involved in systemic iron recycling), and erythroblasts (main location of systemic iron utilization for hemoglobin synthesis during erythropoiesis). (<bold>A</bold>) <italic>Duodenal enterocyte</italic>: absorbed inorganic ferric iron (Fe<sup>3+</sup>) must be first converted to ferrous iron (Fe<sup>2+</sup>) via ferrireductase Dcytb and subsequently taken up by iron importer DMT1. Once inside the cell, iron is shuttled to ferritin via iron chaperones PCBP1/2 and stored there or shuttled out of ferritin by NCOA4 for export via FPN1. During iron export, Fe<sup>2+</sup> must be oxidized to Fe<sup>3+</sup> by HEPH or CP and loaded onto TF for transport in the circulation. Hepcidin prevents iron export at the basolateral cell membrane and results in ferritin iron accumulation within the enterocyte. (<bold>B</bold>) <italic>Macrophage</italic>: splenic and liver macrophages are specifically equipped with mechanisms to enable direct erythrophagocytosis, uptake of Hb:HP complexes via CD163, and heme:HPX complexes via CD91. The heme extracted from these pathways is processed by HMOX1 to liberate iron that is then either incorporated into ferritin or exported from the cell via FPN1 and loaded onto TF for delivery to iron-requiring cells. (<bold>C</bold>) <italic>Erythroblast</italic>: iron-loaded TF binds to TFR1 on the surface of cells with erythroblasts expressing the highest concentration of TFR1 relative to other cells in light of their high iron requirements. These complexes localize to clathrin-coated pits that invaginate to form specialized endosomes where proton pumps decrease the pH and transported Fe<sup>3+</sup> is reduced by STEAP3 for export from the endosome via DMT1. Erythroblasts shuttle much of their iron to the mitochondria by an incompletely understood mechanism where it is incorporated into protoporphyrin. FPN1 is also expressed on erythroblasts but purpose of iron export in erythroblasts is incompletely understood. Finally, iron loaded TF also binds TFR2, which is thought to function as an iron sensor to coordinate iron supply with erythropoietic output by modulating EPOR localization and consequently EPO responsiveness; a detailed mechanistic understanding of TFR2’s role in erythropoiesis (DMT1, divalent metal transporter 1; Dcytb, duodenal cytochrome B reductase; FPN, ferroportin 1; HEPH, hephaestin; CP, ceruloplasmin; TF, transferrin; Fe<sup>3+</sup>, ferric iron; Fe<sup>2+</sup>, ferrous iron; Hb, hemoglobin; HP, haptoglobin; HPX, hemopexin; CD91 and 169, cluster of differentiation 91 and 163; HMOX1, heme oxygenase 1; TFR1 and 2, transferrin receptor 1 and 2; EPO, erythropoietin; EPOR, EPO receptor; PCBP1, poly(rC)-binding protein 1; NCOA4, nuclear receptor coactivator 4; pSTAT5, phosphorylated signal transducer and activator of transcription 5; pAKT, phosphorylated protein kinase B).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90189-fig3-v1.tif"/></fig><p>Hepcidin:ferroportin binding leads to both occlusion of the ferroportin channel (<xref ref-type="bibr" rid="bib14">Aschemeyer et al., 2018</xref>) and induction of a conformational change, leading to ferroportin ubiquitination, endocytosis of the complex (<xref ref-type="bibr" rid="bib197">Qiao et al., 2012</xref>), and its ultimate lysosomal degradation (<xref ref-type="bibr" rid="bib170">Nemeth et al., 2004</xref>; <xref ref-type="fig" rid="fig2">Figure 2B</xref>). More recent work provides further structural and functional detail of the hepcidin:ferroportin interaction using cryogenic electron microscopy, identifying the 80-fold enhanced hepcidin binding to iron-loaded ferroportin and elucidating targeted ferroportin degradation in the presence of iron (<xref ref-type="bibr" rid="bib24">Billesbølle et al., 2020</xref>). From a systemic perspective, this block in cellular iron efflux leads to circulating hypoferremia as a consequence of continued iron uptake from the circulation, leading to iron consumption if it is not replaced by iron efflux from enterocytes, macrophages, and hepatocytes. Thus, maintaining a stable supply of iron in the circulation is dependent on hepcidin-mediated post-translational regulation of ferroportin. In addition, ferroportin expression in erythrophagocytosing macrophages is also transcriptionally regulated by heme (<xref ref-type="bibr" rid="bib161">Marro et al., 2010</xref>) and under translational regulation (i.e. iron response elements on messenger RNA bound to iron response proteins) by mechanisms independent of hepcidin regulation (<xref ref-type="bibr" rid="bib264">Zhang et al., 2009a</xref>). Finally, recent work also provides evidence that transferrin also interacts with ferroportin, leading to ferroportin internalization and degradation by a well-established pathway, and that only extra-physiological levels of hepcidin interfere with the transferrin:ferroportin interaction (<xref ref-type="bibr" rid="bib16">Baringer et al., 2023</xref>). The full physiological significance of these finding remains to be determined.</p><p>Ferroportin expression on the basolateral side of duodenal enterocytes, on splenic and liver macrophages, and on hepatocytes enables hepcidin regulation of iron absorption, recycling, and storage, respectively (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). Because hepcidin is a negative regulator of iron metabolism, decreased hepcidin concentration results in increased iron absorption and increased release of iron from intracellular compartments in hepatocytes and macrophages, enabling recovery from iron deficiency. To elucidate, low hepcidin levels result in greater ferroportin activity on duodenal enterocytes, leading to the depletion of enterocyte iron levels with consequently decreased activity of oxygen- and iron-dependent prolyl hydroxylases that target hypoxia-inducible factors (HIFs) for degradation in proteasomes, stabilizing HIF. HIF2α is an important local regulator of transcription of the apical iron importer divalent metal transporter 1 (DMT1), the iron reductase duodenal cytochrome <italic>b</italic> (DCYTB), and the basolateral exporter ferroportin (<xref ref-type="bibr" rid="bib215">Schwartz et al., 2019</xref>). Taken together, HIF2α stabilization coordinates apical import of dietary iron with the hepcidin-controlled activity of ferroportin to enhance absorption of intestinal iron in iron-deficient conditions.</p><p>In some pathological conditions, insufficiently increased hepcidin results in excessive iron released into the circulation, overwhelming transferrin’s iron binding capacity, resulting in the generation of non-transferrin bound iron (NTBI) (<xref ref-type="bibr" rid="bib61">Esposito et al., 2003</xref>). NTBI, in particular its redox-active form, labile plasma iron (LPI), is thought to be the pathogenetic driver of clinically significant iron overload in diseases of primary and secondary hemochromatosis (<xref ref-type="bibr" rid="bib28">Cabantchik et al., 2005</xref>). NTBI/LPI is unavailable for erythropoiesis, is taken up by non-hematopoietic cells in a dysregulated manner, causes parenchymal iron deposition (<xref ref-type="bibr" rid="bib113">Jenkitkasemwong et al., 2015</xref>), and can result in free radical damage to cells and organs, leading to the morbidity and mortality of iron overload. More detailed pathophysiology of iron overload is beyond the scope of the current review; an excellent review of hepcidin in disorders of iron regulation was recently published (<xref ref-type="bibr" rid="bib172">Nemeth and Ganz, 2023</xref>).</p></sec><sec id="s3-2"><title>Cellular regulation of iron metabolism</title><p>As mentioned, iron is required for homeostatic function in all cells, essential for the production of heme and iron-sulfur clusters, themselves components of proteins/enzymes involved in respiration, nucleic acid replication and repair, metabolic reactions, and host defense. Specifically, iron is necessary for enzymatic reactions in the electron transport chain and the tricarboxylic acid cycle, and iron participates in reactions catalyzed by microsomal cytochromes involved in the detoxification of drugs and other foreign substances. Despite broad functioning in physiological processes, the majority of iron functions as an oxygen carrier in the heme groups of hemoglobin and myoglobin molecules. Because iron can be highly toxic to cells, cellular iron trafficking requires deliberate coordination to enable its safe utilization. Here, we focus on specific cell types that are central to systemic iron metabolism.</p><list list-type="order"><list-item><p><italic>Duodenal enterocytes</italic>: The primary site of dietary iron absorption involves enterocytes within duodenal villi. These polarized cells are in contact with the gut lumen and dietary contents on their apical side and with blood in circulation on their basolateral side (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Non-heme iron is imported from the lumen by the apical enterocyte DMT1 (<xref ref-type="bibr" rid="bib97">Gunshin et al., 1997</xref>; <xref ref-type="bibr" rid="bib71">Fleming et al., 1997</xref>), a metal transporter that takes up iron after iron reduction from ferric (Fe<sup>3+</sup>) to ferrous (Fe<sup>2+</sup>) state (<xref ref-type="bibr" rid="bib162">McKie et al., 2001</xref>). Iron that is not used for enterocyte function is either stored within ferritin or exported by ferroportin on the basolateral surface to be loaded onto transferrin in circulation. As transferrin-bound iron is obligate Fe<sup>3+</sup>, intracellular Fe<sup>2+</sup> must first be oxidized at the basolateral surface to enable its export (<xref ref-type="bibr" rid="bib249">Vulpe et al., 1999</xref>). Finally, iron that is not exported at the enterocyte’s basolateral surface into the circulation is lost during mucosal shedding. The concentration of hepcidin in circulation regulates iron absorption at the basolateral surface of the enterocyte such that low hepcidin levels correlate with increased iron absorption to enable recovery from iron deficiency while high hepcidin levels prevent additional iron absorption (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p></list-item><list-item><p><italic>Reticuloendothelial macrophages</italic>: At the end of their 120-day life cycle, RBC recycling by macrophages in the spleen and liver supports the recovery of iron for further systemic use (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). In addition, RBC hemolysis leads to the release of hemoglobin into the circulation, where it is bound by haptoglobin, and circulating heme:hemopexin complexes, taken up by macrophages via CD163 and CD91, respectively. Macrophages are equipped with mechanisms to recover iron from heme from both intact and hemolyzed RBCs via heme oxygenase 1 (HMOX1) (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). As in duodenal enterocytes, depending on systemic requirements, a fraction of the recovered iron is stored in macrophages, bound for intracellular storage in cytosolic ferritin with the rest exported via ferroportin back into the circulation to bind transferrin when needed to maintain equilibrium of iron flux or when erythropoiesis is increased (<xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p></list-item><list-item><p><italic>Erythroblasts</italic>: The vast majority of transferrin-bound iron in the circulation is targeted to developing erythroid progenitors in the bone marrow to eventually be incorporated into heme (<xref ref-type="bibr" rid="bib69">Finch et al., 1970</xref>). Iron uptake for erythropoiesis is the result of transferrin:transferrin receptor 1 (TFR1) binding (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Transferrin protein, with two iron molecules (also known as holo-transferrin or diferric transferrin), binds with high affinity to TFR1 at physiological pH 7.4; apo-transferrin (lacking iron) does not. Furthermore, monoferric transferrins, which bind TFR1 with affinity intermediate between holo- and apo-transferrin, are the most abundant transferrin moieties in the circulation (<xref ref-type="bibr" rid="bib152">Luck and Mason, 2012</xref>; <xref ref-type="bibr" rid="bib187">Parrow et al., 2019</xref>; <xref ref-type="bibr" rid="bib124">Klausner et al., 1983a</xref>; <xref ref-type="bibr" rid="bib109">Iacopetta et al., 1983</xref>; <xref ref-type="bibr" rid="bib125">Klausner et al., 1983b</xref>; <xref ref-type="bibr" rid="bib46">Dautry-Varsat et al., 1983</xref>; <xref ref-type="bibr" rid="bib244">van Renswoude et al., 1982</xref>). A second transferrin receptor, TFR2, has been shown to mediate signaling events unrelated to meeting cellular iron needs, but a detailed understanding of its role in the crosstalk between erythropoiesis and iron metabolism awaits additional hypothesis-driven evaluation.</p></list-item><list-item><p><italic>Hepatocytes</italic>: Hepatocytes account for 60–80% of liver cell mass, are metabolically active cells with numerous mitochondria, are responsible for carbohydrate metabolism, and contribute to a wide range of regulatory proteins, vitamins, and hormones required for local and systemic function. As such, hepatocytes are the main source of hepcidin synthesis and secretion. As a consequence, the central function of these cells for the purposes of this article is the mechanistic regulation of hepcidin.</p></list-item></list></sec></sec><sec id="s4"><title>Physiological regulation of hepcidin expression</title><p>Hepcidin expression is predominantly regulated by iron, inflammation, and erythropoiesis (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). First, <italic>HAMP</italic> transcription in hepatocytes is upregulated by iron loading and suppressed by iron deficiency as well as expanded or ineffective erythropoiesis. The regulation of hepcidin by iron is incompletely understood. Murine models suggest hepatocytes sense local and systemic iron status by binding bone morphogenetic proteins (BMPs), primarily BMP6, BMP2, and/or their heterodimers via BMP receptors, and transferrin-bound iron via TFR1 and TFR2, leading to signaling to induce hepcidin expression (<xref ref-type="bibr" rid="bib30">Camaschella et al., 2020</xref>; <xref ref-type="fig" rid="fig4">Figure 4B</xref>). Second, hepatocyte hepcidin expression is mediated indirectly by iron in response to iron-induced BMP production by liver sinusoidal endothelial cells (LSECs) (<xref ref-type="bibr" rid="bib58">Enns et al., 2013</xref>). Recent evidence demonstrates that BMP6 expression in primary LSEC ex vivo is induced in response to iron only when co-cultured with primary hepatocytes or supernatants from primary hepatocyte cultures (<xref ref-type="bibr" rid="bib45">Colucci et al., 2022</xref>). Additional recent effort provides evidence for a minor functional role of LSEC TFR1-mediated iron uptake and BMP6 induction in iron limited conditions and TFR1-independent iron-mediated regulation of LSEC BMP6 expression in iron-rich conditions (<xref ref-type="bibr" rid="bib70">Fisher et al., 2022</xref>). Although how BMP expression is induced in LSEC is not fully understood, the BMP pathway is critical for hepcidin the regulation by iron (<xref ref-type="bibr" rid="bib240">Truksa et al., 2006</xref>; <xref ref-type="bibr" rid="bib15">Babitt et al., 2007</xref>). Specifically, BMP6 and BMP2 binding hepatocellular BMP receptor triggers phosphorylation and signaling via SMAD1/5/8 that, coupled with SMAD4, translocate to the nucleus to induce <italic>HAMP</italic> expression (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Third, several hepatocellular surface molecules modulate <italic>HAMP</italic> activation in response to iron status, enabling hepatocytes to directly sense iron via expression of TFR1, TFR2, and HFE. To briefly delineate, HFE association with TFR1 under low iron conditions is displaced when TFR1 binds monoferric or diferric transferrin (<xref ref-type="bibr" rid="bib63">Feder et al., 1998</xref>; <xref ref-type="bibr" rid="bib19">Bennett et al., 2000</xref>; <xref ref-type="bibr" rid="bib86">Giannetti and Björkman, 2004</xref>; <xref ref-type="bibr" rid="bib137">Lebrón et al., 1998</xref>). Although a mechanistic understanding of how TFR2 contributes to hepcidin regulation remains unclear, we surmise that as serum iron concentration increases, increased transferrin:TFR2 binding induces TFR2 membrane stabilization (<xref ref-type="bibr" rid="bib116">Johnson and Enns, 2004</xref>; <xref ref-type="bibr" rid="bib205">Robb and Wessling-Resnick, 2004</xref>) and possibly HFE binding to TFR2. This HFE:TFR2 complex interacts with hemojuvelin (HJV), the iron-specific BMP co-receptor, and potentiates the BMP signaling pathway to <italic>HAMP</italic> expression (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Furthermore, the specific mechanism by which HJV regulates hepcidin is incompletely understood. For example, recent evidence demonstrates that HJV interaction with neogenin, a ubiquitously expressed transmembrane protein, is required for hepcidin regulation (<xref ref-type="bibr" rid="bib60">Enns et al., 2021</xref>). Finally, the pathway is negatively regulated by the transmembrane serine protease matriptase 2 (i.e. TMPRSS6), which by binding HJV, BMP receptor, and/or HFE decreases signaling to <italic>HAMP</italic> expression (<xref ref-type="bibr" rid="bib59">Enns et al., 2020</xref>). Thus, both TFR2 and HFE:TFR1 complex function as the main iron sensors (<xref ref-type="bibr" rid="bib211">Schmidt et al., 2008</xref>; <xref ref-type="bibr" rid="bib205">Robb and Wessling-Resnick, 2004</xref>) and communicate systemic iron status to modify hepatocyte hepcidin production and secretion with multiple co-factors modulating this signal.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Hepcidin regulation.</title><p>(<bold>A</bold>) Systemically, hepcidin is stimulated by transferrin-bound iron in the circulation and liver iron stores as well as by systemic inflammation and suppressed by enhanced erythroid activity. (<bold>B</bold>) Regulation of hepcidin expression in the hepatocyte involves JAK-STAT signaling as a consequence of IL-6 receptor stimulation and SMAD signaling as a consequence of a BMP receptor complex stimulation. IL-6 and BMP2/6 binding their receptors, respectively, leads to stimulation of hepcidin expression. Stimulation of erythropoiesis leads to the expression and secretion of erythroferrone that sequesters BMP2/6 to suppress SMAD signaling, decreasing hepcidin. Additional coregulation via matriptase-2 and hemojuvelin as well as systemic iron sensing by TFR1, HFE, and TFR2 enhance BMP receptor stimulation and increase hepcidin expression. Fe-Tf, transferrin-bound iron; IL-6, interleukin 6; HAMP, gene name for hepcidin; ERFE, erythroferrone; LSEC, liver sinusoidal endothelial cell; TFR1/2, transferrin receptor 1 and 2; HFE, homeostatic iron regulator; HJV, hemojuvelin; MT-2, matriptase 2; JAK-STAT, janus kinase and signal transducer and activator of transcription; SMAD, small mothers against decapentaplegic.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90189-fig4-v1.tif"/></fig><p>Interestingly, hepatocyte TFR1 also influences systemic iron homeostasis by interacting with the hemochromatosis protein HFE to regulate hepcidin production (<xref ref-type="bibr" rid="bib67">Fillebeen et al., 2019</xref>; <xref ref-type="bibr" rid="bib260">Xiao et al., 2023</xref>). Although loss of hepatic <italic>Tfrc</italic> is not associated with grossly altered iron metabolism, hepatocyte-selective <italic>Tfrc</italic> knockout mice show predisposition to anemia making their unchanged hepcidin levels inappropriately high relative to serum and liver iron concentrations and ERFE levels. In addition, ablation of hepatocyte <italic>Tfrc</italic> does not modify the iron phenotype in <italic>Hfe</italic> knockout mice. Lack of <italic>Tfrc</italic> also ameliorates hepcidin deficiency and liver iron loading.</p></sec><sec id="s5"><title>Crosstalk between erythropoiesis and iron metabolism</title><p>Hemoglobin synthesis in erythroblasts requires large amount of iron, providing a strong rationale for erythropoiesis-mediated regulation of iron availability. For instance, stimulated erythropoiesis (e.g. in response to bleeding, repeated or large volume phlebotomy, hypoxia, or administration of exogenous EPO) leads to increased iron absorption, and the last few decades have provided a more robust mechanistic understanding of how iron availability is regulated by erythropoiesis. For the purposes of this article, we will discuss several aspects of this crosstalk, including how iron is taken up and chaperoned in erythroblasts, how erythropoiesis modulates iron metabolism directly and indirectly, and how iron metabolism itself impacts erythropoiesis.</p><sec id="s5-1"><title>Iron uptake and trafficking in erythroblasts</title><p>Hemoglobin, both in circulation and within the bone marrow, contains more than two-thirds of the body’s iron, and the majority of circulating iron is destined for uptake by erythroblasts (<xref ref-type="bibr" rid="bib69">Finch et al., 1970</xref>). Iron uptake for erythropoiesis occurs via transferrin binding to TFR1 (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Transferrin bound to TFR1 is internalized as a complex by receptor-mediated endocytosis (<xref ref-type="bibr" rid="bib124">Klausner et al., 1983a</xref>; <xref ref-type="bibr" rid="bib109">Iacopetta et al., 1983</xref>), which is coordinated with endosomal acidification, resulting in the release of iron from transferrin (<xref ref-type="bibr" rid="bib125">Klausner et al., 1983b</xref>; <xref ref-type="bibr" rid="bib46">Dautry-Varsat et al., 1983</xref>; <xref ref-type="bibr" rid="bib244">van Renswoude et al., 1982</xref>). Several hypotheses have been tested to ascertain how iron is transported within cells, the most compelling of which involves the cytosolic chaperone Poly(rC)-binding protein 1 (PCBP1). PCBP1 delivers iron to ferritin (<xref ref-type="bibr" rid="bib140">Leidgens et al., 2013</xref>; <xref ref-type="bibr" rid="bib207">Ryu et al., 2017</xref>; <xref ref-type="fig" rid="fig3">Figure 3C</xref>). Evidence from <italic>Pcbp1</italic> knockout mice, with microcytosis and anemia, demonstrate that iron delivery to ferritin is required for normal erythropoiesis (<xref ref-type="bibr" rid="bib207">Ryu et al., 2017</xref>). In addition, PCBP2 is also required for ferritin complex formation (<xref ref-type="bibr" rid="bib140">Leidgens et al., 2013</xref>). Furthermore, an autophagic process to extract iron from the ferritin core is mediated by nuclear receptor coactivator 4 (NCOA4), a selective cargo receptor for autophagic ferritin turn-over, critical for regulation of intracellular iron availability (<xref ref-type="bibr" rid="bib157">Mancias et al., 2014</xref>; <xref ref-type="bibr" rid="bib52">Dowdle et al., 2014</xref>; <xref ref-type="fig" rid="fig3">Figure 3C</xref>). In iron-replete states, PCBP1 and PCBP2 expression is enhanced while NCOA4 is targeted to the proteasome for degradation (<xref ref-type="bibr" rid="bib158">Mancias et al., 2015</xref>). This process, termed ferritinophagy, is believed to provide iron to the mitochondria, the main organelle involved in heme and hemoglobin synthesis during erythropoiesis. Alternatively, or in concert, the ‘kiss-and-run’ model may support the of transfer iron without chaperones when transferrin iron containing endosomes and mitochondria come into contact with one another (<xref ref-type="bibr" rid="bib101">Hamdi et al., 2016</xref>). Finally, transferrin-bound iron internalized by TFR2 may undergo trafficking to lysosomes and subsequent transfer to mitochondria via Mucolipin 1 and Mitofusin 2 (<xref ref-type="bibr" rid="bib122">Khalil et al., 2017</xref>; <xref ref-type="fig" rid="fig3">Figure 3C</xref>). Taken together, despite important recently uncovered mechanistic findings, the nuances of how iron trafficking in erythroblasts is dysregulated and contributes to disordered erythropoiesis are incompletely understood.</p></sec><sec id="s5-2"><title>Erythropoiesis-mediated regulation of iron metabolism</title><p>During the last century, investigators have proposed that an erythroid regulator strongly influences iron homeostasis. The discovery of hepcidin as an iron-regulatory hormone heralded a new era in exploring the mechanistic foundation of an erythroid regulator of iron homeostasis. For instance, stimulation of erythropoiesis—by bleeding, anemia, hypoxia, or injection of exogenous EPO—strongly suppresses hepcidin production in mice and humans, and iron absorption increases, often dramatically, during such stress erythropoiesis to accommodate increased iron demand. Initial exploration of EPO itself as a hepcidin suppressor revealed a lack of direct effect in in vitro studies in isolated liver cells (<xref ref-type="bibr" rid="bib76">Gammella et al., 2015</xref>), implicating an intermediary EPO-responsive suppressor of hepcidin.</p><p>To explore the mechanism(s) underlying erythropoiesis-mediated regulation of hepcidin required separating how EPO, hypoxia, anemia, reticulocytosis, and erythropoiesis itself are individually involved. Prior experiments demonstrate that phlebotomy, EPO administration, and hemolysis all resulted in decreased hepcidin expression (<xref ref-type="bibr" rid="bib174">Nicolas et al., 2002a</xref>; <xref ref-type="bibr" rid="bib175">Nicolas et al., 2002b</xref>; <xref ref-type="bibr" rid="bib248">Vokurka et al., 2006</xref>). Additional studies revealed that bone marrow ablation prevents hepcidin suppression in response to phlebotomy, EPO administration, and hemolysis (<xref ref-type="bibr" rid="bib248">Vokurka et al., 2006</xref>; <xref ref-type="bibr" rid="bib180">Pak et al., 2006</xref>), strongly supporting the hypothesis that erythroid regulation of hepcidin is a consequence of expanded, stress, or ineffective erythropoiesis. Consistently, iron-loading anemias exhibit complicated crosstalk between erythropoiesis and iron metabolism that remain incompletely understood. Such diseases of concurrent iron overload and expanded or ineffective erythropoiesis (e.g. β-thalassemia, some cases of myelodysplastic syndromes [MDS], and dyserythropoietic anemias) exhibit lower-than-expected hepcidin expression, insufficiently elevated relative to increased iron stores. In fact, insufficiently elevated hepcidin expression results in iron overload in these diseases, providing further support to the hypothesis that an ‘erythroid factor’ regulates iron metabolism (<xref ref-type="bibr" rid="bib87">Ginzburg et al., 2009</xref>; <xref ref-type="bibr" rid="bib81">Gardenghi et al., 2007</xref>).</p><p>Such an erythroid factor secreted by erythroid precursors, functioning as a hormone to distally suppress hepcidin expression in the liver, was predicted several decades prior to its recent discovery. Although multiple factors correlate with pathologically expanded or ineffective erythropoiesis, they do not support physiological regulation of iron by erythropoiesis. For example, although circulating growth differentiation factor 15 (GDF15) increases in patients with some congenital and acquired anemias and inversely correlates with hepcidin (<xref ref-type="bibr" rid="bib235">Tanno et al., 2007</xref>), levels of GDF15 and hepcidin correlate poorly in phlebotomized mice (<xref ref-type="bibr" rid="bib32">Casanovas et al., 2013</xref>) and in MDS patients (<xref ref-type="bibr" rid="bib209">Santini et al., 2011</xref>), suggesting that mechanisms of hepcidin suppression by erythropoiesis may be disease specific. Furthermore, hypoxia has been shown to decrease hepcidin expression by a novel regulatory pathway exerted via platelet-derived growth factor BB (PDGF-BB), leading to increased availability of circulating iron that can be used for erythropoiesis (<xref ref-type="bibr" rid="bib223">Sonnweber et al., 2014</xref>). To interrogate whether PDGF-BB is directly regulated by erythropoiesis, mice were treated with EPO demonstrating no significant impact on serum PDGF-BB concentration. Additional evaluation of this mechanism of regulation is needed to understand its full impact and contribution to physiological and/or pathophysiological hepcidin regulation.</p><p>Finally and importantly, the discovery of erythroferrone (ERFE) provided a mechanism for the physiological regulation of hepcidin in the absence of chronic disease (<xref ref-type="bibr" rid="bib118">Kautz et al., 2014</xref>). <italic>ERFE</italic> is expressed in bone marrow erythroblasts (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). As <italic>Erfe</italic><sup>-/-</sup> mice exhibit only mild anemia during the postnatal period (<xref ref-type="bibr" rid="bib118">Kautz et al., 2014</xref>), ERFE expression increases post-phlebotomy and in response to exogenous EPO, supporting a hypothesis that its main function is to facilitate iron mobilization during recovery from transient anemia. Consistently, hepcidin suppression is dampened in <italic>Erfe</italic><sup>+/-</sup> and abrogated in <italic>Erfe</italic><sup>-/-</sup> mice (<xref ref-type="bibr" rid="bib118">Kautz et al., 2014</xref>) after phlebotomy. An evaluation of the mechanism of ERFE’s regulation of hepcidin demonstrates that ERFE sequesters BMP2 and BMP6, resulting in decreased BMP:BMPR binding, decreased BMP:SMAD signaling, and decreased hepcidin expression (<xref ref-type="bibr" rid="bib10">Arezes et al., 2018</xref>; <xref ref-type="bibr" rid="bib251">Wang et al., 2020</xref>; <xref ref-type="fig" rid="fig4">Figure 4A and B</xref>), increasing iron absorption and release from intracellular iron stores to meet the iron requirements of temporarily expanded erythropoiesis during recovery from transient anemia. However, additional regulators may also exist in light of some persistent hepcidin suppression in phlebotomized ERFE knockout mice and ongoing iron accumulation in β-thalassemic ERFE knockout mice (<xref ref-type="bibr" rid="bib118">Kautz et al., 2014</xref>; <xref ref-type="bibr" rid="bib119">Kautz et al., 2015</xref>).</p></sec><sec id="s5-3"><title>Iron-mediated regulation of erythropoiesis</title><p>Anemia as a result of systemic iron deficiency is the most common cause of anemia worldwide. There is great consensus that iron deficiency inhibits the production of heme and hemoglobin but is erroneously synonymous with the resultant anemia. However, decreased heme and hemoglobin production in iron-deficient conditions contributes to decreased mean corpuscular volume (MCV) and hemoglobin (MCH). Conversely, disease states of excess iron are often associated with higher MCV and MCH as a functional utilization of iron within a non-toxic compartment (<xref ref-type="bibr" rid="bib163">McLaren et al., 2007</xref>). Anemia, on the other hand, occurs when iron availability decreases below a threshold, impeding the maturation of erythroblasts and thus decreasing production of RBCs. Recent data provides mechanistic evidence of what is termed the ‘iron restriction response,’ demonstrating regulation of erythroid precursor differentiation during iron deficiency (<xref ref-type="bibr" rid="bib27">Bullock et al., 2010</xref>; <xref ref-type="bibr" rid="bib123">Khalil et al., 2018</xref>). The proposed mechanisms involve mitochondrial aconitase enzymes, TFR2, and scribble-mediated EPO receptor regulation, as well as effects on the erythroblast cell cycle (<xref ref-type="bibr" rid="bib233">Talbot et al., 2011</xref>; <xref ref-type="bibr" rid="bib123">Khalil et al., 2018</xref>) that converge on the decreased EPO-responsiveness of erythroblasts.</p><p>Specifically, recent studies reveal a novel iron-sensing function of TFR2 in erythropoiesis, via its interaction with EPOR (<xref ref-type="bibr" rid="bib73">Forejtnikovà et al., 2010</xref>; <xref ref-type="bibr" rid="bib168">Nai et al., 2015</xref>; <xref ref-type="bibr" rid="bib138">Lee et al., 2012</xref>; <xref ref-type="bibr" rid="bib204">Rishi et al., 2016</xref>; <xref ref-type="bibr" rid="bib74">Fouquet et al., 2021</xref>; <xref ref-type="fig" rid="fig3">Figure 3C</xref>). However, the effect of TFR2 on EPO sensitivity remains incompletely understood. While studies in cell culture systems suggest that TFR2 increases EPO sensitivity by enhancing cell surface EPOR and downstream signaling (<xref ref-type="bibr" rid="bib73">Forejtnikovà et al., 2010</xref>; <xref ref-type="bibr" rid="bib74">Fouquet et al., 2021</xref>), mice with TFR2 knockout in the bone marrow demonstrate an increase, rather than the predicted decrease, in EPO sensitivity—but only during iron deficiency (<xref ref-type="bibr" rid="bib204">Rishi et al., 2016</xref>). Likewise, iron-deficient mouse chimeras with <italic>Tfr2</italic>-deficient hematopoietic cells demonstrate increased EPO sensitivity, including erythrocytosis and activation of the JAK2-STAT5 and AKT pathways (<xref ref-type="bibr" rid="bib168">Nai et al., 2015</xref>). Mechanisms by which erythroid TFR2 may regulate EPO sensitivity have not been completely delineated. Recent evidence identified a role for TFR2 in modulating surface EPOR delivery in response to iron availability. Specifically, erythroid iron restriction accelerates TFR2 trafficking to the lysosome and enhances catabolism of TFR2-Scribble complexes. The resultant deficiency of Scribble leads to diminished surface delivery of EPOR vesicles and diminished EPO responsiveness (<xref ref-type="bibr" rid="bib123">Khalil et al., 2018</xref>). These findings suggest that manipulating TFR2 catabolism could provide a therapeutic approach to erythropoietic disorders with aberrant EPO responsiveness. We anticipate that the effect of TFR2 on EPO sensitivity depends upon the relative transferrin forms available for binding in the circulation and therefore reflect systemic iron status on erythropoiesis (<xref ref-type="bibr" rid="bib187">Parrow et al., 2019</xref>).</p><p>Recent studies have also implicated loss of ferritin-induced stabilization of the microtubule cytoskeleton as a contributor to the erythroid iron restriction response, possibly explaining the misshapen RBCs, poikilocytes, characteristic of iron deficiency anemia (<xref ref-type="bibr" rid="bib92">Goldfarb et al., 2021</xref>). Finally, evidence points to the importance of transferrin not only in iron delivery for hemoglobin synthesis but in regulation of erythroblast differentiation. As noted above, transferrin can be found in the circulation as holo-transferrin or diferric transferrin, monoferric transferrin, or apo-transferrin. Monoferric transferrins, either monoferric N (monoN) or monoferric C (monoC) lobe transferrin, are the most abundant transferrin moieties in the circulation (<xref ref-type="bibr" rid="bib152">Luck and Mason, 2012</xref>; <xref ref-type="bibr" rid="bib187">Parrow et al., 2019</xref>; <xref ref-type="bibr" rid="bib124">Klausner et al., 1983a</xref>; <xref ref-type="bibr" rid="bib125">Klausner et al., 1983b</xref>; <xref ref-type="bibr" rid="bib109">Iacopetta et al., 1983</xref>; <xref ref-type="bibr" rid="bib46">Dautry-Varsat et al., 1983</xref>; <xref ref-type="bibr" rid="bib244">van Renswoude et al., 1982</xref>). Interestingly, relative distribution of the monoferric transferrin forms varies with iron status, such that the ratio of monoN to monoC transferrin decreases as serum iron falls (<xref ref-type="bibr" rid="bib179">Pagani et al., 2019</xref>; <xref ref-type="bibr" rid="bib194">Porter, 2020</xref>; <xref ref-type="bibr" rid="bib257">Welch, 1992</xref>). To investigate the potential effects of transferrin lobe-specific iron occupancy, mice in which iron-binding was blocked from binding to either the N or the C lobe of transferrin (<xref ref-type="bibr" rid="bib93">Gomme et al., 2005</xref>) were generated. These mice exhibit important differences from each other in both iron metabolism and erythropoiesis. Specifically, monoC-blocked mice predominantly have circulating monoN transferrin and demonstrate enhanced EPO sensitivity and hepcidin responsiveness to iron compared with monoN-blocked mice in which monoC transferrin is predominantly found in the circulation (<xref ref-type="bibr" rid="bib187">Parrow et al., 2019</xref>). Conversely, primary disease states of excess iron are often associated with expanded RBC size and higher cellular hemoglobin concentrations as a functional utilization of iron within a non-toxic compartment (<xref ref-type="bibr" rid="bib163">McLaren et al., 2007</xref>). Taken together, how iron regulates erythropoiesis remains substantially but incompletely understood.</p></sec></sec><sec id="s6"><title>Mechanisms underlying anemia related to iron metabolism</title><p>Although there is a broad range of anemia-causing mechanisms, we will focus in this review on causes related to iron metabolism. In addition to iron deficiency anemia, these foremost include anemia of chronic inflammation (ACI). In addition, iron refractory iron deficiency anemia (IRIDA) is an interesting albeit rare form of IDA discussed here. In a subsequent section below, we will also discuss iron metabolism in the context of ineffective erythropoiesis in iron loading anemias, namely β-thalassemias and MDS.</p><sec id="s6-1"><title>Anemia of chronic inflammation</title><p>ACI is also termed anemia of chronic disease; while iron deficiency results in sometimes severe (i.e. hemoglobin 5–7 g/dL) microcytic, hypochromic anemia, ACI is typically a milder normocytic normochromic hypoproliferative anemia (i.e. hemoglobin 8–10 g/dL) and is considered the second most frequent anemia in the world, after IDA (<xref ref-type="bibr" rid="bib256">Weiss and Goodnough, 2005</xref>). Both present with decreased circulating serum iron concentration and transferrin saturation, but while IDA is characterized by anemia with depleted iron stores (i.e. serum ferritin below the lower limit of normal), iron stores are ample in ACI. In the setting of inflammation, differentiating ACI from iron deficiency anemia may be challenging, and iron deficiency anemia may co-exist with ACI (<xref ref-type="bibr" rid="bib26">Bressman et al., 2021</xref>). ACI is also the most common anemia in hospitalized patients, found in conditions associated with an activated immune response, including chronic infections, autoimmune and inflammatory illnesses and malignancy. The underlying cause of anemia in these diseases is multifactorial, resulting from the effects of inflammatory cytokines, particularly interleukin-1 (IL-1), IL-6, IL-10, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-ɣ), IFN-α, and IFN-β, all or some of which are increased in most inflammatory processes (<xref ref-type="bibr" rid="bib198">Raj, 2009</xref>). Multiple lines of evidence suggest that elevated inflammatory cytokines lead to increased iron sequestration and resultant decreases in iron availability for erythropoiesis and hemoglobin synthesis, directly and indirectly inhibiting erythroid progenitor differentiation, and resulting in a decreased EPO-responsiveness to anemia (<xref ref-type="fig" rid="fig5">Figure 5</xref>). The mechanism resulting in anemia in ACI is similar to that of IDA when iron stores are depleted (due to poor iron absorption alone or insufficiently enhanced in the setting of bleeding) as both conditions lead to decreased iron availability for erythropoiesis. The decreased iron availability may also act in a synergistic manner with the inflammatory cytokines in ACI, potentiating their capacity for direct suppression of erythroblasts (<xref ref-type="bibr" rid="bib203">Richardson et al., 2013</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Effects of inflammation on iron recycling.</title><p>Under normal conditions, iron recycling from multiple sources within macrophages leads to export of iron via ferroportin back into the circulation where it is loaded onto transferrin and delivered to cells with iron requirements (e.g. for hemoglobin synthesis in erythroblasts during erythropoiesis in the bone marrow). Increased hepcidin in states associated with chronic inflammation lead to binding to and occlusion of the ferroportin channel, preventing iron egress from cells involved in iron recycling (e.g. splenic red pulp macrophages), leading to the accumulation of iron within cellular ferritin core, and causing decreased iron-bound transferrin (low transferrin saturation). This decreased availability of iron for erythropoiesis results in anemia of chronic inflammation. Fe, iron; FPN, ferroportin 1; TF, transferrin; Hb, hemoglobin; HP, haptoglobin; HPX, hemopexin; PCBP1, poly(rC)-binding protein 1; NCOA4, nuclear receptor coactivator 4.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90189-fig5-v1.tif"/></fig><p>Previously considered a diagnosis of exclusion, with treatment of ACI mainly focused on the underlying disease, the identification of the peptide hormone hepcidin and its major role in the pathophysiology of ACI have enabled both an enhanced mechanistic understanding and development of novel therapeutics for ACI. Specifically, production of inflammatory cytokines, such as IL-6 and possibly other cytokines, leads to hepcidin-induced hypoferremia, resulting in iron sequestration within the reticuloendothelial system, thereby decreasing iron availability for erythropoiesis (<xref ref-type="fig" rid="fig5">Figure 5</xref>). The term ‘functional iron deficiency’ refers to insufficient iron availability at the site of erythroblast production, despite adequate body iron stores. It typically applies to the high hepcidin state in patients with renal insufficiency. However, broadly speaking, ACI, another high hepcidin condition, can also conceptually be referred to as functional iron deficiency. The teleological argument for the presence of anemia in conditions associated with inflammation is presumed to be related to iron sequestration, providing an evolutionary advantage in light of the iron dependence of pathogens and rapidly replicating cells. Thus, iron sequestration restricts iron availability and serves to limit growth of pathogens and malignant cells at the expense of hemoglobin synthesis. The specifics of iron regulation in infection with intracellular organisms (e.g. <italic>Salmonella</italic> and others) await additional clarification (<xref ref-type="bibr" rid="bib84">Gehrer et al., 2023</xref>).</p><p>Furthermore, a newly emerging theme in inflammation-associated anemias is the contribution of alarmins, bioactive molecules released from damaged tissues or stressed cells. These factors may enter the circulation and engage receptors on target cells to promote anemia development. In models of sepsis, the release of the protein HMGB1 and of mitochondrial DNA act to suppress erythropoiesis and increase RBC turnover, respectively (<xref ref-type="bibr" rid="bib53">Dulmovits et al., 2022</xref>; <xref ref-type="bibr" rid="bib136">Lam et al., 2021</xref>). HMGB1 appears to directly block EPO-EPOR interaction, while mitochondrial DNA binds TLR9 on RBCs to enhance erythrophagocytosis and activate macrophage secretion of interferons. Notably, prior studies have implicated the alarmins S100A8 and S100A9 in the erythroid differentiation defect associated with a specific subclass of MDS, del(5q) (<xref ref-type="bibr" rid="bib213">Schneider et al., 2016</xref>), raising the possibility that these factors may also contribute to inflammation-associated anemia. Finally, IL-33, recognized as both a cytokine and an alarmin, has been identified as a mediator of anemia in a murine model of inflammatory spondyloarthritis, acting directly on erythroid progenitors via its receptor, ST2 (<xref ref-type="bibr" rid="bib230">Swann et al., 2020</xref>). While alarmin- or cytokine-induced anemia may be more directly causally linked to acute inflammation, similar mechanisms may potentially trigger chronically activated propagating loops, exemplified by the feed-forward relationship between erythrophagocytosis and macrophage activation (<xref ref-type="bibr" rid="bib136">Lam et al., 2021</xref>). The role of iron restriction in alarmin-induced anemias remains to be established but is suggested by studies in which hepcidin neutralization or loss in a mouse model of acute inflammation ameliorates anemia (<xref ref-type="bibr" rid="bib210">Sasu et al., 2010</xref>; <xref ref-type="bibr" rid="bib82">Gardenghi et al., 2014</xref>).</p><p>IRIDA is a rare autosomal-recessive disorder caused by mutations in <italic>TMPRSS6</italic> (<italic>transmembrane serine protease 6</italic>) (<xref ref-type="bibr" rid="bib68">Finberg et al., 2008</xref>). <italic>TMPRSS6</italic> is expressed primarily by the liver (<xref ref-type="bibr" rid="bib68">Finberg et al., 2008</xref>; <xref ref-type="bibr" rid="bib107">Hooper et al., 2003</xref>) and encodes matriptase-2, a member of a family of transmembrane serine proteases (<xref ref-type="bibr" rid="bib201">Ramsay et al., 2008</xref>). Matriptase-2 acts as a negative regulator of BMP signaling for hepcidin production by cleaving the BMP co-receptor hemojuvelin from the cell membrane (<xref ref-type="bibr" rid="bib220">Silvestri et al., 2008</xref>), and <italic>TMPRSS6</italic> mutations that impact the matriptase-2 catalytic domain result in impaired hemojuvelin cleavage. More recent evidence reveals that TMPRSS6 also targets other components of the BMP receptor complex by both proteolytic and nonproteolytic mechanisms (<xref ref-type="bibr" rid="bib59">Enns et al., 2020</xref>; <xref ref-type="bibr" rid="bib131">Krijt et al., 2021</xref>). As a consequence, patients with IRIDA exhibit hepcidin levels that are inappropriately elevated relative to their body iron stores.</p><p>Patients with IRIDA present with hypochromic, microcytic anemia (hemoglobin 6–9 g/dL), very low MCV (45–65 fL) and transferrin saturation (&lt;5%), suppressed oral iron absorption, and abnormal iron utilization in response to parenteral iron. Surprisingly, infants with IRIDA demonstrate normal birth weights, normal growth and development, without cognitive concerns on long-term follow-up. Because these patients are generally healthy, anemia diagnosis is made via routine screening conducted in the first few years of life (<xref ref-type="bibr" rid="bib188">Pearson and Lukens, 1999</xref>; <xref ref-type="bibr" rid="bib164">Melis et al., 2008</xref>; <xref ref-type="bibr" rid="bib13">Arsenault et al., 2016</xref>). Close to 50 different <italic>TMPRSS6</italic> mutations have been reported in IRIDA with most variants unique to individual families (<xref ref-type="bibr" rid="bib104">Heeney and Finberg, 2014</xref>), and some evidence suggests linkage between common single-nucleotide polymorphisms in <italic>TMPRSS6</italic> and various hematological and iron-related laboratory parameters (<xref ref-type="bibr" rid="bib21">Benyamin et al., 2009</xref>; <xref ref-type="bibr" rid="bib37">Chambers et al., 2009</xref>; <xref ref-type="bibr" rid="bib77">Ganesh et al., 2009</xref>; <xref ref-type="bibr" rid="bib226">Soranzo et al., 2009</xref>). Taken together, although the pathophysiology underlying IRIDA has been elucidated, a robust understanding of the influence of TMPRSS6 mutations on hepcidin regulation and iron availability and the resultant compensatory mechanisms at various life stages that prevent a greater plethora of symptoms awaits discovery.</p></sec></sec><sec id="s7"><title>What is ineffective erythropoiesis?</title><p>Ineffective erythropoiesis can be defined as the diminished production of enucleated RBCs despite an increase in the number of erythroid precursors (<xref ref-type="fig" rid="fig6">Figure 6</xref>). When the quantity and/or the ability of enucleated RBCs to transport oxygen declines below a certain level, patients require RBC transfusions for survival (<xref ref-type="bibr" rid="bib117">Kattamis et al., 2022</xref>; <xref ref-type="bibr" rid="bib88">Ginzburg and Rivella, 2011</xref>). Ineffective erythropoiesis has been a subject of intensive investigation in β-thalassemia, a disease in which ineffective erythropoiesis manifests with an expanded number of erythroid precursors and their reduced ability to differentiate, an increase in erythroblast death in these terminally differentiated cells, and reduced survival of enucleated RBCs (<xref ref-type="bibr" rid="bib88">Ginzburg and Rivella, 2011</xref>). The proposed underlying mechanism leading to ineffective erythropoiesis in β-thalassemia is the relative excess of alpha-globin chains (EACs) (<xref ref-type="bibr" rid="bib117">Kattamis et al., 2022</xref>; <xref ref-type="bibr" rid="bib88">Ginzburg and Rivella, 2011</xref>). EACs alter erythropoiesis in at least two ways: in complex with free heme molecules, they form hemichromes, which are the main source of oxidative stress and cell death (<xref ref-type="bibr" rid="bib117">Kattamis et al., 2022</xref>). In addition, EACs reduce the stability of GATA1, the main erythroid transcription factor in erythroblasts, interfering with their survival and maturation (<xref ref-type="bibr" rid="bib12">Arlet et al., 2014</xref>). Furthermore, the abnormal and reduced number of RBCs in circulation lead to hypoxia-mediated EPO production, which in turn exacerbates further the expanded number of immature erythroid precursors (<xref ref-type="bibr" rid="bib145">Libani et al., 2008</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Ineffective erythropoiesis.</title><p>Under normal conditions, small numbers of differentiating erythroblasts are needed to efficiently differentiate and enucleate to reticulocytes and ultimately mature red blood cells (erythrocytes). In conditions associated with ineffective erythropoiesis (e.g. β-thalassemia, myelodysplastic syndrome, and others), a block in erythroblast differentiation leads to the accumulation of immature erythroblasts, preventing efficient production of erythrocytes, resulting in anemia.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90189-fig6-v1.tif"/></fig><p>Expansion in the number of erythroid precursors leads to increased ERFE production and consequent hepcidin suppression (<xref ref-type="bibr" rid="bib118">Kautz et al., 2014</xref>). Hypoxia also plays a role by increasing expression of genes responsible for iron absorption in the duodenum (<xref ref-type="bibr" rid="bib7">Anderson et al., 2013</xref>). Although in severely affected patients organ iron overload develops because of frequent RBC transfusions, in individuals with β-thalassemia who are not regularly transfused, the mechanisms responsible for increased iron absorption (i.e. insufficiently elevated hepcidin expression), along with chronic hemolysis, lead to progressive tissue iron deposition and toxicity, requiring even in these cases the use of iron chelators to prevent significant morbidity and mortality (<xref ref-type="bibr" rid="bib117">Kattamis et al., 2022</xref>; <xref ref-type="bibr" rid="bib167">Musallam et al., 2021</xref>).</p><p>Novel drugs and genetic approaches are now being translated to improve the quality of life in β-thalassemia (and other) patients or even cure them. Although a full description of these therapeutics is beyond the scope of the current review, these drugs can be broadly classified based on their mechanism of action as shown in <xref ref-type="table" rid="table1">Table 1</xref>. Among these, only gene therapy provides a curative approach. However, the risks remain high and alternative therapeutic options are welcome for those patients who are ineligible for cure. Drugs that act on iron metabolism (e.g. hepcidin-mimetics and transferrin) could also improve RBC quality and survival by limiting erythroid iron intake and hemichromes formation, as shown in mouse models of β-thalassemia (<xref ref-type="bibr" rid="bib142">Li et al., 2010</xref>; <xref ref-type="bibr" rid="bib98">Guo et al., 2013</xref>). However, even these drugs may fail to do so in β-thalassemia patients, their use could reduce iron absorption in combination with iron chelators if the patient is already iron overloaded. In addition, they could prevent iron from being accumulated in combination with drugs that improve RBC quality and production (e.g. luspatercept, mitapivat, and TFR2 inhibitors).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Novel agents in development for β-thalassemia (and other) patients.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Mechanism of action</th><th align="left" valign="bottom">Agent name</th><th align="left" valign="bottom">Producer</th><th align="left" valign="bottom">Stage of development</th><th align="left" valign="bottom">Reference</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="3">Improve RBC quality and production</td><td align="left" valign="bottom">Luspatercept</td><td align="left" valign="bottom">BMS</td><td align="left" valign="bottom">FDA approved for TD β-thalassemia and MDS-RS</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Cappellini et al., 2023</xref></td></tr><tr><td align="left" valign="bottom">Mitapivat</td><td align="left" valign="bottom">Agios</td><td align="left" valign="bottom">FDA approved for PKD; in phase II clinical trial for NTD α- and β-thalassemia patients</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib134">Kuo et al., 2022</xref></td></tr><tr><td align="left" valign="bottom">TFR2 inhibitors</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Preclinical</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib48">Di Modica et al., 2022</xref></td></tr><tr><td align="left" valign="bottom" rowspan="2">Gene therapy to normalize the underlying genetic defect</td><td align="left" valign="bottom">Gene addition</td><td align="left" valign="bottom" rowspan="2"/><td align="left" valign="bottom" rowspan="2"/><td align="left" valign="bottom" rowspan="2"><xref ref-type="bibr" rid="bib55">Eckrich and Frangoul, 2023</xref>; <xref ref-type="bibr" rid="bib43">Christakopoulos et al., 2023</xref></td></tr><tr><td align="left" valign="bottom">Gene editing</td></tr><tr><td align="left" valign="bottom">Suppress erythropoiesis and prevent or reverse splenomegaly</td><td align="left" valign="bottom">JAK2 inhibitors</td><td align="left" valign="bottom">Novartis</td><td align="left" valign="bottom">Phase IIa (failed)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib231">Taher et al., 2018</xref></td></tr><tr><td align="left" valign="bottom">Alter iron import</td><td align="left" valign="bottom">Transferrin</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Preclinical</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib25">Boshuizen et al., 2017</xref></td></tr><tr><td align="left" valign="bottom" rowspan="5">Limit iron absorption</td><td align="left" valign="bottom">Hepcidin agonist rusfertide</td><td align="left" valign="bottom">Protagonist</td><td align="left" valign="bottom">Currently in phase II and III clinical trials for PV patients</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib102">Handa et al., 2023</xref></td></tr><tr><td align="left" valign="bottom">Hepcidin inducer sapablursen</td><td align="left" valign="bottom">Ionis</td><td align="left" valign="bottom">Currently in phase II clinical trials for PV patients</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib79">Ganz et al., 2023</xref></td></tr><tr><td align="left" valign="bottom">Ferroportin inhibitor Vamifeport</td><td align="left" valign="bottom">Vifor</td><td align="left" valign="bottom">Currently in phase II clinical trials for SCD patients</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib177">Nyffenegger et al., 2022</xref></td></tr><tr><td align="left" valign="bottom">SLN124</td><td align="left" valign="bottom">Silence</td><td align="left" valign="bottom">Currently in phase I clinical trial for β-thalassemia and PV patients</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">ERFE inhibitors</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Preclinical</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib11">Arezes et al., 2020</xref></td></tr></tbody></table><table-wrap-foot><fn><p>RBC, red blood cell; BMS, Bristol Myers Squibb; FDA, Food and Drug Administration; TD, transfusion dependent; MDS-RS, myelodysplastic syndrome with ringed sideroblasts; PKD, pyruvate kinase deficiency; NTD, non-transfusion dependent; TFR2, transferrin receptor 2; SCD, sickle cell disease; ERFE, erythroferrone.</p></fn></table-wrap-foot></table-wrap><p>Beyond the inherited forms of iron-loading anemias, that is, β-thalassemia, MDS is an acquired form of ineffective erythropoiesis associated with iron overload. MDS is a heterogeneous group of bone marrow stem cell disorders; several subtypes of MDS are characterized by ineffective erythropoiesis, leading to blood cytopenias and increased incidence of transformation to acute myeloid leukemia (<xref ref-type="bibr" rid="bib100">Haferlach, 2019</xref>). The majority of MDS patients have a long median survival (e.g. 10 y), with 30–50% requiring only regular RBC transfusions to alleviate anemia and its associated symptoms (<xref ref-type="bibr" rid="bib47">Dayyani et al., 2010</xref>; <xref ref-type="bibr" rid="bib132">Kröger, 2019</xref>). RBC transfusions, however, are the main cause of progressive iron overload and consequent end-organ damage in transfusion-dependent MDS patients (<xref ref-type="bibr" rid="bib178">Oliva et al., 2010</xref>). However, the risk–benefit ratio of treating iron overload in MDS patients remains controversial. Furthermore, RBC transfusion-dependence and iron overload correlate strongly with decreased survival in MDS patients (<xref ref-type="bibr" rid="bib153">Malcovati et al., 2005</xref>; <xref ref-type="bibr" rid="bib154">Malcovati et al., 2006</xref>; <xref ref-type="bibr" rid="bib80">Garcia-Manero et al., 2008</xref>; <xref ref-type="bibr" rid="bib155">Malcovati et al., 2011</xref>). In vitro experiments demonstrate that excess iron inhibits erythroid lineage differentiation in both murine and human hematopoietic progenitors, exhibiting dysplastic changes with increased intracellular reactive oxygen species (ROS), decreased expression of anti-apoptotic genes, and DNA damage, triggering apoptosis, and worsening disease in MDS (<xref ref-type="bibr" rid="bib184">Pan et al., 1999</xref>; <xref ref-type="bibr" rid="bib29">Camaschella et al., 2007</xref>; <xref ref-type="bibr" rid="bib66">Fibach and Rachmilewitz, 2012</xref>; <xref ref-type="bibr" rid="bib236">Taoka et al., 2012</xref>; <xref ref-type="bibr" rid="bib103">Hartmann et al., 2013</xref>).</p><p>The TELESTO trial was designed and executed to test whether iron chelation provides clinical benefit in iron-overloaded lower risk MDS patients (<xref ref-type="bibr" rid="bib9">Angelucci et al., 2020</xref>). The results demonstrate prolonged event-free survival in deferasirox-treated MDS patients without clear improvement in hemoglobin, reduction of RBC transfusion burden, or effect on overall survival. We hypothesize, based on evidence from mutant monoferric mice (see above), that the lack of effect of deferasirox on erythropoiesis is a consequence of the specific iron chelator selected. Deferasirox and most other commercially available iron chelators have a higher iron binding affinity relative to transferrin (<xref ref-type="bibr" rid="bib221">Sohn et al., 2008</xref>); only deferiprone iron-chelating effect enables iron transfer from parenchymal cells to increased transferrin saturation (<xref ref-type="bibr" rid="bib212">Schmidt et al., 2015</xref>; <xref ref-type="bibr" rid="bib33">Casu et al., 2016a</xref>), potentially modulating monoferric transferrin concentrations. Furthermore, increasing transferrin saturation itself results in increased hepcidin expression in the liver (<xref ref-type="bibr" rid="bib212">Schmidt et al., 2015</xref>; <xref ref-type="bibr" rid="bib34">Casu et al., 2016b</xref>), in turn preventing further iron absorption and recycling, trapping iron within macrophages (<xref ref-type="bibr" rid="bib78">Ganz, 2005</xref>), and decreasing iron availability for erythropoiesis to potentially ameliorate ineffective erythropoiesis in MDS. A direct beneficial effect of DFP on erythropoiesis in MDS has yet to be demonstrated. Recent data demonstrates partial reversal of ineffective erythropoiesis in addition to iron overload, normalizing erythroblast iron trafficking and restoring EPO responsiveness in deferiprone-treated mouse model of MDS, NUP98-HOXD13 transgenic mice (<xref ref-type="bibr" rid="bib6">An et al., 2022</xref>).</p><p>In addition, a specific subtype of low-risk MDS, namely MDS with ringed sideroblasts, occurs in 20% of all MDS patients. Splicing factor 3 B subunit 1 (<italic>SF3B1</italic>) mutations in hematopoietic stem and progenitor cells is a hallmark of this disease, inducing aberrant splicing of genes involved in heme biosynthesis and mitochondrial iron transport, leading to the abnormal deposition of iron in erythroblasts, and resulting in dysfunctional hemoglobin synthesis and formation of ringed sideroblasts (<xref ref-type="bibr" rid="bib247">Visconte et al., 2015</xref>; <xref ref-type="bibr" rid="bib49">Dolatshad et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Dolatshad et al., 2016</xref>; <xref ref-type="bibr" rid="bib218">Shiozawa et al., 2018</xref>; <xref ref-type="bibr" rid="bib44">Clough et al., 2022</xref>). Although preclinical data in mouse models predicted a therapeutic effect of splicing inhibition, a recent phase I clinical trial did not yield significant clinical improvement (<xref ref-type="bibr" rid="bib139">Lee et al., 2016</xref>; <xref ref-type="bibr" rid="bib227">Steensma et al., 2021</xref>). Growing evidence suggests that the heme-regulated EIF2AK1 kinase pathway affects erythropoiesis in health and disease. For example, EIF2AK1 effector DDIT3 is overexpressed in MDS hematopoietic stem and progenitor cells (<xref ref-type="bibr" rid="bib22">Berastegui et al., 2021</xref>), DDIT3 overexpression delays erythroid differentiation in CD34-positive cells from MDS patients, and EIF2AK1 inhibition increases expression of both mitochondrial heme biosynthesis enzymes and iron transporters, reversing <italic>SF3B1</italic> mutation-induced arrest of erythroid differentiation in vitro (<xref ref-type="bibr" rid="bib1">Adema et al., 2022</xref>).</p><p>Lastly, novel therapy has recently been US Food and Drug Administration (FDA) and European Medicines Agency (EMA)-approved for very low- to intermediate-risk MDS with ringed sideroblasts. Luspatercept is a modified activin receptor IIB ligand trap, a member of the transforming growth factor-β (TGF-β) superfamily. While this agent was studied in multiple different MDS subgroups of patients in a phase II trial, its efficacy was most robust in patients with MDS with ringed sideroblasts (<xref ref-type="bibr" rid="bib192">Platzbecker et al., 2017</xref>) and led to the phase III MEDALIST trial, a double-blind, placebo-controlled, multicenter study in transfusion requiring patients with MDS with ringed sideroblasts (<xref ref-type="bibr" rid="bib64">Fenaux et al., 2018</xref>). In the MEDALIST trial, luspatercept led to transfusion independence for &gt;8 wk in 45% of enrolled subjects and median duration of response was 6 mo (<xref ref-type="bibr" rid="bib62">Farrukh et al., 2022</xref>). To consider how MDS with ringed sideroblasts is unique, prior evidence demonstrates that these patients exhibit iron overload prior to the initiation of RBC transfusion (<xref ref-type="bibr" rid="bib83">Gattermann, 2005</xref>) likely as a consequence of especially suppressed hepcidin relative to other MDS subtypes (<xref ref-type="bibr" rid="bib96">Gu et al., 2013</xref>; <xref ref-type="bibr" rid="bib209">Santini et al., 2011</xref>) and <italic>HFE</italic> gene polymorphisms that predispose to iron overload are detected in up to 21% of MDS with ringed sideroblasts, significantly higher than in other MDS subtypes (<xref ref-type="bibr" rid="bib169">Nearman et al., 2007</xref>; <xref ref-type="bibr" rid="bib243">Valent et al., 2008</xref>). A more complete understanding of how the formation of ringed sideroblasts in MDS contributes to worsening ineffective erythropoiesis is currently lacking. Taken together, these recent findings provide supporting evidence for dysregulated iron trafficking in the pathophysiology of ineffective erythropoiesis in MDS.</p></sec><sec id="s8"><title>Iron metabolism dysregulation in polycythemia vera</title><p>Polycythemia vera (PV), one of the chronic myeloproliferative neoplasms, is a clonal hematopoietic stem cell disorder driven by EPO hypersensitive signaling via the JAK2-STAT5 pathway, resulting in excess proliferation of erythroid precursors (<xref ref-type="bibr" rid="bib200">Rampal et al., 2014</xref>; <xref ref-type="bibr" rid="bib141">Levine et al., 2005</xref>; <xref ref-type="bibr" rid="bib18">Baxter et al., 2005</xref>; <xref ref-type="bibr" rid="bib129">Kralovics et al., 2005</xref>; <xref ref-type="bibr" rid="bib111">James et al., 2005</xref>; <xref ref-type="bibr" rid="bib151">Lu et al., 2008</xref>; <xref ref-type="bibr" rid="bib2">Akada et al., 2010</xref>). The vast majority of PV patients are the result of acquired <italic>JAK2</italic> mutations in their stem cells, namely <italic>JAK2</italic>V617F on exon 14 (95% of PV patients) or mutations in exon 12 of the <italic>JAK2</italic> gene (2–3% of PV patients) (<xref ref-type="bibr" rid="bib185">Pardanani et al., 2007</xref>; <xref ref-type="bibr" rid="bib216">Scott et al., 2007</xref>). PV patients are frequently iron deficient at the time of diagnosis (<xref ref-type="bibr" rid="bib85">Gianelli et al., 2008</xref>; <xref ref-type="bibr" rid="bib238">Thiele et al., 2001</xref>; <xref ref-type="bibr" rid="bib135">Kwapisz et al., 2009</xref>), and this is further exacerbated by therapeutic phlebotomies administered with the goal of maintaining hematocrit below 45% to decrease thrombotic risk (<xref ref-type="bibr" rid="bib160">Marchioli et al., 2013</xref>). Repeated phlebotomies may in part dampen erythropoiesis by inducing iron deficiency but also potentially contribute to PV-associated systemic symptoms due to the depletion of iron stores in non-hematopoietic tissues (<xref ref-type="bibr" rid="bib195">Pratt and Khan, 2016</xref>). Recent analysis of PV patients treated with ruxolitinib, a JAK1/2 inhibitor, corroborates the role of iron deficiency in the manifestations of this disease as symptom improvement with ruxolitinib is at least partly attributable to reversal of systemic iron deficiency (<xref ref-type="bibr" rid="bib245">Verstovsek et al., 2017</xref>).</p><p>We previously demonstrate that PV, compared to secondary forms of erythrocytosis, is associated with relative suppression of hepcidin, potentially due to more expanded erythropoiesis and iron depletion (<xref ref-type="bibr" rid="bib89">Ginzburg et al., 2018</xref>). In addition, PV patients experience erythrocytosis despite a more profound iron deficiency relative to healthy blood donors (<xref ref-type="bibr" rid="bib65">Feola et al., 2019</xref>; <xref ref-type="bibr" rid="bib228">Stetka et al., 2023</xref>). This is evidenced by significantly lower MCVs, serum iron and ferritin concentrations, and transferrin saturation; this systemic iron deficiency in PV patients does not resolve despite elevated ERFE with consequent hepcidin suppression. Hepcidin suppression would be expected to result in enhanced intestinal iron absorption and mobilization of intracellular recycled and stored iron, leading to cellular iron efflux, more circulating iron, and recovery from systemic iron deficiency. However, recovery from iron deficiency does not occur in PV, where a low hepcidin state is insufficient to replenish iron stores, implying dysregulated iron homeostasis.</p><p>We hypothesize that relative hepcidin suppression without recovery from iron deficiency in PV may result from the combined effects of concurrent inflammation, insufficiently elevated ERFE with insufficiently suppressed hepcidin, and/or aberrant hypoxia signaling in the intestine preventing recovery from iron deficiency (<xref ref-type="bibr" rid="bib171">Nemeth and Ganz, 2014</xref>; <xref ref-type="bibr" rid="bib75">Frise et al., 2016</xref>; <xref ref-type="bibr" rid="bib217">Shah et al., 2009</xref>). A recent report suggests that ERFE exerts a relatively diminished effect on hepcidin regulation relative to that of inflammation in PV patients (<xref ref-type="bibr" rid="bib20">Bennett et al., 2023</xref>). In this study, <italic>Erfe</italic> deletion in <italic>Jak2</italic><sup>V617F</sup> mice did not alter hepcidin levels or disease severity, resulting in stably elevated hematocrits and RBC counts. Using a human hepatocyte cell line, HepG2 cells, the authors further explored the hypothesis that PV-associated inflammation leads to hepcidin upregulation, demonstrating that the increased hepcidin expression was induced by plasma from PV patients but not plasma from normal controls and was normalized by blocking IL-6 binding to its receptor (<xref ref-type="bibr" rid="bib20">Bennett et al., 2023</xref>). These findings suggest that inflammatory cytokines in PV may be crucial to disordered iron utilization. In addition, persistent erythropoiesis despite iron deficiency in PV may also occur as a consequence of aberrant erythropoiesis that is insensitive to iron deficiency, preventing physiological mechanisms that normally coordinate iron supply with erythropoietic output (<xref ref-type="bibr" rid="bib122">Khalil et al., 2017</xref>; <xref ref-type="bibr" rid="bib123">Khalil et al., 2018</xref>; <xref ref-type="bibr" rid="bib65">Feola et al., 2019</xref>). An excellent review on dysregulated iron metabolism in PV was recently published (<xref ref-type="bibr" rid="bib89">Ginzburg et al., 2018</xref>).</p><p>To elucidate briefly, suboptimally suppressed hepcidin prevents recovery from iron deficiency, enables absorption of iron to maintain pathologically enhanced erythropoiesis, and provides a rationale for maximizing this finding for therapeutic purposes in PV. Said another way, although we do not yet understand the pathophysiological mechanism that enables persistent erythropoiesis in PV despite iron deficiency, we anticipate that using hepcidin mimetics to further suppress iron absorption and recycling may prevent erythropoiesis in PV, redistributing iron to non-hematopoietic cells and possibly reversing iron deficiency associated symptoms in PV patients.</p><p>Lastly, significant advances in the translation of hepcidin mimetics in PV are worth noting. Our understanding about hepcidin’s mechanism of action predicts that hepcidin elevation would be expected to sequester recycled and stored iron and prevent iron absorption, resulting in reduced iron availability for erythropoiesis and replenishing iron stores within liver and splenic macrophages, thus aiding in recovery from systemic iron deficiency (<xref ref-type="bibr" rid="bib35">Casu et al., 2018</xref>, <xref ref-type="bibr" rid="bib14">Aschemeyer et al., 2018</xref>; <xref ref-type="bibr" rid="bib89">Ginzburg et al., 2018</xref>; <xref ref-type="bibr" rid="bib90">Ginzburg, 2019</xref>; <xref ref-type="fig" rid="fig7">Figure 7</xref>). Preclinical studies demonstrated proof of principle for this approach using minihepcidins, engineered peptides with the necessary functional ferroportin binding domain (<xref ref-type="bibr" rid="bib196">Preza et al., 2011</xref>), resulting in a significant dose-dependent decrease in RBC count, hematocrit, and splenomegaly in <italic>Jak2</italic><sup>V617F</sup> mice, a well-established mouse model of PV (<xref ref-type="bibr" rid="bib34">Casu et al., 2016b</xref>). In addition, minihepcidin results in increased iron in the splenic red pulp of <italic>Jak2</italic><sup>V617F</sup> mice, consistent with sequestration of recycled iron. More recently, another hepcidin mimetic agent—antisense oligonucleotide targeting TMPRSS6, leading to the downregulation of TMPRSS6 gene product that prevents the degradation of HJV, yielding an increase in endogenous hepcidin expression in the liver—used in <italic>Jak2</italic><sup>V617F</sup> mice also resulted in decreased RBC counts and hematocrit levels as well as suppression of bone marrow erythroblast numbers (<xref ref-type="bibr" rid="bib36">Casu et al., 2021</xref>). Similar findings were also recently demonstrated using a parenteral synthetic hepcidin (<xref ref-type="bibr" rid="bib237">Taranath et al., 2021</xref>) and an orally bioavailable ferroportin inhibitor (<xref ref-type="bibr" rid="bib228">Stetka et al., 2023</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Effects of hepcidin-mimetic on erythropoiesis in polycythemia vera.</title><p>Similar to normal erythropoiesis, in polycythemia vera, iron recycling from multiple sources within macrophages leads to export of iron via ferroportin back into the circulation where it is loaded onto transferrin and delivered to cells with iron requirements (e.g. for hemoglobin synthesis in erythroblasts during erythropoiesis in the bone marrow). Unlike normal erythropoiesis, erythropoiesis proceeds despite iron deficiency and hepcidin remains low, enabling continued iron release into the circulation to support continued erythropoiesis. Increased hepcidin leads to binding to and occlusion of the ferroportin channel, preventing iron egress from cells involved in iron recycling (e.g. splenic red pulp macrophages), leading to the accumulation of iron within cellular ferritin core, and causing decreased iron-bound transferrin (low transferrin saturation). This decreased availability of iron for erythropoiesis results in reduction of erythrocytosis in polycythemia Vera. RBC, red blood cell; Fe, iron; TF, transferrin; FPN, ferroportin 1.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90189-fig7-v1.tif"/></fig><p>Most recently, preliminary results from phase II clinical trials evaluating the safety and efficacy of hepcidin mimetic rusfertide (PTG-300) in phlebotomy-requiring PV patients demonstrate a virtual elimination of phlebotomy requirements, control of RBC count, increase in systemic iron stores, and a potential decrease in systemic symptoms (<xref ref-type="bibr" rid="bib105">Hoffman, 2021</xref>; <xref ref-type="bibr" rid="bib106">Hoffman et al., 2022</xref>; <xref ref-type="bibr" rid="bib91">Ginzburg et al., 2021</xref>). A dramatic reduction in phlebotomy requirements, with 84% of PV subjects achieving phlebotomy-independence, was observed in the first 28 wk of treatment, and hematocrit control was sustained for up to 2 y on study drug. Several other hepcidin-inducing agents are either enrolling PV patients to a phase II clinical trial (NCT05143957) or in planning stages, and the global, multicenter, randomized, placebo-controlled phase III trial (NCT05210790) is currently underway (<xref ref-type="bibr" rid="bib246">Verstovsek et al., 2021</xref>) to further clarify the potential role of rusfertide in the management of patients with PV.</p></sec><sec id="s9"><title>What role do macrophages play in supporting normal and disordered erythropoiesis?</title><p>Erythropoiesis occurs at the erythroblastic island (EBI) that is composed of a central macrophage surrounded by developing erythroid cells (<xref ref-type="bibr" rid="bib23">Bessis, 1958</xref>) and granulocyte progenitors (<xref ref-type="bibr" rid="bib206">Romano et al., 2022</xref>). The functional role of EBI was first suggested by Mohandas and colleague, who showed that in hyper-transfused rats, the numbers of EBI in the bone marrow were significantly decreased (<xref ref-type="bibr" rid="bib165">Mohandas and Prenant, 1978</xref>). The importance of the central macrophage in supporting normal erythropoiesis was further supported by the abnormal macrophage differentiation in EMP-null (<xref ref-type="bibr" rid="bib255">Wei et al., 2019</xref>; <xref ref-type="bibr" rid="bib222">Soni et al., 2006</xref>), KLF1-null (<xref ref-type="bibr" rid="bib166">Mukherjee et al., 2021</xref>; <xref ref-type="bibr" rid="bib193">Porcu et al., 2011</xref>), and other mouse models (<xref ref-type="bibr" rid="bib42">Chow et al., 2013</xref>; <xref ref-type="bibr" rid="bib208">Sadahira et al., 1995</xref>; <xref ref-type="bibr" rid="bib120">Kawane et al., 2001</xref>; <xref ref-type="bibr" rid="bib159">Mankelow et al., 2004</xref>), leading to significantly impaired erythropoiesis and anemia. Furthermore, the depletion of macrophages with either clodronate liposomes or CD169-diptheria toxin leading to impaired erythropoiesis provide direct evidence that macrophages play critical roles in supporting erythropoiesis in vivo, particularly during stress erythropoiesis (<xref ref-type="bibr" rid="bib42">Chow et al., 2013</xref>; <xref ref-type="bibr" rid="bib199">Ramos et al., 2013</xref>). In vitro studies showed that macrophages promoted erythroblast proliferation/survival (<xref ref-type="bibr" rid="bib202">Rhodes et al., 2008</xref>; <xref ref-type="bibr" rid="bib150">Lopez-Yrigoyen et al., 2019</xref>; <xref ref-type="bibr" rid="bib189">Perron-Deshaies et al., 2020</xref>). It has been reported that fetal liver macrophages can efficiently engulf extruded nuclei in a phosphotidylserine-dependent manner (<xref ref-type="bibr" rid="bib262">Yoshida et al., 2005</xref>) and that failing to degrade the engulfed DNA by macrophages due to lack of DNAase II led to severe anemia and embryonic death (<xref ref-type="bibr" rid="bib208">Sadahira et al., 1995</xref>). Notably, in both <italic>Jak2</italic><sup>V617F</sup> (PV mouse model) and <italic>Hbb</italic><sup>3/+</sup> (transfusion independent β-thalassemia mouse model) mice, macrophage depletion normalized erythropoiesis (<xref ref-type="bibr" rid="bib199">Ramos et al., 2013</xref>). Together, these findings indicate that macrophages play important roles in supporting normal erythropoiesis and can be targeted to at least partly ameliorate the disordered erythropoiesis in PV and β-thalassemia. However, due to the inability to identify and isolate EBI macrophages for cellular and molecular studies, the mechanisms by which EBI macrophages support normal erythropoiesis or contribute to disordered erythropoiesis have not been fully interrogated. We recently discovered that EBI macrophages are characterized by the expression of EPOR (<xref ref-type="bibr" rid="bib144">Li et al., 2019</xref>; <xref ref-type="bibr" rid="bib267">Zhang et al., 2021</xref>) and that EPO enhanced the ability of macrophages to form EBIs with erythroblasts both in vitro and in vivo (<xref ref-type="bibr" rid="bib144">Li et al., 2019</xref>). Supporting the functional role of EPO/EPOR in EBI macrophages, others also documented that Epo/EpoR signaling in macrophages is required for stress erythropoiesis in the spleen (<xref ref-type="bibr" rid="bib40">Chen et al., 2020</xref>). In addition, fine characterization of EBIs indicates neutrophil precursors specifically associated with BM EBI macrophages, suggesting that erythro-(myelo)-blastic islands are a site for terminal granulopoiesis and erythropoiesis (<xref ref-type="bibr" rid="bib206">Romano et al., 2022</xref>). Finally, the relative proportion of granulocytes within EBIs increases during inflammatory conditions and decreases during stress erythropoiesis, suggestive of a functional plasticity of the central macrophage within the EBIs (<xref ref-type="bibr" rid="bib206">Romano et al., 2022</xref>).</p><p>To develop a comprehensive characterization of the EBI macrophages at the molecular level and gain insights into the mechanisms by which they support erythropoiesis, we performed RNA-seq analyses on the sorted bone marrow F4/80<sup>+</sup>EpoR<sup>+</sup> and F4/80<sup>+</sup>EpoR<sup>-</sup> macrophages (<xref ref-type="bibr" rid="bib144">Li et al., 2019</xref>). Bioinformatics analyses revealed that the expression levels of <italic>Vcam1</italic> and <italic>CD169</italic> known to be involved in macrophage–erythroblast interaction (<xref ref-type="bibr" rid="bib42">Chow et al., 2013</xref>; <xref ref-type="bibr" rid="bib208">Sadahira et al., 1995</xref>) were significantly higher in F480<sup>+</sup>EpoR<sup>+</sup> than in F480<sup>+</sup>EpoR<sup>-</sup> macrophages. Similarly, the expression levels of <italic>Mertk</italic> required for pyrenocyte engulfment (<xref ref-type="bibr" rid="bib239">Toda et al., 2014</xref>), and DNase2α (<italic>DNAse2</italic>) critical for DNA degradation of the engulfed nuclei (<xref ref-type="bibr" rid="bib120">Kawane et al., 2001</xref>), were also significantly higher in the F480<sup>+</sup>EpoR<sup>+</sup> macrophages. Intriguingly, key molecules involved in iron recycling such as phosphotidylserine receptor Tim4, heme oxygenase-1, iron exporter ferroportin, and iron transporter transferrin are also abundantly expressed in bone marrow F4/80<sup>+</sup>EpoR<sup>+</sup> macrophages. In addition, insulin growth factor 1, one of the known erythropoiesis-promoting cytokines, is expressed in EBI macrophages but not non-EBI macrophages. These findings provide support for the long-standing expectation that EBI macrophages are unique in providing essential elements to enable differentiation of the surrounding erythroblasts. Further evidence is forthcoming regarding the mechanistic nature of the support EBI macrophages provide to differentiating erythroblasts.</p></sec><sec id="s10"><title>Tools and analytic endpoints for studying erythropoiesis and iron metabolism</title><p>To study erythropoiesis, it is important to identify and isolate erythroid lineage cells at distinct stages of differentiation. During the past decade, considerable progress has been made, and methods for analyzing and isolating murine and human erythroblasts at distinct developmental stages have been developed. Here, we summarize these methods.</p><sec id="s10-1"><title>Isolation of murine erythroid progenitors</title><p>Traditionally, the erythroid progenitors BFU-E and CFU-E have been functionally defined by their ability to form erythroid colonies of distinct kinetics and morphology (<xref ref-type="bibr" rid="bib110">Iscove and Sieber, 1975</xref>; <xref ref-type="bibr" rid="bib94">Gregory and Eaves, 1977</xref>). It should be pointed out that the erythroid colonies contain terminally differentiated erythroid cells and not the BFU-E and CFU-E cells themselves. With the development of flow technology for analysis and sorting of cells using lineage-specific surface markers, a flow cytometry-based method was developed to isolate erythroid progenitors from mouse fetal liver (<xref ref-type="bibr" rid="bib72">Flygare et al., 2011</xref>). Briefly, the fetal liver lineage<sup>+</sup> cells were depleted by antibodies against murine Ter119, B220, CD3, Gr-1, CD41, Sca-1, CD34, Mac-1, and CD16/CD32. The resulting lineage<sup>-</sup> cells were stained with CD117 (c-Kit) and CD71. Within the Kit<sup>+</sup> fraction, the level of CD71 expression was used to separate BFU-E (CD71<sup>10%low</sup>) and CFU-E (CD71<sup>20%high</sup>) with more than 90% purity (<xref ref-type="bibr" rid="bib72">Flygare et al., 2011</xref>). A similar strategy can be used to isolate murine bone marrow erythroid progenitors, but unlike fetal liver BFU-E, the bone marrow BFU-E cells are Kit<sup>+</sup>CD71<sup>-</sup> (<xref ref-type="bibr" rid="bib267">Zhang et al., 2021</xref>).</p></sec><sec id="s10-2"><title>Isolation of human erythroid progenitors</title><p>To identify the surface markers for human BFU-E and CFU-E, we systematically examined the expression of surface markers CD34, IL-3R, CD36, CD71, CD45, and GPA during human early stage erythropoiesis in vitro. Based on the expression profiles of these surface markers and the related colony-forming ability, the surface marker profiles for human BFU-E and CFU-E are CD45<sup>+</sup>GPA<sup>-</sup>IL-3R<sup>-</sup>CD34<sup>+</sup>CD36<sup>-</sup>CD71<sup>low</sup> and CD45<sup>+</sup>GPA<sup>-</sup>IL-3R<sup>-</sup>CD34<sup>-</sup>CD36<sup>+</sup>CD71<sup>high</sup>, respectively (<xref ref-type="bibr" rid="bib143">Li et al., 2014</xref>). Importantly, this method can be used to isolate primary BFU-E and CFU-E cells from human bone marrow, umbilical cord blood, and peripheral blood (<xref ref-type="bibr" rid="bib143">Li et al., 2014</xref>). A recent study documented that early human erythroid progenitors can be further subdivided into four subpopulations as they lose CD34 staining and acquire CD105 during progression from BFU-E to immature CFU-E and sequentially mature CFU-Es (<xref ref-type="bibr" rid="bib261">Yan et al., 2021</xref>).</p></sec><sec id="s10-3"><title>Isolation and quantification of murine erythroblasts terminal differentiation</title><p>To identify surface markers for isolating murine erythroblasts, we examined the changes in RBC membrane proteins during murine terminal erythroid differentiation and found that the expression of CD44 dramatically decreased during erythroid differentiation, with more than a 30-fold decrease from Pro to Ortho erythroblasts. Use of CD44 in conjunction with erythroid lineage marker TER119 and forward scatter (cell size) enabled stage-specific purification of murine erythroblasts with more than 90% purity (<xref ref-type="bibr" rid="bib39">Chen et al., 2009</xref>). Under physiological conditions, murine Pro undergo three rounds of mitosis to sequentially generate Baso, Poly, and Ortho erythroblasts. It is therefore expected that during normal terminal erythroid differentiation the ratio of Pro:Baso:Poly:Ortho should follow a 1:2:4:8 pattern. We further improved this method, enabling quantification of this process in vivo, and identified stage-specific alterations during terminal erythroid differentiation of β-thalassemia mouse bone marrow (<xref ref-type="bibr" rid="bib148">Liu et al., 2013</xref>).</p></sec><sec id="s10-4"><title>Isolation and quantification of human erythroblasts during terminal differentiation</title><p>To identify surface markers for staging human erythroblasts, we examined changes in surface markers during human terminal erythroid differentiation in vitro. Notably, different from mouse, CD44 demonstrates no significant changes during terminal erythropoiesis. Interestingly, while cell surface band 3 progressively increases, α4 integrin decreases. The use of band 3 and α4 integrin in conjunction with the human erythroid lineage marker glycophorin A enabled separation of highly purified populations of erythroblasts at distinct stages in culture, designated as Pro (α4 integrin<sup>hi</sup>band3<sup>neg</sup>), early Baso (α4 integrin<sup>hi</sup>band3<sup>low</sup>), late Baso (α4 integrin<sup>hi</sup>band 3<sup>med</sup>), Poly (α4 integrin<sup>med</sup>band3<sup>med</sup>), and Ortho (α4 integrin<sup>low</sup>band 3<sup>hi</sup>) erythroblasts (<xref ref-type="bibr" rid="bib108">Hu et al., 2013</xref>). Importantly, the surface markers identified using the in vitro erythroid culture system can be used to separate erythroblasts at distinct developmental stages from primary human bone marrow cells. Furthermore, the ratio of erythroblasts at successive stage in human bone marrow followed the predicted 1:2:4:8:16 pattern. Analyses of bone marrow from patients with MDS and sickle cell disease revealed the expected alteration in terminal erythroid differentiation profiles (<xref ref-type="bibr" rid="bib108">Hu et al., 2013</xref>; <xref ref-type="bibr" rid="bib3">Ali et al., 2018</xref>; <xref ref-type="bibr" rid="bib57">El Hoss et al., 2021</xref>). These methods offer novel strategies for quantitative assessment of erythroid differentiation in mouse disease models and human erythroid disorders.</p></sec><sec id="s10-5"><title>Assessment of enucleation by flow cytometry</title><p>Enucleation is the process during which the condensed nucleus is extruded from the erythroblast to yield the reticulocyte and the ‘pyrenocyte.’ Discrimination of nucleated erythroblasts, reticulocytes, and extruded nuclei by flow cytometry is based on DNA staining, surface expression of erythrocyte-specific markers, or forward scatter. The enucleation of murine erythroblasts is assessed by surface expression of the murine erythrocyte marker TER119 and DNA staining (<xref ref-type="bibr" rid="bib114">Ji et al., 2008</xref>; <xref ref-type="bibr" rid="bib263">Zhang et al., 2003</xref>). Three discrete populations that represent nucleated erythroblasts, reticulocytes, and extruded nuclei are defined as Hoechst<sup>med</sup>TER119<sup>high</sup>, Hoechst<sup>low</sup>TER119<sup>high</sup>, and Hoechst<sup>high</sup>TER119<sup>med</sup>, respectively (<xref ref-type="bibr" rid="bib114">Ji et al., 2008</xref>; <xref ref-type="bibr" rid="bib263">Zhang et al., 2003</xref>). Another nuclei acid staining dye, SYTO16, is used for the assessment of human enucleation in combination with forward scatter. For human cells, the three populations that represent nucleated erythroblasts (high forward scatter SYTO16<sup>+</sup>), reticulocyte (high forward scatter SYTO16<sup>-</sup>), and extruded nuclei (low forward scatter SYTO16<sup>+</sup>) are thus identified (<xref ref-type="bibr" rid="bib262">Yoshida et al., 2005</xref>).</p></sec><sec id="s10-6"><title>Models for iron-restricted anemias</title><p>Cell culture and in vivo techniques have been developed for analysis of the effects of iron restriction on erythropoiesis. In in vitro cell culture, human or murine hematopoietic stem and progenitors are subjected to a two-stage system using defined, serum-free conditions. Progenitors successfully studied have included human CD34<sup>+</sup> peripheral blood-mobilized progenitors and murine Lin<sup>-</sup>Kit<sup>+</sup> splenic stress progenitors (<xref ref-type="bibr" rid="bib27">Bullock et al., 2010</xref>; <xref ref-type="bibr" rid="bib123">Khalil et al., 2018</xref>). In the initial phase of culture, progenitors undergo expansion for ~2 d in the presence of early-acting cytokines, SCF, FLT3-ligand, TPO, and IL-3. The cells are then shifted into erythroid medium containing SCF and EPO. By adding different proportions of apo- and holo-transferrin, the transferrin saturation (%TSAT) can be adjusted to create iron-replete or iron-restricted conditions. Initial studies with human progenitors identified a TSAT level of 15% as showing a selective inhibition of erythropoiesis while not affecting granulopoiesis or megakaryopoiesis (<xref ref-type="bibr" rid="bib27">Bullock et al., 2010</xref>). In subsequent studies with human stem and progenitor cultures, either TNFα or IFNγ when combined with a TSAT of 15% (instead of 100%) resulted in a synergistic suppression of erythropoiesis, suggesting a means for modeling ACI in vitro (<xref ref-type="bibr" rid="bib203">Richardson et al., 2013</xref>). The most straightforward in vivo model for iron-restricted anemia consists of placing mice on low iron diet using customized mouse chow (Envigo Teklad 2.5–4 ppm iron). Important considerations in this model are to use male weanlings, enhance susceptibility to the development of iron deficiency, and use control customized iron-replete chow (containing ~35–50 ppm) that is matched in composition to the low iron chow. Robust in vivo models for iron-restricted anemia in the setting of chronic inflammation have included rat adjuvant arthritis, caused by injection of the streptococcal cell wall peptidoglycan-polysaccharide and murine chronic inflammation induced by weekly injections of low dose killed <italic>Brucella abortus</italic> combined with customized iron-replete chow (Envigo Teklad 35–50 ppm) (<xref ref-type="bibr" rid="bib203">Richardson et al., 2013</xref>; <xref ref-type="bibr" rid="bib99">Guo et al., 2019</xref>; <xref ref-type="bibr" rid="bib92">Goldfarb et al., 2021</xref>). Evidence supporting a role for iron restriction in these rodent ACI models consisted of the amelioration of the anemia with isocitrate injections (<xref ref-type="bibr" rid="bib203">Richardson et al., 2013</xref>; <xref ref-type="bibr" rid="bib92">Goldfarb et al., 2021</xref>). Finally, as discussed in respective section above, several mouse models that recapitulate diseases such as β-thalassemia, MDS, and PV are commercially available.</p></sec></sec><sec id="s11"><title>Perspectives and future directions (all)</title><p>Taken together, a great deal is currently known about the physiology of erythropoiesis and iron metabolism as well as the pathophysiology of diseases in which these biological systems are dysregulated. Despite this, significant unknowns remain, both regarding the mechanisms of normal function and their disordered regulation in disease; we thus include here an incomplete list to guide the next generation of targeted inquiry along these lines:</p><list list-type="bullet"><list-item><p>A mechanistic molecular understanding of ineffective erythropoiesis and a more complete delineation of how EPO responsiveness is modulated in both physiological and pathological conditions remains elusive. This direction of investigation could yield novel therapeutic development for a variety of diseases associated with anemia, for example, anemia of chronic inflammation and in renal failure.</p></list-item><list-item><p>The role of and purpose for iron and heme export from erythroblasts (via ferroportin and FLVCR, respectively) is counterintuitive and incompletely understood.</p></list-item><list-item><p>Whether and how iron-specific proteins (Tfr1, Tfr2, transferrin, etc.) in non-hepatocyte cells regulate the crosstalk between iron metabolism, immunity, and erythropoiesis is not well understood. Such exploration may yield novel therapeutic targets for a variety of disorders.</p></list-item><list-item><p>Whether and how EPOR expression outside of erythroid lineage cells regulate the crosstalk between iron metabolism and erythropoiesis remains to be more completely elucidated.</p></list-item><list-item><p>How iron deficiency anemia exerts and influences platelet production remains largely unknown despite the long-standing clinical recognition of thrombocytosis as a common co-occurrence. Such mechanisms could potentially be exploited in designing novel treatments for thrombocytopenia.</p></list-item><list-item><p>Genetic factors most likely contribute to heterogeneity in the human response to iron deficiency. Why do individuals with the same degree of iron deficiency show differences in the extent of anemia and of thrombocytosis? Understanding such factors may enable a more personalized approach toward iron-related therapies.</p></list-item><list-item><p>A novel mechanism for cell death, ferroptosis, was recently discovered, an iron-mediated mechanism leading to lipid peroxidation and cell death that is being targeted as a therapeutic approach in various cancers. Understanding the role of ferroptosis as it pertains to iron trafficking in erythroblasts may shed light on iron-loading anemias associated with ineffective erythropoiesis (i.e. β-thalassemia and MDS).</p></list-item><list-item><p>Given the critical role of EBI macrophages in supporting erythropoiesis, understanding whether and how EPO/EPOR signaling in these cells further enables coordination of erythropoiesis and enucleation in normal and disordered erythropoiesis is important.</p></list-item></list></sec></body><back><sec sec-type="additional-information" id="s12"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>Reviewing editor, <italic>eLife</italic></p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Supervision, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Writing - original draft, Writing - review and editing</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adema</surname><given-names>V</given-names></name><name><surname>Ma</surname><given-names>F</given-names></name><name><surname>Kanagal-Shamanna</surname><given-names>R</given-names></name><name><surname>Thongon</surname><given-names>N</given-names></name><name><surname>Montalban-Bravo</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Peslak</surname><given-names>SA</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Acha</surname><given-names>P</given-names></name><name><surname>Sole</surname><given-names>F</given-names></name><name><surname>Lockyer</surname><given-names>P</given-names></name><name><surname>Cassari</surname><given-names>M</given-names></name><name><surname>Maciejewski</surname><given-names>JP</given-names></name><name><surname>Visconte</surname><given-names>V</given-names></name><name><surname>Gañán-Gómez</surname><given-names>I</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Bueso-Ramos</surname><given-names>C</given-names></name><name><surname>Pellegrini</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>TM</given-names></name><name><surname>Bejar</surname><given-names>R</given-names></name><name><surname>Carew</surname><given-names>JS</given-names></name><name><surname>Halene</surname><given-names>S</given-names></name><name><surname>Santini</surname><given-names>V</given-names></name><name><surname>Al-Atrash</surname><given-names>G</given-names></name><name><surname>Clise-Dwyer</surname><given-names>K</given-names></name><name><surname>Garcia-Manero</surname><given-names>G</given-names></name><name><surname>Blobel</surname><given-names>GA</given-names></name><name><surname>Colla</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Targeting the EIF2AK1 signaling pathway rescues red blood cell production in SF3B1-mutant myelodysplastic syndromes with ringed sideroblasts</article-title><source>Blood Cancer Discovery</source><volume>3</volume><fpage>554</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1158/2643-3230.BCD-21-0220</pub-id><pub-id pub-id-type="pmid">35926182</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akada</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>D</given-names></name><name><surname>Zou</surname><given-names>H</given-names></name><name><surname>Fiering</surname><given-names>S</given-names></name><name><surname>Hutchison</surname><given-names>RE</given-names></name><name><surname>Mohi</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease</article-title><source>Blood</source><volume>115</volume><fpage>3589</fpage><lpage>3597</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-04-215848</pub-id><pub-id pub-id-type="pmid">20197548</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>AM</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Pinheiro</surname><given-names>RF</given-names></name><name><surname>Xue</surname><given-names>F</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Iverson</surname><given-names>N</given-names></name><name><surname>Hoehn</surname><given-names>D</given-names></name><name><surname>Coutinho</surname><given-names>D</given-names></name><name><surname>Kayani</surname><given-names>J</given-names></name><name><surname>Chernak</surname><given-names>B</given-names></name><name><surname>Lane</surname><given-names>J</given-names></name><name><surname>Hillyer</surname><given-names>C</given-names></name><name><surname>Galili</surname><given-names>N</given-names></name><name><surname>Jurcic</surname><given-names>J</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name><name><surname>An</surname><given-names>X</given-names></name><name><surname>Raza</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes</article-title><source>Blood Advances</source><volume>2</volume><fpage>1393</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2018018440</pub-id><pub-id pub-id-type="pmid">29903708</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>X</given-names></name><name><surname>Schulz</surname><given-names>VP</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>F</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name><name><surname>Gallagher</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Global transcriptome analyses of human and murine terminal erythroid differentiation</article-title><source>Blood</source><volume>123</volume><fpage>3466</fpage><lpage>3477</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-01-548305</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Xue</surname><given-names>F</given-names></name><name><surname>Nie</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Yazdanbakhsh</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name><name><surname>An</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Vesicular formation regulated by ERK/MAPK pathway mediates human erythroblast enucleation</article-title><source>Blood Advances</source><volume>5</volume><fpage>4648</fpage><lpage>4661</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2021004859</pub-id><pub-id pub-id-type="pmid">34551066</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>W</given-names></name><name><surname>Aluri</surname><given-names>S</given-names></name><name><surname>Levy</surname><given-names>M</given-names></name><name><surname>Fibach</surname><given-names>E</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name><name><surname>Ginzburg</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Iron chelation improves ineffective erythropoiesis and iron overload in a mouse model of myelodysplastic syndrome</article-title><source>Blood</source><volume>140</volume><fpage>2458</fpage><lpage>2459</lpage><pub-id pub-id-type="doi">10.1182/blood-2022-163631</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>ER</given-names></name><name><surname>Taylor</surname><given-names>M</given-names></name><name><surname>Xue</surname><given-names>X</given-names></name><name><surname>Ramakrishnan</surname><given-names>SK</given-names></name><name><surname>Martin</surname><given-names>A</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Bredell</surname><given-names>BX</given-names></name><name><surname>Gardenghi</surname><given-names>S</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>YM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Intestinal HIF2α promotes tissue-iron accumulation in disorders of iron overload with anemia</article-title><source>PNAS</source><volume>110</volume><fpage>E4922</fpage><lpage>E4930</lpage><pub-id pub-id-type="doi">10.1073/pnas.1314197110</pub-id><pub-id pub-id-type="pmid">24282296</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrieu-Soler</surname><given-names>C</given-names></name><name><surname>Soler</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Erythroid cell research: 3D Chromatin, transcription factors and beyond</article-title><source>International Journal of Molecular Sciences</source><volume>23</volume><elocation-id>6149</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23116149</pub-id><pub-id pub-id-type="pmid">35682828</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angelucci</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Greenberg</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Hou</surname><given-names>M</given-names></name><name><surname>Montano Figueroa</surname><given-names>EH</given-names></name><name><surname>Rodriguez</surname><given-names>MG</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Ghosh</surname><given-names>J</given-names></name><name><surname>Izquierdo</surname><given-names>M</given-names></name><name><surname>Garcia-Manero</surname><given-names>G</given-names></name><collab>on behalf of the TELESTO Study Investigators</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Iron chelation in transfusion-dependent patients with low- to intermediate-1–risk myelodysplastic syndromes</article-title><source>Annals of Internal Medicine</source><volume>172</volume><elocation-id>513</elocation-id><pub-id pub-id-type="doi">10.7326/M19-0916</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arezes</surname><given-names>J</given-names></name><name><surname>Foy</surname><given-names>N</given-names></name><name><surname>McHugh</surname><given-names>K</given-names></name><name><surname>Sawant</surname><given-names>A</given-names></name><name><surname>Quinkert</surname><given-names>D</given-names></name><name><surname>Terraube</surname><given-names>V</given-names></name><name><surname>Brinth</surname><given-names>A</given-names></name><name><surname>Tam</surname><given-names>M</given-names></name><name><surname>LaVallie</surname><given-names>ER</given-names></name><name><surname>Taylor</surname><given-names>S</given-names></name><name><surname>Armitage</surname><given-names>AE</given-names></name><name><surname>Pasricha</surname><given-names>S-R</given-names></name><name><surname>Cunningham</surname><given-names>O</given-names></name><name><surname>Lambert</surname><given-names>M</given-names></name><name><surname>Draper</surname><given-names>SJ</given-names></name><name><surname>Jasuja</surname><given-names>R</given-names></name><name><surname>Drakesmith</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Erythroferrone inhibits the induction of hepcidin by BMP6</article-title><source>Blood</source><volume>132</volume><fpage>1473</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-06-857995</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arezes</surname><given-names>J</given-names></name><name><surname>Foy</surname><given-names>N</given-names></name><name><surname>McHugh</surname><given-names>K</given-names></name><name><surname>Quinkert</surname><given-names>D</given-names></name><name><surname>Benard</surname><given-names>S</given-names></name><name><surname>Sawant</surname><given-names>A</given-names></name><name><surname>Frost</surname><given-names>JN</given-names></name><name><surname>Armitage</surname><given-names>AE</given-names></name><name><surname>Pasricha</surname><given-names>S-R</given-names></name><name><surname>Lim</surname><given-names>PJ</given-names></name><name><surname>Tam</surname><given-names>MS</given-names></name><name><surname>Lavallie</surname><given-names>E</given-names></name><name><surname>Pittman</surname><given-names>DD</given-names></name><name><surname>Cunningham</surname><given-names>O</given-names></name><name><surname>Lambert</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>JE</given-names></name><name><surname>Draper</surname><given-names>SJ</given-names></name><name><surname>Jasuja</surname><given-names>R</given-names></name><name><surname>Drakesmith</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia</article-title><source>Blood</source><volume>135</volume><fpage>547</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1182/blood.2019003140</pub-id><pub-id pub-id-type="pmid">31899794</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arlet</surname><given-names>J-B</given-names></name><name><surname>Ribeil</surname><given-names>J-A</given-names></name><name><surname>Guillem</surname><given-names>F</given-names></name><name><surname>Negre</surname><given-names>O</given-names></name><name><surname>Hazoume</surname><given-names>A</given-names></name><name><surname>Marcion</surname><given-names>G</given-names></name><name><surname>Beuzard</surname><given-names>Y</given-names></name><name><surname>Dussiot</surname><given-names>M</given-names></name><name><surname>Moura</surname><given-names>IC</given-names></name><name><surname>Demarest</surname><given-names>S</given-names></name><name><surname>de Beauchêne</surname><given-names>IC</given-names></name><name><surname>Belaid-Choucair</surname><given-names>Z</given-names></name><name><surname>Sevin</surname><given-names>M</given-names></name><name><surname>Maciel</surname><given-names>TT</given-names></name><name><surname>Auclair</surname><given-names>C</given-names></name><name><surname>Leboulch</surname><given-names>P</given-names></name><name><surname>Chretien</surname><given-names>S</given-names></name><name><surname>Tchertanov</surname><given-names>L</given-names></name><name><surname>Baudin-Creuza</surname><given-names>V</given-names></name><name><surname>Seigneuric</surname><given-names>R</given-names></name><name><surname>Fontenay</surname><given-names>M</given-names></name><name><surname>Garrido</surname><given-names>C</given-names></name><name><surname>Hermine</surname><given-names>O</given-names></name><name><surname>Courtois</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia</article-title><source>Nature</source><volume>514</volume><fpage>242</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1038/nature13614</pub-id><pub-id pub-id-type="pmid">25156257</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arsenault</surname><given-names>V</given-names></name><name><surname>Mailloux</surname><given-names>C</given-names></name><name><surname>Bonnefoy</surname><given-names>A</given-names></name><name><surname>Lemyre</surname><given-names>E</given-names></name><name><surname>Pastore</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Iron-refractory iron deficiency anemia may not lead to neurocognitive dysfunction: a case report</article-title><source>Pediatrics</source><volume>138</volume><elocation-id>e20153608</elocation-id><pub-id pub-id-type="doi">10.1542/peds.2015-3608</pub-id><pub-id pub-id-type="pmid">27365303</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aschemeyer</surname><given-names>S</given-names></name><name><surname>Qiao</surname><given-names>B</given-names></name><name><surname>Stefanova</surname><given-names>D</given-names></name><name><surname>Valore</surname><given-names>EV</given-names></name><name><surname>Sek</surname><given-names>AC</given-names></name><name><surname>Ruwe</surname><given-names>TA</given-names></name><name><surname>Vieth</surname><given-names>KR</given-names></name><name><surname>Jung</surname><given-names>G</given-names></name><name><surname>Casu</surname><given-names>C</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name><name><surname>Jormakka</surname><given-names>M</given-names></name><name><surname>Mackenzie</surname><given-names>B</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>Nemeth</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin</article-title><source>Blood</source><volume>131</volume><fpage>899</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-05-786590</pub-id><pub-id pub-id-type="pmid">29237594</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babitt</surname><given-names>JL</given-names></name><name><surname>Huang</surname><given-names>FW</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Sidis</surname><given-names>Y</given-names></name><name><surname>Andrews</surname><given-names>NC</given-names></name><name><surname>Lin</surname><given-names>HY</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance</article-title><source>The Journal of Clinical Investigation</source><volume>117</volume><fpage>1933</fpage><lpage>1939</lpage><pub-id pub-id-type="doi">10.1172/JCI31342</pub-id><pub-id pub-id-type="pmid">17607365</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baringer</surname><given-names>SL</given-names></name><name><surname>Palsa</surname><given-names>K</given-names></name><name><surname>Spiegelman</surname><given-names>VS</given-names></name><name><surname>Simpson</surname><given-names>IA</given-names></name><name><surname>Connor</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Apo- and holo-transferrin differentially interact with hephaestin and ferroportin in a novel mechanism of cellular iron release regulation</article-title><source>Journal of Biomedical Science</source><volume>30</volume><elocation-id>36</elocation-id><pub-id pub-id-type="doi">10.1186/s12929-023-00934-2</pub-id><pub-id pub-id-type="pmid">37277838</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baron</surname><given-names>MH</given-names></name><name><surname>Vacaru</surname><given-names>A</given-names></name><name><surname>Nieves</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Erythroid development in the mammalian embryo</article-title><source>Blood Cells, Molecules &amp; Diseases</source><volume>51</volume><fpage>213</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.bcmd.2013.07.006</pub-id><pub-id pub-id-type="pmid">23932234</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baxter</surname><given-names>EJ</given-names></name><name><surname>Scott</surname><given-names>LM</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>East</surname><given-names>C</given-names></name><name><surname>Fourouclas</surname><given-names>N</given-names></name><name><surname>Swanton</surname><given-names>S</given-names></name><name><surname>Vassiliou</surname><given-names>GS</given-names></name><name><surname>Bench</surname><given-names>AJ</given-names></name><name><surname>Boyd</surname><given-names>EM</given-names></name><name><surname>Curtin</surname><given-names>N</given-names></name><name><surname>Scott</surname><given-names>MA</given-names></name><name><surname>Erber</surname><given-names>WN</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name><collab>Cancer Genome Project</collab></person-group><year iso-8601-date="2005">2005</year><article-title>Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</article-title><source>Lancet</source><volume>365</volume><fpage>1054</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)71142-9</pub-id><pub-id pub-id-type="pmid">15781101</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>MJ</given-names></name><name><surname>Lebrón</surname><given-names>JA</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor</article-title><source>Nature</source><volume>403</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1038/47417</pub-id><pub-id pub-id-type="pmid">10638746</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>C</given-names></name><name><surname>Jackson</surname><given-names>VE</given-names></name><name><surname>Pettikiriarachchi</surname><given-names>A</given-names></name><name><surname>Hayman</surname><given-names>T</given-names></name><name><surname>Schaeper</surname><given-names>U</given-names></name><name><surname>Moir-Meyer</surname><given-names>G</given-names></name><name><surname>Fielding</surname><given-names>K</given-names></name><name><surname>Ataide</surname><given-names>R</given-names></name><name><surname>Clucas</surname><given-names>D</given-names></name><name><surname>Baldi</surname><given-names>A</given-names></name><name><surname>Garnham</surname><given-names>AL</given-names></name><name><surname>Li-Wai-Suen</surname><given-names>CSN</given-names></name><name><surname>Loughran</surname><given-names>SJ</given-names></name><name><surname>Baxter</surname><given-names>EJ</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name><name><surname>Alexander</surname><given-names>WS</given-names></name><name><surname>Bahlo</surname><given-names>M</given-names></name><name><surname>Burbury</surname><given-names>K</given-names></name><name><surname>Ng</surname><given-names>AP</given-names></name><name><surname>Pasricha</surname><given-names>S-R</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Iron homeostasis governs erythroid phenotype in polycythemia vera</article-title><source>Blood</source><volume>141</volume><fpage>3199</fpage><lpage>3214</lpage><pub-id pub-id-type="doi">10.1182/blood.2022016779</pub-id><pub-id pub-id-type="pmid">36928379</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benyamin</surname><given-names>B</given-names></name><name><surname>Ferreira</surname><given-names>MAR</given-names></name><name><surname>Willemsen</surname><given-names>G</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><name><surname>Middelberg</surname><given-names>RPS</given-names></name><name><surname>McEvoy</surname><given-names>BP</given-names></name><name><surname>Hottenga</surname><given-names>J-J</given-names></name><name><surname>Henders</surname><given-names>AK</given-names></name><name><surname>Campbell</surname><given-names>MJ</given-names></name><name><surname>Wallace</surname><given-names>L</given-names></name><name><surname>Frazer</surname><given-names>IH</given-names></name><name><surname>Heath</surname><given-names>AC</given-names></name><name><surname>de Geus</surname><given-names>EJC</given-names></name><name><surname>Nyholt</surname><given-names>DR</given-names></name><name><surname>Visscher</surname><given-names>PM</given-names></name><name><surname>Penninx</surname><given-names>BW</given-names></name><name><surname>Boomsma</surname><given-names>DI</given-names></name><name><surname>Martin</surname><given-names>NG</given-names></name><name><surname>Montgomery</surname><given-names>GW</given-names></name><name><surname>Whitfield</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Common variants in TMPRSS6 are associated with iron status and erythrocyte volume</article-title><source>Nature Genetics</source><volume>41</volume><fpage>1173</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1038/ng.456</pub-id><pub-id pub-id-type="pmid">19820699</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Berastegui</surname><given-names>N</given-names></name><name><surname>Ainciburu</surname><given-names>M</given-names></name><name><surname>Romero</surname><given-names>JP</given-names></name><name><surname>Alfonso-Pierola</surname><given-names>A</given-names></name><name><surname>Philippe</surname><given-names>C</given-names></name><name><surname>Vilas</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>PS</given-names></name><name><surname>Ordoñez</surname><given-names>R</given-names></name><name><surname>Alignani</surname><given-names>D</given-names></name><name><surname>Sarvide</surname><given-names>S</given-names></name><name><surname>Castro</surname><given-names>L</given-names></name><name><surname>Lamo-Espinosa</surname><given-names>JM</given-names></name><name><surname>San-Julian</surname><given-names>M</given-names></name><name><surname>Jimenez</surname><given-names>T</given-names></name><name><surname>López</surname><given-names>F</given-names></name><name><surname>Muntion</surname><given-names>S</given-names></name><name><surname>Sanchez-Guijo</surname><given-names>F</given-names></name><name><surname>Molero</surname><given-names>A</given-names></name><name><surname>Montoro</surname><given-names>J</given-names></name><name><surname>Tazón</surname><given-names>B</given-names></name><name><surname>Serrano</surname><given-names>G</given-names></name><name><surname>Diaz-Mazkiaran</surname><given-names>A</given-names></name><name><surname>Hernaez</surname><given-names>M</given-names></name><name><surname>Huerga</surname><given-names>S</given-names></name><name><surname>Copley</surname><given-names>F</given-names></name><name><surname>Rio-Machin</surname><given-names>A</given-names></name><name><surname>Maurano</surname><given-names>MT</given-names></name><name><surname>Díez-Campelo</surname><given-names>M</given-names></name><name><surname>Valcarcel</surname><given-names>D</given-names></name><name><surname>Rouault-Pierre</surname><given-names>K</given-names></name><name><surname>Lara-Astiaso</surname><given-names>D</given-names></name><name><surname>Ezponda</surname><given-names>T</given-names></name><name><surname>Prosper</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Transcriptional Regulation of HSCs in Aging and MDS Reveals DDIT3 as a Potential Driver of Dyserythropoiesis</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.09.08.459384</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bessis</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1958">1958</year><article-title>Erythroblastic island, functional unity of bone marrow</article-title><source>Revue d’hematologie</source><volume>13</volume><fpage>8</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">13555228</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Billesbølle</surname><given-names>CB</given-names></name><name><surname>Azumaya</surname><given-names>CM</given-names></name><name><surname>Kretsch</surname><given-names>RC</given-names></name><name><surname>Powers</surname><given-names>AS</given-names></name><name><surname>Gonen</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>S</given-names></name><name><surname>Arvedson</surname><given-names>T</given-names></name><name><surname>Dror</surname><given-names>RO</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Manglik</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms</article-title><source>Nature</source><volume>586</volume><fpage>807</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2668-z</pub-id><pub-id pub-id-type="pmid">32814342</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boshuizen</surname><given-names>M</given-names></name><name><surname>van der Ploeg</surname><given-names>K</given-names></name><name><surname>von Bonsdorff</surname><given-names>L</given-names></name><name><surname>Biemond</surname><given-names>BJ</given-names></name><name><surname>Zeerleder</surname><given-names>SS</given-names></name><name><surname>van Bruggen</surname><given-names>R</given-names></name><name><surname>Juffermans</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Therapeutic use of transferrin to modulate anemia and conditions of iron toxicity</article-title><source>Blood Reviews</source><volume>31</volume><fpage>400</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/j.blre.2017.07.005</pub-id><pub-id pub-id-type="pmid">28755795</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bressman</surname><given-names>E</given-names></name><name><surname>Jhang</surname><given-names>J</given-names></name><name><surname>McClaskey</surname><given-names>J</given-names></name><name><surname>Ginzburg</surname><given-names>YZ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Tackling the unknowns in understanding and management of hospital acquired anemia</article-title><source>Blood Reviews</source><volume>49</volume><elocation-id>100830</elocation-id><pub-id pub-id-type="doi">10.1016/j.blre.2021.100830</pub-id><pub-id pub-id-type="pmid">33810899</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bullock</surname><given-names>GC</given-names></name><name><surname>Delehanty</surname><given-names>LL</given-names></name><name><surname>Talbot</surname><given-names>A-L</given-names></name><name><surname>Gonias</surname><given-names>SL</given-names></name><name><surname>Tong</surname><given-names>W-H</given-names></name><name><surname>Rouault</surname><given-names>TA</given-names></name><name><surname>Dewar</surname><given-names>B</given-names></name><name><surname>Macdonald</surname><given-names>JM</given-names></name><name><surname>Chruma</surname><given-names>JJ</given-names></name><name><surname>Goldfarb</surname><given-names>AN</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Iron control of erythroid development by a novel aconitase-associated regulatory pathway</article-title><source>Blood</source><volume>116</volume><fpage>97</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-10-251496</pub-id><pub-id pub-id-type="pmid">20407036</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabantchik</surname><given-names>ZI</given-names></name><name><surname>Breuer</surname><given-names>W</given-names></name><name><surname>Zanninelli</surname><given-names>G</given-names></name><name><surname>Cianciulli</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>LPI-labile plasma iron in iron overload</article-title><source>Best Practice &amp; Research. Clinical Haematology</source><volume>18</volume><fpage>277</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1016/j.beha.2004.10.003</pub-id><pub-id pub-id-type="pmid">15737890</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camaschella</surname><given-names>C</given-names></name><name><surname>Campanella</surname><given-names>A</given-names></name><name><surname>De Falco</surname><given-names>L</given-names></name><name><surname>Boschetto</surname><given-names>L</given-names></name><name><surname>Merlini</surname><given-names>R</given-names></name><name><surname>Silvestri</surname><given-names>L</given-names></name><name><surname>Levi</surname><given-names>S</given-names></name><name><surname>Iolascon</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload</article-title><source>Blood</source><volume>110</volume><fpage>1353</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-02-072520</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camaschella</surname><given-names>C.</given-names></name><name><surname>Nai</surname><given-names>A</given-names></name><name><surname>Silvestri</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Iron metabolism and iron disorders revisited in the hepcidin era</article-title><source>Haematologica</source><volume>105</volume><fpage>260</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.3324/haematol.2019.232124</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cappellini</surname><given-names>MD</given-names></name><name><surname>Taher</surname><given-names>AT</given-names></name><name><surname>Piga</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>F</given-names></name><name><surname>Voskaridou</surname><given-names>E</given-names></name><name><surname>Viprakasit</surname><given-names>V</given-names></name><name><surname>Porter</surname><given-names>JB</given-names></name><name><surname>Hermine</surname><given-names>O</given-names></name><name><surname>Neufeld</surname><given-names>EJ</given-names></name><name><surname>Thompson</surname><given-names>AA</given-names></name><name><surname>Tang</surname><given-names>D</given-names></name><name><surname>Yucel</surname><given-names>A</given-names></name><name><surname>Lord-Bessen</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Shetty</surname><given-names>JK</given-names></name><name><surname>Miteva</surname><given-names>D</given-names></name><name><surname>Zinger</surname><given-names>T</given-names></name><name><surname>Backstrom</surname><given-names>JT</given-names></name><name><surname>Oliva</surname><given-names>EN</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept</article-title><source>European Journal of Haematology</source><volume>111</volume><fpage>113</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1111/ejh.13975</pub-id><pub-id pub-id-type="pmid">37095595</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casanovas</surname><given-names>G</given-names></name><name><surname>Vujić Spasic</surname><given-names>M</given-names></name><name><surname>Casu</surname><given-names>C</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name><name><surname>Strelau</surname><given-names>J</given-names></name><name><surname>Unsicker</surname><given-names>K</given-names></name><name><surname>Muckenthaler</surname><given-names>MU</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice</article-title><source>Haematologica</source><volume>98</volume><fpage>444</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.3324/haematol.2012.069807</pub-id><pub-id pub-id-type="pmid">22983584</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casu</surname><given-names>C</given-names></name><name><surname>Aghajan</surname><given-names>M</given-names></name><name><surname>Oikonomidou</surname><given-names>PR</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Monia</surname><given-names>BP</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016a</year><article-title>Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia</article-title><source>Haematologica</source><volume>101</volume><fpage>e8</fpage><lpage>e11</lpage><pub-id pub-id-type="doi">10.3324/haematol.2015.133348</pub-id><pub-id pub-id-type="pmid">26405152</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casu</surname><given-names>C</given-names></name><name><surname>Oikonomidou</surname><given-names>PR</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Nandi</surname><given-names>V</given-names></name><name><surname>Ginzburg</surname><given-names>Y</given-names></name><name><surname>Prasad</surname><given-names>P</given-names></name><name><surname>Fleming</surname><given-names>RE</given-names></name><name><surname>Shah</surname><given-names>YM</given-names></name><name><surname>Valore</surname><given-names>EV</given-names></name><name><surname>Nemeth</surname><given-names>E</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>MacDonald</surname><given-names>B</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016b</year><article-title>Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera</article-title><source>Blood</source><volume>128</volume><fpage>265</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-10-676742</pub-id><pub-id pub-id-type="pmid">27154187</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casu</surname><given-names>C</given-names></name><name><surname>Nemeth</surname><given-names>E</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hepcidin agonists as therapeutic tools</article-title><source>Blood</source><volume>131</volume><fpage>1790</fpage><lpage>1794</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-11-737411</pub-id><pub-id pub-id-type="pmid">29523504</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>De Rosa</surname><given-names>G</given-names></name><name><surname>Low</surname><given-names>A</given-names></name><name><surname>Suzuki</surname><given-names>A</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Ginzburg</surname><given-names>YZ</given-names></name><name><surname>Abrams</surname><given-names>C</given-names></name><name><surname>Aghajan</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Tmprss6-ASO as a tool for the treatment of Polycythemia Vera mice</article-title><source>PLOS ONE</source><volume>16</volume><elocation-id>e0251995</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0251995</pub-id><pub-id pub-id-type="pmid">34890402</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>JC</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Sehmi</surname><given-names>J</given-names></name><name><surname>Wass</surname><given-names>MN</given-names></name><name><surname>Zabaneh</surname><given-names>D</given-names></name><name><surname>Hoggart</surname><given-names>C</given-names></name><name><surname>Bayele</surname><given-names>H</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Peltonen</surname><given-names>L</given-names></name><name><surname>Freimer</surname><given-names>NB</given-names></name><name><surname>Srai</surname><given-names>SK</given-names></name><name><surname>Maxwell</surname><given-names>PH</given-names></name><name><surname>Sternberg</surname><given-names>MJE</given-names></name><name><surname>Ruokonen</surname><given-names>A</given-names></name><name><surname>Abecasis</surname><given-names>G</given-names></name><name><surname>Jarvelin</surname><given-names>M-R</given-names></name><name><surname>Scott</surname><given-names>J</given-names></name><name><surname>Elliott</surname><given-names>P</given-names></name><name><surname>Kooner</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels</article-title><source>Nature Genetics</source><volume>41</volume><fpage>1170</fpage><lpage>1172</lpage><pub-id pub-id-type="doi">10.1038/ng.462</pub-id><pub-id pub-id-type="pmid">19820698</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chasis</surname><given-names>JA</given-names></name><name><surname>Prenant</surname><given-names>M</given-names></name><name><surname>Leung</surname><given-names>A</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Membrane assembly and remodeling during reticulocyte maturation</article-title><source>Blood</source><volume>74</volume><fpage>1112</fpage><lpage>1120</lpage><pub-id pub-id-type="pmid">2752157</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Heck</surname><given-names>S</given-names></name><name><surname>Chasis</surname><given-names>JA</given-names></name><name><surname>An</surname><given-names>X</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis</article-title><source>PNAS</source><volume>106</volume><fpage>17413</fpage><lpage>17418</lpage><pub-id pub-id-type="doi">10.1073/pnas.0909296106</pub-id><pub-id pub-id-type="pmid">19805084</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>F</given-names></name><name><surname>Diwakar</surname><given-names>BT</given-names></name><name><surname>Ruan</surname><given-names>B</given-names></name><name><surname>Hao</surname><given-names>S</given-names></name><name><surname>Prabhu</surname><given-names>KS</given-names></name><name><surname>Paulson</surname><given-names>RF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Epo receptor signaling in macrophages alters the splenic niche to promote erythroid differentiation</article-title><source>Blood</source><volume>136</volume><fpage>235</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1182/blood.2019003480</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Hillyer</surname><given-names>CD</given-names></name><name><surname>Blanc</surname><given-names>L</given-names></name><name><surname>An</surname><given-names>X</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dynamic changes in murine erythropoiesis from birth to adulthood: implications for the study of murine models of anemia</article-title><source>Blood Advances</source><volume>5</volume><fpage>16</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2020003632</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>A</given-names></name><name><surname>Huggins</surname><given-names>M</given-names></name><name><surname>Ahmed</surname><given-names>J</given-names></name><name><surname>Hashimoto</surname><given-names>D</given-names></name><name><surname>Lucas</surname><given-names>D</given-names></name><name><surname>Kunisaki</surname><given-names>Y</given-names></name><name><surname>Pinho</surname><given-names>S</given-names></name><name><surname>Leboeuf</surname><given-names>M</given-names></name><name><surname>Noizat</surname><given-names>C</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>ZJ</given-names></name><name><surname>Bergman</surname><given-names>A</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Frenette</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CD169+ macrophages provide a niche promoting erythropoiesis under homeostasis and stress</article-title><source>Nature Medicine</source><volume>19</volume><fpage>429</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1038/nm.3057</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christakopoulos</surname><given-names>GE</given-names></name><name><surname>Telange</surname><given-names>R</given-names></name><name><surname>Yen</surname><given-names>J</given-names></name><name><surname>Weiss</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Gene therapy and gene editing for β-thalassemia</article-title><source>Hematology/Oncology Clinics of North America</source><volume>37</volume><fpage>433</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1016/j.hoc.2022.12.012</pub-id><pub-id pub-id-type="pmid">36907613</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clough</surname><given-names>CA</given-names></name><name><surname>Pangallo</surname><given-names>J</given-names></name><name><surname>Sarchi</surname><given-names>M</given-names></name><name><surname>Ilagan</surname><given-names>JO</given-names></name><name><surname>North</surname><given-names>K</given-names></name><name><surname>Bergantinos</surname><given-names>R</given-names></name><name><surname>Stolla</surname><given-names>MC</given-names></name><name><surname>Naru</surname><given-names>J</given-names></name><name><surname>Nugent</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Stirewalt</surname><given-names>DL</given-names></name><name><surname>Subramaniam</surname><given-names>AR</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Abkowitz</surname><given-names>JL</given-names></name><name><surname>Bradley</surname><given-names>RK</given-names></name><name><surname>Doulatov</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome</article-title><source>Blood</source><volume>139</volume><fpage>2038</fpage><lpage>2049</lpage><pub-id pub-id-type="doi">10.1182/blood.2021012652</pub-id><pub-id pub-id-type="pmid">34861039</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colucci</surname><given-names>S</given-names></name><name><surname>Altamura</surname><given-names>S</given-names></name><name><surname>Marques</surname><given-names>O</given-names></name><name><surname>Müdder</surname><given-names>K</given-names></name><name><surname>Agarvas</surname><given-names>AR</given-names></name><name><surname>Hentze</surname><given-names>MW</given-names></name><name><surname>Muckenthaler</surname><given-names>MU</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Iron-dependent BMP6 regulation in liver sinusoidal endothelial cells is instructed by hepatocyte-derived secretory signals</article-title><source>HemaSphere</source><volume>6</volume><elocation-id>e773</elocation-id><pub-id pub-id-type="doi">10.1097/HS9.0000000000000773</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dautry-Varsat</surname><given-names>A</given-names></name><name><surname>Ciechanover</surname><given-names>A</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>pH and the recycling of transferrin during receptor-mediated endocytosis</article-title><source>PNAS</source><volume>80</volume><fpage>2258</fpage><lpage>2262</lpage><pub-id pub-id-type="doi">10.1073/pnas.80.8.2258</pub-id><pub-id pub-id-type="pmid">6300903</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dayyani</surname><given-names>F</given-names></name><name><surname>Conley</surname><given-names>AP</given-names></name><name><surname>Strom</surname><given-names>SS</given-names></name><name><surname>Stevenson</surname><given-names>W</given-names></name><name><surname>Cortes</surname><given-names>JE</given-names></name><name><surname>Borthakur</surname><given-names>G</given-names></name><name><surname>Faderl</surname><given-names>S</given-names></name><name><surname>O’Brien</surname><given-names>S</given-names></name><name><surname>Pierce</surname><given-names>S</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Garcia-Manero</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cause of death in patients with lower-risk myelodysplastic syndrome</article-title><source>Cancer</source><volume>116</volume><fpage>2174</fpage><lpage>2179</lpage><pub-id pub-id-type="doi">10.1002/cncr.24984</pub-id><pub-id pub-id-type="pmid">20162709</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Modica</surname><given-names>SM</given-names></name><name><surname>Tanzi</surname><given-names>E</given-names></name><name><surname>Olivari</surname><given-names>V</given-names></name><name><surname>Lidonnici</surname><given-names>MR</given-names></name><name><surname>Pettinato</surname><given-names>M</given-names></name><name><surname>Pagani</surname><given-names>A</given-names></name><name><surname>Tiboni</surname><given-names>F</given-names></name><name><surname>Furiosi</surname><given-names>V</given-names></name><name><surname>Silvestri</surname><given-names>L</given-names></name><name><surname>Ferrari</surname><given-names>G</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name><name><surname>Nai</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia</article-title><source>American Journal of Hematology</source><volume>97</volume><fpage>1324</fpage><lpage>1336</lpage><pub-id pub-id-type="doi">10.1002/ajh.26673</pub-id><pub-id pub-id-type="pmid">36071579</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolatshad</surname><given-names>H</given-names></name><name><surname>Pellagatti</surname><given-names>A</given-names></name><name><surname>Fernandez-Mercado</surname><given-names>M</given-names></name><name><surname>Yip</surname><given-names>BH</given-names></name><name><surname>Malcovati</surname><given-names>L</given-names></name><name><surname>Attwood</surname><given-names>M</given-names></name><name><surname>Przychodzen</surname><given-names>B</given-names></name><name><surname>Sahgal</surname><given-names>N</given-names></name><name><surname>Kanapin</surname><given-names>AA</given-names></name><name><surname>Lockstone</surname><given-names>H</given-names></name><name><surname>Scifo</surname><given-names>L</given-names></name><name><surname>Vandenberghe</surname><given-names>P</given-names></name><name><surname>Papaemmanuil</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>CWJ</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name><name><surname>Maciejewski</surname><given-names>JP</given-names></name><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Savage</surname><given-names>KI</given-names></name><name><surname>Boultwood</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells</article-title><source>Leukemia</source><volume>29</volume><fpage>1092</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1038/leu.2014.331</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolatshad</surname><given-names>H</given-names></name><name><surname>Pellagatti</surname><given-names>A</given-names></name><name><surname>Liberante</surname><given-names>FG</given-names></name><name><surname>Llorian</surname><given-names>M</given-names></name><name><surname>Repapi</surname><given-names>E</given-names></name><name><surname>Steeples</surname><given-names>V</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Scifo</surname><given-names>L</given-names></name><name><surname>Armstrong</surname><given-names>RN</given-names></name><name><surname>Shaw</surname><given-names>J</given-names></name><name><surname>Yip</surname><given-names>BH</given-names></name><name><surname>Killick</surname><given-names>S</given-names></name><name><surname>Kušec</surname><given-names>R</given-names></name><name><surname>Taylor</surname><given-names>S</given-names></name><name><surname>Mills</surname><given-names>KI</given-names></name><name><surname>Savage</surname><given-names>KI</given-names></name><name><surname>Smith</surname><given-names>CWJ</given-names></name><name><surname>Boultwood</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes</article-title><source>Leukemia</source><volume>30</volume><fpage>2322</fpage><lpage>2331</lpage><pub-id pub-id-type="doi">10.1038/leu.2016.149</pub-id><pub-id pub-id-type="pmid">27211273</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donovan</surname><given-names>A</given-names></name><name><surname>Lima</surname><given-names>CA</given-names></name><name><surname>Pinkus</surname><given-names>JL</given-names></name><name><surname>Pinkus</surname><given-names>GS</given-names></name><name><surname>Zon</surname><given-names>LI</given-names></name><name><surname>Robine</surname><given-names>S</given-names></name><name><surname>Andrews</surname><given-names>NC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis</article-title><source>Cell Metabolism</source><volume>1</volume><fpage>191</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2005.01.003</pub-id><pub-id pub-id-type="pmid">16054062</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowdle</surname><given-names>WE</given-names></name><name><surname>Nyfeler</surname><given-names>B</given-names></name><name><surname>Nagel</surname><given-names>J</given-names></name><name><surname>Elling</surname><given-names>RA</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Triantafellow</surname><given-names>E</given-names></name><name><surname>Menon</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Honda</surname><given-names>A</given-names></name><name><surname>Pardee</surname><given-names>G</given-names></name><name><surname>Cantwell</surname><given-names>J</given-names></name><name><surname>Luu</surname><given-names>C</given-names></name><name><surname>Cornella-Taracido</surname><given-names>I</given-names></name><name><surname>Harrington</surname><given-names>E</given-names></name><name><surname>Fekkes</surname><given-names>P</given-names></name><name><surname>Lei</surname><given-names>H</given-names></name><name><surname>Fang</surname><given-names>Q</given-names></name><name><surname>Digan</surname><given-names>ME</given-names></name><name><surname>Burdick</surname><given-names>D</given-names></name><name><surname>Powers</surname><given-names>AF</given-names></name><name><surname>Helliwell</surname><given-names>SB</given-names></name><name><surname>D’Aquin</surname><given-names>S</given-names></name><name><surname>Bastien</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wiederschain</surname><given-names>D</given-names></name><name><surname>Kuerth</surname><given-names>J</given-names></name><name><surname>Bergman</surname><given-names>P</given-names></name><name><surname>Schwalb</surname><given-names>D</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Ugwonali</surname><given-names>S</given-names></name><name><surname>Harbinski</surname><given-names>F</given-names></name><name><surname>Tallarico</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>CJ</given-names></name><name><surname>Myer</surname><given-names>VE</given-names></name><name><surname>Porter</surname><given-names>JA</given-names></name><name><surname>Bussiere</surname><given-names>DE</given-names></name><name><surname>Finan</surname><given-names>PM</given-names></name><name><surname>Labow</surname><given-names>MA</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>Hamann</surname><given-names>LG</given-names></name><name><surname>Manning</surname><given-names>BD</given-names></name><name><surname>Valdez</surname><given-names>RA</given-names></name><name><surname>Nicholson</surname><given-names>T</given-names></name><name><surname>Schirle</surname><given-names>M</given-names></name><name><surname>Knapp</surname><given-names>MS</given-names></name><name><surname>Keaney</surname><given-names>EP</given-names></name><name><surname>Murphy</surname><given-names>LO</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo</article-title><source>Nature Cell Biology</source><volume>16</volume><fpage>1069</fpage><lpage>1079</lpage><pub-id pub-id-type="doi">10.1038/ncb3053</pub-id><pub-id pub-id-type="pmid">25327288</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dulmovits</surname><given-names>BM</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Papoin</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Addorisio</surname><given-names>ME</given-names></name><name><surname>Kennedy</surname><given-names>L</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Brindley</surname><given-names>E</given-names></name><name><surname>Ashley</surname><given-names>RJ</given-names></name><name><surname>Ackert-Bicknell</surname><given-names>C</given-names></name><name><surname>Hale</surname><given-names>J</given-names></name><name><surname>Kurita</surname><given-names>R</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Diamond</surname><given-names>B</given-names></name><name><surname>Barnes</surname><given-names>BJ</given-names></name><name><surname>Hermine</surname><given-names>O</given-names></name><name><surname>Gallagher</surname><given-names>PG</given-names></name><name><surname>Steiner</surname><given-names>LA</given-names></name><name><surname>Lipton</surname><given-names>JM</given-names></name><name><surname>Taylor</surname><given-names>N</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name><name><surname>Andersson</surname><given-names>U</given-names></name><name><surname>Al-Abed</surname><given-names>Y</given-names></name><name><surname>Tracey</surname><given-names>KJ</given-names></name><name><surname>Blanc</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>HMGB1-mediated restriction of EPO signaling contributes to anemia of inflammation</article-title><source>Blood</source><volume>139</volume><fpage>3181</fpage><lpage>3193</lpage><pub-id pub-id-type="doi">10.1182/blood.2021012048</pub-id><pub-id pub-id-type="pmid">35040907</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dzierzak</surname><given-names>E</given-names></name><name><surname>Philipsen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Erythropoiesis: development and differentiation</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>3</volume><elocation-id>a011601</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a011601</pub-id><pub-id pub-id-type="pmid">23545573</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckrich</surname><given-names>MJ</given-names></name><name><surname>Frangoul</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach</article-title><source>Seminars in Hematology</source><volume>60</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1053/j.seminhematol.2022.12.001</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>CR</given-names></name><name><surname>Ritchie</surname><given-names>W</given-names></name><name><surname>Wong</surname><given-names>JJ-L</given-names></name><name><surname>Schmitz</surname><given-names>U</given-names></name><name><surname>Middleton</surname><given-names>R</given-names></name><name><surname>An</surname><given-names>X</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name><name><surname>Rasko</surname><given-names>JEJ</given-names></name><name><surname>Blobel</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A dynamic intron retention program in the mammalian megakaryocyte and erythrocyte lineages</article-title><source>Blood</source><volume>127</volume><fpage>e24</fpage><lpage>e34</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-01-692764</pub-id><pub-id pub-id-type="pmid">26962124</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Hoss</surname><given-names>S</given-names></name><name><surname>Cochet</surname><given-names>S</given-names></name><name><surname>Godard</surname><given-names>A</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Dussiot</surname><given-names>M</given-names></name><name><surname>Frati</surname><given-names>G</given-names></name><name><surname>Boutonnat-Faucher</surname><given-names>B</given-names></name><name><surname>Laurance</surname><given-names>S</given-names></name><name><surname>Renaud</surname><given-names>O</given-names></name><name><surname>Joseph</surname><given-names>L</given-names></name><name><surname>Miccio</surname><given-names>A</given-names></name><name><surname>Brousse</surname><given-names>V</given-names></name><name><surname>Narla</surname><given-names>M</given-names></name><name><surname>El Nemer</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease</article-title><source>Haematologica</source><volume>106</volume><fpage>2707</fpage><lpage>2719</lpage><pub-id pub-id-type="doi">10.3324/haematol.2020.265462</pub-id><pub-id pub-id-type="pmid">32855279</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enns</surname><given-names>CA</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ueno</surname><given-names>A</given-names></name><name><surname>Worthen</surname><given-names>C</given-names></name><name><surname>Tsukamoto</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Increased iron loading induces Bmp6 expression in the non-parenchymal cells of the liver independent of the BMP-signaling pathway</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e60534</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0060534</pub-id><pub-id pub-id-type="pmid">23565256</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enns</surname><given-names>CA</given-names></name><name><surname>Jue</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The ectodomain of matriptase-2 plays an important nonproteolytic role in suppressing hepcidin expression in mice</article-title><source>Blood</source><volume>136</volume><fpage>989</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1182/blood.2020005222</pub-id><pub-id pub-id-type="pmid">32384154</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enns</surname><given-names>CA</given-names></name><name><surname>Jue</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>A-S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hepatocyte neogenin is required for hemojuvelin-mediated hepcidin expression and iron homeostasis in mice</article-title><source>Blood</source><volume>138</volume><fpage>486</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1182/blood.2020009485</pub-id><pub-id pub-id-type="pmid">33824974</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esposito</surname><given-names>BP</given-names></name><name><surname>Breuer</surname><given-names>W</given-names></name><name><surname>Sirankapracha</surname><given-names>P</given-names></name><name><surname>Pootrakul</surname><given-names>P</given-names></name><name><surname>Hershko</surname><given-names>C</given-names></name><name><surname>Cabantchik</surname><given-names>ZI</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Labile plasma iron in iron overload: redox activity and susceptibility to chelation</article-title><source>Blood</source><volume>102</volume><fpage>2670</fpage><lpage>2677</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-03-0807</pub-id><pub-id pub-id-type="pmid">12805056</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrukh</surname><given-names>F</given-names></name><name><surname>Chetram</surname><given-names>D</given-names></name><name><surname>Al-Kali</surname><given-names>A</given-names></name><name><surname>Foran</surname><given-names>J</given-names></name><name><surname>Patnaik</surname><given-names>M</given-names></name><name><surname>Badar</surname><given-names>T</given-names></name><name><surname>Begna</surname><given-names>K</given-names></name><name><surname>Hook</surname><given-names>C</given-names></name><name><surname>Hogan</surname><given-names>W</given-names></name><name><surname>McCullough</surname><given-names>KB</given-names></name><name><surname>Mangaonkar</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>R</given-names></name><name><surname>Gangat</surname><given-names>N</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts</article-title><source>American Journal of Hematology</source><volume>97</volume><fpage>E210</fpage><lpage>E214</lpage><pub-id pub-id-type="doi">10.1002/ajh.26533</pub-id><pub-id pub-id-type="pmid">35293000</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feder</surname><given-names>JN</given-names></name><name><surname>Penny</surname><given-names>DM</given-names></name><name><surname>Irrinki</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>VK</given-names></name><name><surname>Lebrón</surname><given-names>JA</given-names></name><name><surname>Watson</surname><given-names>N</given-names></name><name><surname>Tsuchihashi</surname><given-names>Z</given-names></name><name><surname>Sigal</surname><given-names>E</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Schatzman</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding</article-title><source>PNAS</source><volume>95</volume><fpage>1472</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.4.1472</pub-id><pub-id pub-id-type="pmid">9465039</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenaux</surname><given-names>P</given-names></name><name><surname>Platzbecker</surname><given-names>U</given-names></name><name><surname>Mufti</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The medalist trial: results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept to treat anemia in patients with very low-, low-, or intermediate-risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) who require Red Blood Cell (RBC) transfusions</article-title><source>Blood</source><volume>132</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.1182/blood-2018-99-110805</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feola</surname><given-names>M</given-names></name><name><surname>Moskop</surname><given-names>D</given-names></name><name><surname>Terra</surname><given-names>N</given-names></name><name><surname>Park</surname><given-names>YC</given-names></name><name><surname>Dunbar</surname><given-names>A</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Hoffman</surname><given-names>R</given-names></name><name><surname>Ginzburg</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Aberrant responsiveness of erythropoiesis to iron deficiency in polycythemia vera</article-title><source>Blood</source><volume>134</volume><elocation-id>131095</elocation-id><pub-id pub-id-type="doi">10.1182/blood-2019-131095</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fibach</surname><given-names>E</given-names></name><name><surname>Rachmilewitz</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Selective toxicity towards myelodysplastic hematopoietic progenitors - another rationale for iron chelation in MDS</article-title><source>Leukemia Research</source><volume>36</volume><fpage>962</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2012.04.030</pub-id><pub-id pub-id-type="pmid">22633002</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fillebeen</surname><given-names>C</given-names></name><name><surname>Charlebois</surname><given-names>E</given-names></name><name><surname>Wagner</surname><given-names>J</given-names></name><name><surname>Katsarou</surname><given-names>A</given-names></name><name><surname>Mui</surname><given-names>J</given-names></name><name><surname>Vali</surname><given-names>H</given-names></name><name><surname>Garcia-Santos</surname><given-names>D</given-names></name><name><surname>Ponka</surname><given-names>P</given-names></name><name><surname>Presley</surname><given-names>J</given-names></name><name><surname>Pantopoulos</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Transferrin receptor 1 controls systemic iron homeostasis by fine-tuning hepcidin expression to hepatocellular iron load</article-title><source>Blood</source><volume>133</volume><fpage>344</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-05-850404</pub-id><pub-id pub-id-type="pmid">30538134</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finberg</surname><given-names>KE</given-names></name><name><surname>Heeney</surname><given-names>MM</given-names></name><name><surname>Campagna</surname><given-names>DR</given-names></name><name><surname>Aydinok</surname><given-names>Y</given-names></name><name><surname>Pearson</surname><given-names>HA</given-names></name><name><surname>Hartman</surname><given-names>KR</given-names></name><name><surname>Mayo</surname><given-names>MM</given-names></name><name><surname>Samuel</surname><given-names>SM</given-names></name><name><surname>Strouse</surname><given-names>JJ</given-names></name><name><surname>Markianos</surname><given-names>K</given-names></name><name><surname>Andrews</surname><given-names>NC</given-names></name><name><surname>Fleming</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA)</article-title><source>Nature Genetics</source><volume>40</volume><fpage>569</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1038/ng.130</pub-id><pub-id pub-id-type="pmid">18408718</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finch</surname><given-names>CA</given-names></name><name><surname>Deubelbeiss</surname><given-names>K</given-names></name><name><surname>Cook</surname><given-names>JD</given-names></name><name><surname>Eschbach</surname><given-names>JW</given-names></name><name><surname>Harker</surname><given-names>LA</given-names></name><name><surname>Funk</surname><given-names>DD</given-names></name><name><surname>Marsaglia</surname><given-names>G</given-names></name><name><surname>Hillman</surname><given-names>RS</given-names></name><name><surname>Slichter</surname><given-names>S</given-names></name><name><surname>Adamson</surname><given-names>JW</given-names></name><name><surname>Ganzoni</surname><given-names>A</given-names></name><name><surname>Biblett</surname><given-names>ER</given-names></name></person-group><year iso-8601-date="1970">1970</year><article-title>Ferrokinetics in man</article-title><source>Medicine</source><volume>49</volume><fpage>17</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1097/00005792-197001000-00002</pub-id><pub-id pub-id-type="pmid">4908580</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>AL</given-names></name><name><surname>Wang</surname><given-names>C-Y</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Joachim</surname><given-names>K</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Phillips</surname><given-names>S</given-names></name><name><surname>Moschetta</surname><given-names>GA</given-names></name><name><surname>Alfaro-Magallanes</surname><given-names>VM</given-names></name><name><surname>Babitt</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Functional role of endothelial transferrin receptor 1 in iron sensing and homeostasis</article-title><source>American Journal of Hematology</source><volume>97</volume><fpage>1548</fpage><lpage>1559</lpage><pub-id pub-id-type="doi">10.1002/ajh.26716</pub-id><pub-id pub-id-type="pmid">36069607</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>MD</given-names></name><name><surname>Trenor</surname><given-names>CC</given-names></name><name><surname>Su</surname><given-names>MA</given-names></name><name><surname>Foernzler</surname><given-names>D</given-names></name><name><surname>Beier</surname><given-names>DR</given-names></name><name><surname>Dietrich</surname><given-names>WF</given-names></name><name><surname>Andrews</surname><given-names>NC</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene</article-title><source>Nature Genetics</source><volume>16</volume><fpage>383</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1038/ng0897-383</pub-id><pub-id pub-id-type="pmid">9241278</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flygare</surname><given-names>J</given-names></name><name><surname>Rayon Estrada</surname><given-names>V</given-names></name><name><surname>Shin</surname><given-names>C</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>HIF1alpha synergizes with glucocorticoids to promote BFU-E progenitor self-renewal</article-title><source>Blood</source><volume>117</volume><fpage>3435</fpage><lpage>3444</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-07-295550</pub-id><pub-id pub-id-type="pmid">21177435</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forejtnikovà</surname><given-names>H</given-names></name><name><surname>Vieillevoye</surname><given-names>M</given-names></name><name><surname>Zermati</surname><given-names>Y</given-names></name><name><surname>Lambert</surname><given-names>M</given-names></name><name><surname>Pellegrino</surname><given-names>RM</given-names></name><name><surname>Guihard</surname><given-names>S</given-names></name><name><surname>Gaudry</surname><given-names>M</given-names></name><name><surname>Camaschella</surname><given-names>C</given-names></name><name><surname>Lacombe</surname><given-names>C</given-names></name><name><surname>Roetto</surname><given-names>A</given-names></name><name><surname>Mayeux</surname><given-names>P</given-names></name><name><surname>Verdier</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis</article-title><source>Blood</source><volume>116</volume><fpage>5357</fpage><lpage>5367</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-04-281360</pub-id><pub-id pub-id-type="pmid">20826723</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fouquet</surname><given-names>G</given-names></name><name><surname>Thongsa-Ad</surname><given-names>U</given-names></name><name><surname>Lefevre</surname><given-names>C</given-names></name><name><surname>Rousseau</surname><given-names>A</given-names></name><name><surname>Tanhuad</surname><given-names>N</given-names></name><name><surname>Khongkla</surname><given-names>E</given-names></name><name><surname>Saengsawang</surname><given-names>W</given-names></name><name><surname>Anurathapan</surname><given-names>U</given-names></name><name><surname>Hongeng</surname><given-names>S</given-names></name><name><surname>Maciel</surname><given-names>TT</given-names></name><name><surname>Hermine</surname><given-names>O</given-names></name><name><surname>Bhukhai</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Iron-loaded transferrin potentiates erythropoietin effects on erythroblast proliferation and survival: a novel role through transferrin receptors</article-title><source>Experimental Hematology</source><volume>99</volume><fpage>12</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.exphem.2021.05.005</pub-id><pub-id pub-id-type="pmid">34077792</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frise</surname><given-names>MC</given-names></name><name><surname>Cheng</surname><given-names>H-Y</given-names></name><name><surname>Nickol</surname><given-names>AH</given-names></name><name><surname>Curtis</surname><given-names>MK</given-names></name><name><surname>Pollard</surname><given-names>KA</given-names></name><name><surname>Roberts</surname><given-names>DJ</given-names></name><name><surname>Ratcliffe</surname><given-names>PJ</given-names></name><name><surname>Dorrington</surname><given-names>KL</given-names></name><name><surname>Robbins</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Clinical iron deficiency disturbs normal human responses to hypoxia</article-title><source>The Journal of Clinical Investigation</source><volume>126</volume><fpage>2139</fpage><lpage>2150</lpage><pub-id pub-id-type="doi">10.1172/JCI85715</pub-id><pub-id pub-id-type="pmid">27140401</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gammella</surname><given-names>E</given-names></name><name><surname>Diaz</surname><given-names>V</given-names></name><name><surname>Recalcati</surname><given-names>S</given-names></name><name><surname>Buratti</surname><given-names>P</given-names></name><name><surname>Samaja</surname><given-names>M</given-names></name><name><surname>Dey</surname><given-names>S</given-names></name><name><surname>Noguchi</surname><given-names>CT</given-names></name><name><surname>Gassmann</surname><given-names>M</given-names></name><name><surname>Cairo</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Erythropoietin’s inhibiting impact on hepcidin expression occurs indirectly</article-title><source>American Journal of Physiology. Regulatory, Integrative and Comparative Physiology</source><volume>308</volume><fpage>R330</fpage><lpage>R335</lpage><pub-id pub-id-type="doi">10.1152/ajpregu.00410.2014</pub-id><pub-id pub-id-type="pmid">25519735</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganesh</surname><given-names>SK</given-names></name><name><surname>Zakai</surname><given-names>NA</given-names></name><name><surname>van Rooij</surname><given-names>FJA</given-names></name><name><surname>Soranzo</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>AV</given-names></name><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Chen</surname><given-names>M-H</given-names></name><name><surname>Kottgen</surname><given-names>A</given-names></name><name><surname>Glazer</surname><given-names>NL</given-names></name><name><surname>Dehghan</surname><given-names>A</given-names></name><name><surname>Kuhnel</surname><given-names>B</given-names></name><name><surname>Aspelund</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Jaffe</surname><given-names>A</given-names></name><name><surname>Bis</surname><given-names>JCM</given-names></name><name><surname>Verwoert</surname><given-names>GC</given-names></name><name><surname>Teumer</surname><given-names>A</given-names></name><name><surname>Fox</surname><given-names>CS</given-names></name><name><surname>Guralnik</surname><given-names>JM</given-names></name><name><surname>Ehret</surname><given-names>GB</given-names></name><name><surname>Rice</surname><given-names>K</given-names></name><name><surname>Felix</surname><given-names>JF</given-names></name><name><surname>Rendon</surname><given-names>A</given-names></name><name><surname>Eiriksdottir</surname><given-names>G</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Patel</surname><given-names>KV</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Sambrook</surname><given-names>JG</given-names></name><name><surname>Hernandez</surname><given-names>DG</given-names></name><name><surname>Zheng</surname><given-names>G</given-names></name><name><surname>Bandinelli</surname><given-names>S</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Lumley</surname><given-names>T</given-names></name><name><surname>Uitterlinden</surname><given-names>AG</given-names></name><name><surname>Vangils</surname><given-names>JM</given-names></name><name><surname>Launer</surname><given-names>LJ</given-names></name><name><surname>Cupples</surname><given-names>LA</given-names></name><name><surname>Oostra</surname><given-names>BA</given-names></name><name><surname>Zwaginga</surname><given-names>J-J</given-names></name><name><surname>Ouwehand</surname><given-names>WH</given-names></name><name><surname>Thein</surname><given-names>S-L</given-names></name><name><surname>Meisinger</surname><given-names>C</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Spector</surname><given-names>TD</given-names></name><name><surname>Gieger</surname><given-names>C</given-names></name><name><surname>Gudnason</surname><given-names>V</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Chakravarti</surname><given-names>A</given-names></name><name><surname>Greinacher</surname><given-names>A</given-names></name><name><surname>O’Donnell</surname><given-names>CJ</given-names></name><name><surname>Witteman</surname><given-names>JCM</given-names></name><name><surname>Furth</surname><given-names>S</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name><name><surname>Lin</surname><given-names>J-P</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium</article-title><source>Nature Genetics</source><volume>41</volume><fpage>1191</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1038/ng.466</pub-id><pub-id pub-id-type="pmid">19862010</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganz</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Hepcidin--a regulator of intestinal iron absorption and iron recycling by macrophages</article-title><source>Best Practice &amp; Research. Clinical Haematology</source><volume>18</volume><fpage>171</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.beha.2004.08.020</pub-id><pub-id pub-id-type="pmid">15737883</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>Nemeth</surname><given-names>E</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name><name><surname>Goldberg</surname><given-names>P</given-names></name><name><surname>Dibble</surname><given-names>AR</given-names></name><name><surname>McCaleb</surname><given-names>ML</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Monia</surname><given-names>BP</given-names></name><name><surname>Barrett</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>TMPRSS6 as a therapeutic target for disorders of erythropoiesis and iron homeostasis</article-title><source>Advances in Therapy</source><volume>40</volume><fpage>1317</fpage><lpage>1333</lpage><pub-id pub-id-type="doi">10.1007/s12325-022-02421-w</pub-id><pub-id pub-id-type="pmid">36690839</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Manero</surname><given-names>G</given-names></name><name><surname>Shan</surname><given-names>J</given-names></name><name><surname>Faderl</surname><given-names>S</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Ravandi</surname><given-names>F</given-names></name><name><surname>Borthakur</surname><given-names>G</given-names></name><name><surname>Wierda</surname><given-names>WG</given-names></name><name><surname>Pierce</surname><given-names>S</given-names></name><name><surname>Estey</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A prognostic score for patients with lower risk myelodysplastic syndrome</article-title><source>Leukemia</source><volume>22</volume><fpage>538</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2405070</pub-id><pub-id pub-id-type="pmid">18079733</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardenghi</surname><given-names>S</given-names></name><name><surname>Marongiu</surname><given-names>MF</given-names></name><name><surname>Ramos</surname><given-names>P</given-names></name><name><surname>Guy</surname><given-names>E</given-names></name><name><surname>Breda</surname><given-names>L</given-names></name><name><surname>Chadburn</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Amariglio</surname><given-names>N</given-names></name><name><surname>Rechavi</surname><given-names>G</given-names></name><name><surname>Rachmilewitz</surname><given-names>EA</given-names></name><name><surname>Breuer</surname><given-names>W</given-names></name><name><surname>Cabantchik</surname><given-names>ZI</given-names></name><name><surname>Wrighting</surname><given-names>DM</given-names></name><name><surname>Andrews</surname><given-names>NC</given-names></name><name><surname>de Sousa</surname><given-names>M</given-names></name><name><surname>Giardina</surname><given-names>PJ</given-names></name><name><surname>Grady</surname><given-names>RW</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Ineffective erythropoiesis in β-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin</article-title><source>Blood</source><volume>109</volume><fpage>5027</fpage><lpage>5035</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-09-048868</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardenghi</surname><given-names>S</given-names></name><name><surname>Renaud</surname><given-names>TM</given-names></name><name><surname>Meloni</surname><given-names>A</given-names></name><name><surname>Casu</surname><given-names>C</given-names></name><name><surname>Crielaard</surname><given-names>BJ</given-names></name><name><surname>Bystrom</surname><given-names>LM</given-names></name><name><surname>Greenberg-Kushnir</surname><given-names>N</given-names></name><name><surname>Sasu</surname><given-names>BJ</given-names></name><name><surname>Cooke</surname><given-names>KS</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Distinct roles for hepcidin and interleukin-6 in the recovery from anemia in mice injected with heat-killed Brucella abortus</article-title><source>Blood</source><volume>123</volume><fpage>1137</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-08-521625</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gattermann</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Clinical consequences of iron overload in myelodysplastic syndromes and treatment with chelators</article-title><source>Hematology/Oncology Clinics</source><volume>19</volume><fpage>13</fpage><lpage>17</lpage></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gehrer</surname><given-names>CM</given-names></name><name><surname>Mitterstiller</surname><given-names>AM</given-names></name><name><surname>Grubwieser</surname><given-names>P</given-names></name><name><surname>Meyron-Holtz</surname><given-names>EG</given-names></name><name><surname>Weiss</surname><given-names>G</given-names></name><name><surname>Nairz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Advances in ferritin physiology and possible implications in bacterial infection</article-title><source>International Journal of Molecular Sciences</source><volume>24</volume><elocation-id>4659</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24054659</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gianelli</surname><given-names>U</given-names></name><name><surname>Iurlo</surname><given-names>A</given-names></name><name><surname>Vener</surname><given-names>C</given-names></name><name><surname>Moro</surname><given-names>A</given-names></name><name><surname>Fermo</surname><given-names>E</given-names></name><name><surname>Bianchi</surname><given-names>P</given-names></name><name><surname>Graziani</surname><given-names>D</given-names></name><name><surname>Radaelli</surname><given-names>F</given-names></name><name><surname>Coggi</surname><given-names>G</given-names></name><name><surname>Bosari</surname><given-names>S</given-names></name><name><surname>Deliliers</surname><given-names>GL</given-names></name><name><surname>Zanella</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the “early” prepolycythemic phase of polycythemia vera and essential thrombocythemia</article-title><source>American Journal of Clinical Pathology</source><volume>130</volume><fpage>336</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1309/6BQ5K8LHVYAKUAF4</pub-id><pub-id pub-id-type="pmid">18701405</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannetti</surname><given-names>AM</given-names></name><name><surname>Björkman</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>HFE and transferrin directly compete for transferrin receptor in solution and at the cell surface</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>25866</fpage><lpage>25875</lpage><pub-id pub-id-type="doi">10.1074/jbc.M401467200</pub-id><pub-id pub-id-type="pmid">15056661</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginzburg</surname><given-names>YZ</given-names></name><name><surname>Rybicki</surname><given-names>AC</given-names></name><name><surname>Suzuka</surname><given-names>SM</given-names></name><name><surname>Hall</surname><given-names>CB</given-names></name><name><surname>Breuer</surname><given-names>W</given-names></name><name><surname>Cabantchik</surname><given-names>ZI</given-names></name><name><surname>Bouhassira</surname><given-names>EE</given-names></name><name><surname>Fabry</surname><given-names>ME</given-names></name><name><surname>Nagel</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Exogenous iron increases hemoglobin in beta-thalassemic mice</article-title><source>Experimental Hematology</source><volume>37</volume><fpage>172</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.exphem.2008.10.004</pub-id><pub-id pub-id-type="pmid">19059700</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginzburg</surname><given-names>Y</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism</article-title><source>Blood</source><volume>118</volume><fpage>4321</fpage><lpage>4330</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-03-283614</pub-id><pub-id pub-id-type="pmid">21768301</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginzburg</surname><given-names>YZ</given-names></name><name><surname>Feola</surname><given-names>M</given-names></name><name><surname>Zimran</surname><given-names>E</given-names></name><name><surname>Varkonyi</surname><given-names>J</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>Hoffman</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dysregulated iron metabolism in polycythemia vera: etiology and consequences</article-title><source>Leukemia</source><volume>32</volume><fpage>2105</fpage><lpage>2116</lpage><pub-id pub-id-type="doi">10.1038/s41375-018-0207-9</pub-id><pub-id pub-id-type="pmid">30042411</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginzburg</surname><given-names>Y.Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hepcidin-ferroportin axis in health and disease</article-title><source>Vitamins and Hormones</source><volume>110</volume><fpage>17</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/bs.vh.2019.01.002</pub-id><pub-id pub-id-type="pmid">30798811</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginzburg</surname><given-names>Y</given-names></name><name><surname>Kirubamoorthy</surname><given-names>K</given-names></name><name><surname>Salleh</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>SE</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Selvaratnam</surname><given-names>V</given-names></name><name><surname>Gupta</surname><given-names>SK</given-names></name><name><surname>Valone</surname><given-names>F</given-names></name><name><surname>Khanna</surname><given-names>S</given-names></name><name><surname>Modi</surname><given-names>NB</given-names></name><name><surname>Hoffman</surname><given-names>R</given-names></name><name><surname>Chew</surname><given-names>LP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic phlebotomy</article-title><source>Blood</source><volume>138</volume><elocation-id>149205</elocation-id><pub-id pub-id-type="doi">10.1182/blood-2021-149205</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldfarb</surname><given-names>AN</given-names></name><name><surname>Freeman</surname><given-names>KC</given-names></name><name><surname>Sahu</surname><given-names>RK</given-names></name><name><surname>Elagib</surname><given-names>KE</given-names></name><name><surname>Holy</surname><given-names>M</given-names></name><name><surname>Arneja</surname><given-names>A</given-names></name><name><surname>Polanowska-Grabowska</surname><given-names>R</given-names></name><name><surname>Gru</surname><given-names>AA</given-names></name><name><surname>White</surname><given-names>Z</given-names></name><name><surname>Khalil</surname><given-names>S</given-names></name><name><surname>Kerins</surname><given-names>MJ</given-names></name><name><surname>Ooi</surname><given-names>A</given-names></name><name><surname>Leitinger</surname><given-names>N</given-names></name><name><surname>Luckey</surname><given-names>CJ</given-names></name><name><surname>Delehanty</surname><given-names>LL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Iron control of erythroid microtubule cytoskeleton as a potential target in treatment of iron-restricted anemia</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>1645</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-21938-2</pub-id><pub-id pub-id-type="pmid">33712594</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomme</surname><given-names>PT</given-names></name><name><surname>McCann</surname><given-names>KB</given-names></name><name><surname>Bertolini</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Transferrin: structure, function and potential therapeutic actions</article-title><source>Drug Discovery Today</source><volume>10</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1016/S1359-6446(04)03333-1</pub-id><pub-id pub-id-type="pmid">15708745</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>CJ</given-names></name><name><surname>Eaves</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="1977">1977</year><article-title>Human marrow cells capable of erythropoietic differentiation in vitro: definition of three erythroid colony responses</article-title><source>Blood</source><volume>49</volume><fpage>855</fpage><lpage>864</lpage><pub-id pub-id-type="pmid">861374</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gronowicz</surname><given-names>G</given-names></name><name><surname>Swift</surname><given-names>H</given-names></name><name><surname>Steck</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Maturation of the reticulocyte in vitro</article-title><source>Journal of Cell Science</source><volume>71</volume><fpage>177</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1242/jcs.71.1.177</pub-id><pub-id pub-id-type="pmid">6097593</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Fei</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The evaluation of iron overload through hepcidin level and its related factors in myelodysplastic syndromes</article-title><source>Hematology</source><volume>18</volume><fpage>286</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1179/1607845412Y.0000000064</pub-id><pub-id pub-id-type="pmid">23540794</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunshin</surname><given-names>H</given-names></name><name><surname>Mackenzie</surname><given-names>B</given-names></name><name><surname>Berger</surname><given-names>UV</given-names></name><name><surname>Gunshin</surname><given-names>Y</given-names></name><name><surname>Romero</surname><given-names>MF</given-names></name><name><surname>Boron</surname><given-names>WF</given-names></name><name><surname>Nussberger</surname><given-names>S</given-names></name><name><surname>Gollan</surname><given-names>JL</given-names></name><name><surname>Hediger</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Cloning and characterization of a mammalian proton-coupled metal-ion transporter</article-title><source>Nature</source><volume>388</volume><fpage>482</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1038/41343</pub-id><pub-id pub-id-type="pmid">9242408</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Casu</surname><given-names>C</given-names></name><name><surname>Gardenghi</surname><given-names>S</given-names></name><name><surname>Booten</surname><given-names>S</given-names></name><name><surname>Aghajan</surname><given-names>M</given-names></name><name><surname>Peralta</surname><given-names>R</given-names></name><name><surname>Watt</surname><given-names>A</given-names></name><name><surname>Freier</surname><given-names>S</given-names></name><name><surname>Monia</surname><given-names>BP</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice</article-title><source>Journal of Clinical Investigation</source><volume>123</volume><fpage>1531</fpage><lpage>1541</lpage><pub-id pub-id-type="doi">10.1172/JCI66969</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Jing</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Analysis of the correlation of gestational diabetes mellitus and peripheral ferritin with iron levels in early pregnancy</article-title><source>Minerva Endocrinologica</source><volume>44</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.23736/S0391-1977.18.02734-7</pub-id><pub-id pub-id-type="pmid">29442476</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haferlach</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The molecular pathology of myelodysplastic syndrome</article-title><source>Pathobiology</source><volume>86</volume><fpage>24</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1159/000488712</pub-id><pub-id pub-id-type="pmid">29791902</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamdi</surname><given-names>A</given-names></name><name><surname>Roshan</surname><given-names>TM</given-names></name><name><surname>Kahawita</surname><given-names>TM</given-names></name><name><surname>Mason</surname><given-names>AB</given-names></name><name><surname>Sheftel</surname><given-names>AD</given-names></name><name><surname>Ponka</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Erythroid cell mitochondria receive endosomal iron by a “kiss-and-run” mechanism</article-title><source>Biochimica et Biophysica Acta</source><volume>1863</volume><fpage>2859</fpage><lpage>2867</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2016.09.008</pub-id><pub-id pub-id-type="pmid">27627839</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Handa</surname><given-names>S</given-names></name><name><surname>Ginzburg</surname><given-names>Y</given-names></name><name><surname>Hoffman</surname><given-names>R</given-names></name><name><surname>Kremyanskaya</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis</article-title><source>Current Opinion in Hematology</source><volume>30</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1097/MOH.0000000000000747</pub-id><pub-id pub-id-type="pmid">36728649</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>J</given-names></name><name><surname>Braulke</surname><given-names>F</given-names></name><name><surname>Sinzig</surname><given-names>U</given-names></name><name><surname>Wulf</surname><given-names>G</given-names></name><name><surname>Maas</surname><given-names>JH</given-names></name><name><surname>Konietschke</surname><given-names>F</given-names></name><name><surname>Haase</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes</article-title><source>Leukemia Research</source><volume>37</volume><fpage>327</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2012.11.005</pub-id><pub-id pub-id-type="pmid">23259989</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heeney</surname><given-names>MM</given-names></name><name><surname>Finberg</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Iron-refractory iron deficiency anemia (IRIDA)</article-title><source>Hematology/Oncology Clinics of North America</source><volume>28</volume><fpage>637</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1016/j.hoc.2014.04.009</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Rusfertide (PTG-300) controls hematocrit levels and essentially eliminates phlebotomy requirement in polycythemia vera patients</article-title><source>Blood</source><volume>138</volume><elocation-id>388</elocation-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>R</given-names></name><name><surname>Ginzburg</surname><given-names>Y</given-names></name><name><surname>Kremyanskaya</surname><given-names>M</given-names></name><name><surname>Khanna</surname><given-names>S</given-names></name><name><surname>Modi</surname><given-names>N</given-names></name><name><surname>Valone</surname><given-names>FH</given-names></name><name><surname>O’Connor</surname><given-names>PG</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Saks</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients</article-title><source>Journal of Clinical Oncology</source><volume>40</volume><elocation-id>7003</elocation-id><pub-id pub-id-type="doi">10.1200/JCO.2022.40.16_suppl.7003</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooper</surname><given-names>JD</given-names></name><name><surname>Campagnolo</surname><given-names>L</given-names></name><name><surname>Goodarzi</surname><given-names>G</given-names></name><name><surname>Truong</surname><given-names>TN</given-names></name><name><surname>Stuhlmann</surname><given-names>H</given-names></name><name><surname>Quigley</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Mouse matriptase-2: identification, characterization and comparative mRNA expression analysis with mouse hepsin in adult and embryonic tissues</article-title><source>The Biochemical Journal</source><volume>373</volume><fpage>689</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1042/BJ20030390</pub-id><pub-id pub-id-type="pmid">12744720</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>F</given-names></name><name><surname>Halverson</surname><given-names>G</given-names></name><name><surname>Reid</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Raza</surname><given-names>A</given-names></name><name><surname>Galili</surname><given-names>N</given-names></name><name><surname>Jaffray</surname><given-names>J</given-names></name><name><surname>Lane</surname><given-names>J</given-names></name><name><surname>Chasis</surname><given-names>JA</given-names></name><name><surname>Taylor</surname><given-names>N</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name><name><surname>An</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo</article-title><source>Blood</source><volume>121</volume><fpage>3246</fpage><lpage>3253</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-01-476390</pub-id><pub-id pub-id-type="pmid">23422750</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iacopetta</surname><given-names>BJ</given-names></name><name><surname>Morgan</surname><given-names>EH</given-names></name><name><surname>Yeoh</surname><given-names>GC</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Receptor-mediated endocytosis of transferrin by developing erythroid cells from the fetal rat liver</article-title><source>The Journal of Histochemistry and Cytochemistry</source><volume>31</volume><fpage>336</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1177/31.2.6300220</pub-id><pub-id pub-id-type="pmid">6300220</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iscove</surname><given-names>NN</given-names></name><name><surname>Sieber</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1975">1975</year><article-title>Erythroid progenitors in mouse bone marrow detected by macroscopic colony formation in culture</article-title><source>Experimental Hematology</source><volume>3</volume><fpage>32</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">1157835</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>C</given-names></name><name><surname>Ugo</surname><given-names>V</given-names></name><name><surname>Le Couédic</surname><given-names>J-P</given-names></name><name><surname>Staerk</surname><given-names>J</given-names></name><name><surname>Delhommeau</surname><given-names>F</given-names></name><name><surname>Lacout</surname><given-names>C</given-names></name><name><surname>Garçon</surname><given-names>L</given-names></name><name><surname>Raslova</surname><given-names>H</given-names></name><name><surname>Berger</surname><given-names>R</given-names></name><name><surname>Bennaceur-Griscelli</surname><given-names>A</given-names></name><name><surname>Villeval</surname><given-names>JL</given-names></name><name><surname>Constantinescu</surname><given-names>SN</given-names></name><name><surname>Casadevall</surname><given-names>N</given-names></name><name><surname>Vainchenker</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera</article-title><source>Nature</source><volume>434</volume><fpage>1144</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1038/nature03546</pub-id><pub-id pub-id-type="pmid">15793561</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeffery</surname><given-names>NN</given-names></name><name><surname>Davidson</surname><given-names>C</given-names></name><name><surname>Peslak</surname><given-names>SA</given-names></name><name><surname>Kingsley</surname><given-names>PD</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Palis</surname><given-names>J</given-names></name><name><surname>Bulger</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Histone H2A.X phosphorylation and Caspase-Initiated Chromatin Condensation in late-stage erythropoiesis</article-title><source>Epigenetics &amp; Chromatin</source><volume>14</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.1186/s13072-021-00408-5</pub-id><pub-id pub-id-type="pmid">34330317</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkitkasemwong</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>C-Y</given-names></name><name><surname>Coffey</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Chan</surname><given-names>A</given-names></name><name><surname>Biel</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>J-S</given-names></name><name><surname>Hojyo</surname><given-names>S</given-names></name><name><surname>Fukada</surname><given-names>T</given-names></name><name><surname>Knutson</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>SLC39A14 Is required for the development of hepatocellular iron overload in murine models of hereditary hemochromatosis</article-title><source>Cell Metabolism</source><volume>22</volume><fpage>138</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2015.05.002</pub-id><pub-id pub-id-type="pmid">26028554</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>P.</given-names></name><name><surname>Jayapal</surname><given-names>SR</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Enucleation of cultured mouse fetal erythroblasts requires Rac GTPases and mDia2</article-title><source>Nature Cell Biology</source><volume>10</volume><fpage>314</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1038/ncb1693</pub-id><pub-id pub-id-type="pmid">18264091</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>Peng</given-names></name><name><surname>Yeh</surname><given-names>V</given-names></name><name><surname>Ramirez</surname><given-names>T</given-names></name><name><surname>Murata-Hori</surname><given-names>M</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Histone deacetylase 2 is required for chromatin condensation and subsequent enucleation of cultured mouse fetal erythroblasts</article-title><source>Haematologica</source><volume>95</volume><fpage>2013</fpage><lpage>2021</lpage><pub-id pub-id-type="doi">10.3324/haematol.2010.029827</pub-id><pub-id pub-id-type="pmid">20823130</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>MB</given-names></name><name><surname>Enns</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Diferric transferrin regulates transferrin receptor 2 protein stability</article-title><source>Blood</source><volume>104</volume><fpage>4287</fpage><lpage>4293</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-06-2477</pub-id><pub-id pub-id-type="pmid">15319290</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kattamis</surname><given-names>A</given-names></name><name><surname>Kwiatkowski</surname><given-names>JL</given-names></name><name><surname>Aydinok</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Thalassaemia</article-title><source>Lancet</source><volume>399</volume><fpage>2310</fpage><lpage>2324</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)00536-0</pub-id><pub-id pub-id-type="pmid">35691301</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kautz</surname><given-names>L</given-names></name><name><surname>Jung</surname><given-names>G</given-names></name><name><surname>Valore</surname><given-names>EV</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name><name><surname>Nemeth</surname><given-names>E</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of erythroferrone as an erythroid regulator of iron metabolism</article-title><source>Nature Genetics</source><volume>46</volume><fpage>678</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1038/ng.2996</pub-id><pub-id pub-id-type="pmid">24880340</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kautz</surname><given-names>L</given-names></name><name><surname>Jung</surname><given-names>G</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Gabayan</surname><given-names>V</given-names></name><name><surname>Chapman</surname><given-names>J</given-names></name><name><surname>Nasoff</surname><given-names>M</given-names></name><name><surname>Nemeth</surname><given-names>E</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia</article-title><source>Blood</source><volume>126</volume><fpage>2031</fpage><lpage>2037</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-07-658419</pub-id><pub-id pub-id-type="pmid">26276665</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawane</surname><given-names>K</given-names></name><name><surname>Fukuyama</surname><given-names>H</given-names></name><name><surname>Kondoh</surname><given-names>G</given-names></name><name><surname>Takeda</surname><given-names>J</given-names></name><name><surname>Ohsawa</surname><given-names>Y</given-names></name><name><surname>Uchiyama</surname><given-names>Y</given-names></name><name><surname>Nagata</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Requirement of DNase II for definitive erythropoiesis in the mouse fetal liver</article-title><source>Science</source><volume>292</volume><fpage>1546</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1126/science.292.5521.1546</pub-id><pub-id pub-id-type="pmid">11375492</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keerthivasan</surname><given-names>G</given-names></name><name><surname>Small</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wickrema</surname><given-names>A</given-names></name><name><surname>Crispino</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Vesicle trafficking plays a novel role in erythroblast enucleation</article-title><source>Blood</source><volume>116</volume><fpage>3331</fpage><lpage>3340</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-03-277426</pub-id><pub-id pub-id-type="pmid">20644112</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>S</given-names></name><name><surname>Holy</surname><given-names>M</given-names></name><name><surname>Grado</surname><given-names>S</given-names></name><name><surname>Fleming</surname><given-names>R</given-names></name><name><surname>Kurita</surname><given-names>R</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Goldfarb</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A specialized pathway for erythroid iron delivery through lysosomal trafficking of transferrin receptor 2</article-title><source>Blood Advances</source><volume>1</volume><fpage>1181</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2016003772</pub-id><pub-id pub-id-type="pmid">29296759</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>S</given-names></name><name><surname>Delehanty</surname><given-names>L</given-names></name><name><surname>Grado</surname><given-names>S</given-names></name><name><surname>Holy</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>Z</given-names></name><name><surname>Freeman</surname><given-names>K</given-names></name><name><surname>Kurita</surname><given-names>R</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Bullock</surname><given-names>G</given-names></name><name><surname>Goldfarb</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor</article-title><source>The Journal of Experimental Medicine</source><volume>215</volume><fpage>661</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1084/jem.20170396</pub-id><pub-id pub-id-type="pmid">29282252</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klausner</surname><given-names>RD</given-names></name><name><surname>Ashwell</surname><given-names>G</given-names></name><name><surname>van Renswoude</surname><given-names>J</given-names></name><name><surname>Harford</surname><given-names>JB</given-names></name><name><surname>Bridges</surname><given-names>KR</given-names></name></person-group><year iso-8601-date="1983">1983a</year><article-title>Binding of apotransferrin to K562 cells: explanation of the transferrin cycle</article-title><source>PNAS</source><volume>80</volume><fpage>2263</fpage><lpage>2266</lpage><pub-id pub-id-type="doi">10.1073/pnas.80.8.2263</pub-id><pub-id pub-id-type="pmid">6300904</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klausner</surname><given-names>RD</given-names></name><name><surname>Van Renswoude</surname><given-names>J</given-names></name><name><surname>Ashwell</surname><given-names>G</given-names></name><name><surname>Kempf</surname><given-names>C</given-names></name><name><surname>Schechter</surname><given-names>AN</given-names></name><name><surname>Dean</surname><given-names>A</given-names></name><name><surname>Bridges</surname><given-names>KR</given-names></name></person-group><year iso-8601-date="1983">1983b</year><article-title>Receptor-mediated endocytosis of transferrin in K562 cells</article-title><source>The Journal of Biological Chemistry</source><volume>258</volume><fpage>4715</fpage><lpage>4724</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)32481-5</pub-id><pub-id pub-id-type="pmid">6300098</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolbus</surname><given-names>A</given-names></name><name><surname>Blázquez-Domingo</surname><given-names>M</given-names></name><name><surname>Carotta</surname><given-names>S</given-names></name><name><surname>Bakker</surname><given-names>W</given-names></name><name><surname>Luedemann</surname><given-names>S</given-names></name><name><surname>von Lindern</surname><given-names>M</given-names></name><name><surname>Steinlein</surname><given-names>P</given-names></name><name><surname>Beug</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cooperative signaling between cytokine receptors and the glucocorticoid receptor in the expansion of erythroid progenitors: molecular analysis by expression profiling</article-title><source>Blood</source><volume>102</volume><fpage>3136</fpage><lpage>3146</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-03-0923</pub-id><pub-id pub-id-type="pmid">12869505</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konstantinidis</surname><given-names>DG</given-names></name><name><surname>Pushkaran</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>JF</given-names></name><name><surname>Cancelas</surname><given-names>JA</given-names></name><name><surname>Manganaris</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>CE</given-names></name><name><surname>Williams</surname><given-names>DA</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Kalfa</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Signaling and cytoskeletal requirements in erythroblast enucleation</article-title><source>Blood</source><volume>119</volume><fpage>6118</fpage><lpage>6127</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-09-379263</pub-id><pub-id pub-id-type="pmid">22461493</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kragesteen</surname><given-names>BK</given-names></name><name><surname>Giladi</surname><given-names>A</given-names></name><name><surname>David</surname><given-names>E</given-names></name><name><surname>Halevi</surname><given-names>S</given-names></name><name><surname>Geirsdóttir</surname><given-names>L</given-names></name><name><surname>Lempke</surname><given-names>OM</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Bapst</surname><given-names>AM</given-names></name><name><surname>Xie</surname><given-names>K</given-names></name><name><surname>Katzenelenbogen</surname><given-names>Y</given-names></name><name><surname>Dahl</surname><given-names>SL</given-names></name><name><surname>Sheban</surname><given-names>F</given-names></name><name><surname>Gurevich-Shapiro</surname><given-names>A</given-names></name><name><surname>Zada</surname><given-names>M</given-names></name><name><surname>Phan</surname><given-names>TS</given-names></name><name><surname>Avellino</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>SY</given-names></name><name><surname>Barboy</surname><given-names>O</given-names></name><name><surname>Shlomi-Loubaton</surname><given-names>S</given-names></name><name><surname>Winning</surname><given-names>S</given-names></name><name><surname>Markwerth</surname><given-names>PP</given-names></name><name><surname>Dekalo</surname><given-names>S</given-names></name><name><surname>Keren-Shaul</surname><given-names>H</given-names></name><name><surname>Kedmi</surname><given-names>M</given-names></name><name><surname>Sikora</surname><given-names>M</given-names></name><name><surname>Fandrey</surname><given-names>J</given-names></name><name><surname>Korneliussen</surname><given-names>TS</given-names></name><name><surname>Prchal</surname><given-names>JT</given-names></name><name><surname>Rosenzweig</surname><given-names>B</given-names></name><name><surname>Yutkin</surname><given-names>V</given-names></name><name><surname>Racimo</surname><given-names>F</given-names></name><name><surname>Willerslev</surname><given-names>E</given-names></name><name><surname>Gur</surname><given-names>C</given-names></name><name><surname>Wenger</surname><given-names>RH</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The transcriptional and regulatory identity of erythropoietin producing cells</article-title><source>Nature Medicine</source><volume>29</volume><fpage>1191</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02314-7</pub-id><pub-id pub-id-type="pmid">37106166</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kralovics</surname><given-names>R</given-names></name><name><surname>Passamonti</surname><given-names>F</given-names></name><name><surname>Buser</surname><given-names>AS</given-names></name><name><surname>Teo</surname><given-names>S-S</given-names></name><name><surname>Tiedt</surname><given-names>R</given-names></name><name><surname>Passweg</surname><given-names>JR</given-names></name><name><surname>Tichelli</surname><given-names>A</given-names></name><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Skoda</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A gain-of-function mutation of JAK2 in myeloproliferative disorders</article-title><source>The New England Journal of Medicine</source><volume>352</volume><fpage>1779</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa051113</pub-id><pub-id pub-id-type="pmid">15858187</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>A</given-names></name><name><surname>Neitz</surname><given-names>S</given-names></name><name><surname>Mägert</surname><given-names>HJ</given-names></name><name><surname>Schulz</surname><given-names>A</given-names></name><name><surname>Forssmann</surname><given-names>WG</given-names></name><name><surname>Schulz-Knappe</surname><given-names>P</given-names></name><name><surname>Adermann</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity</article-title><source>FEBS Letters</source><volume>480</volume><fpage>147</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/s0014-5793(00)01920-7</pub-id><pub-id pub-id-type="pmid">11034317</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krijt</surname><given-names>J</given-names></name><name><surname>Frýdlová</surname><given-names>J</given-names></name><name><surname>Gurieva</surname><given-names>I</given-names></name><name><surname>Přikryl</surname><given-names>P</given-names></name><name><surname>Báječný</surname><given-names>M</given-names></name><name><surname>Steinbicker</surname><given-names>AU</given-names></name><name><surname>Vokurka</surname><given-names>M</given-names></name><name><surname>Truksa</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Matriptase-2 and hemojuvelin in hepcidin regulation: in vivo immunoblot studies in mask mice</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>2650</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22052650</pub-id><pub-id pub-id-type="pmid">33800732</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kröger</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Induction, bridging, or straight ahead: The ongoing dilemma of allografting in advanced myelodysplastic syndrome</article-title><source>Biology of Blood and Marrow Transplantation</source><volume>25</volume><fpage>e247</fpage><lpage>e249</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2019.06.016</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kundu</surname><given-names>M</given-names></name><name><surname>Lindsten</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>C-Y</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Selak</surname><given-names>MA</given-names></name><name><surname>Ney</surname><given-names>PA</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Ulk1 plays a critical role in the autophagic clearance of mitochondria and ribosomes during reticulocyte maturation</article-title><source>Blood</source><volume>112</volume><fpage>1493</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-02-137398</pub-id><pub-id pub-id-type="pmid">18539900</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>KHM</given-names></name><name><surname>Layton</surname><given-names>DM</given-names></name><name><surname>Lal</surname><given-names>A</given-names></name><name><surname>Al-Samkari</surname><given-names>H</given-names></name><name><surname>Bhatia</surname><given-names>J</given-names></name><name><surname>Kosinski</surname><given-names>PA</given-names></name><name><surname>Tong</surname><given-names>B</given-names></name><name><surname>Lynch</surname><given-names>M</given-names></name><name><surname>Uhlig</surname><given-names>K</given-names></name><name><surname>Vichinsky</surname><given-names>EP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study</article-title><source>The Lancet</source><volume>400</volume><fpage>493</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)01337-X</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwapisz</surname><given-names>J</given-names></name><name><surname>Zekanowska</surname><given-names>E</given-names></name><name><surname>Jasiniewska</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Decreased serum prohepcidin concentration in patients with polycythemia vera</article-title><source>Journal of Zhejiang University. Science. B</source><volume>10</volume><fpage>791</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1631/jzus.B0920217</pub-id><pub-id pub-id-type="pmid">19882752</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>LKM</given-names></name><name><surname>Murphy</surname><given-names>S</given-names></name><name><surname>Kokkinaki</surname><given-names>D</given-names></name><name><surname>Venosa</surname><given-names>A</given-names></name><name><surname>Sherrill-Mix</surname><given-names>S</given-names></name><name><surname>Casu</surname><given-names>C</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name><name><surname>Weiner</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Vaughan</surname><given-names>AE</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Odom John</surname><given-names>AR</given-names></name><name><surname>Meyer</surname><given-names>NJ</given-names></name><name><surname>Hunter</surname><given-names>CA</given-names></name><name><surname>Worthen</surname><given-names>GS</given-names></name><name><surname>Mangalmurti</surname><given-names>NS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>DNA binding to TLR9 expressed by red blood cells promotes innate immune activation and anemia</article-title><source>Science Translational Medicine</source><volume>13</volume><elocation-id>eabj1008</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abj1008</pub-id><pub-id pub-id-type="pmid">34669439</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebrón</surname><given-names>JA</given-names></name><name><surname>Bennett</surname><given-names>MJ</given-names></name><name><surname>Vaughn</surname><given-names>DE</given-names></name><name><surname>Chirino</surname><given-names>AJ</given-names></name><name><surname>Snow</surname><given-names>PM</given-names></name><name><surname>Mintier</surname><given-names>GA</given-names></name><name><surname>Feder</surname><given-names>JN</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor</article-title><source>Cell</source><volume>93</volume><fpage>111</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)81151-4</pub-id><pub-id pub-id-type="pmid">9546397</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Hsu</surname><given-names>M-H</given-names></name><name><surname>Welser-Alves</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Severe microcytic anemia but increased erythropoiesis in mice lacking Hfe or Tfr2 and Tmprss6</article-title><source>Blood Cells, Molecules, and Diseases</source><volume>48</volume><fpage>173</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/j.bcmd.2011.12.005</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SC-W</given-names></name><name><surname>Dvinge</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Micol</surname><given-names>J-B</given-names></name><name><surname>Chung</surname><given-names>YR</given-names></name><name><surname>Durham</surname><given-names>BH</given-names></name><name><surname>Yoshimi</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Lobry</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>C-W</given-names></name><name><surname>Pastore</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Krivtsov</surname><given-names>A</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name><name><surname>Palacino</surname><given-names>J</given-names></name><name><surname>Buonamici</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>PG</given-names></name><name><surname>Bradley</surname><given-names>RK</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins</article-title><source>Nature Medicine</source><volume>22</volume><fpage>672</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1038/nm.4097</pub-id><pub-id pub-id-type="pmid">27135740</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leidgens</surname><given-names>S</given-names></name><name><surname>Bullough</surname><given-names>KZ</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Shakoury-Elizeh</surname><given-names>M</given-names></name><name><surname>Yabe</surname><given-names>T</given-names></name><name><surname>Subramanian</surname><given-names>P</given-names></name><name><surname>Hsu</surname><given-names>E</given-names></name><name><surname>Natarajan</surname><given-names>N</given-names></name><name><surname>Nandal</surname><given-names>A</given-names></name><name><surname>Stemmler</surname><given-names>TL</given-names></name><name><surname>Philpott</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Each member of the Poly-r(C)-binding Protein 1 (PCBP) family exhibits iron chaperone activity toward ferritin</article-title><source>Journal of Biological Chemistry</source><volume>288</volume><fpage>17791</fpage><lpage>17802</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.460253</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Wadleigh</surname><given-names>M</given-names></name><name><surname>Cools</surname><given-names>J</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Wernig</surname><given-names>G</given-names></name><name><surname>Huntly</surname><given-names>BJP</given-names></name><name><surname>Boggon</surname><given-names>TJ</given-names></name><name><surname>Wlodarska</surname><given-names>I</given-names></name><name><surname>Clark</surname><given-names>JJ</given-names></name><name><surname>Moore</surname><given-names>S</given-names></name><name><surname>Adelsperger</surname><given-names>J</given-names></name><name><surname>Koo</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Mercher</surname><given-names>T</given-names></name><name><surname>D’Andrea</surname><given-names>A</given-names></name><name><surname>Fröhling</surname><given-names>S</given-names></name><name><surname>Döhner</surname><given-names>K</given-names></name><name><surname>Marynen</surname><given-names>P</given-names></name><name><surname>Vandenberghe</surname><given-names>P</given-names></name><name><surname>Mesa</surname><given-names>RA</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Griffin</surname><given-names>JD</given-names></name><name><surname>Eck</surname><given-names>MJ</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</article-title><source>Cancer Cell</source><volume>7</volume><fpage>387</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2005.03.023</pub-id><pub-id pub-id-type="pmid">15837627</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Rybicki</surname><given-names>AC</given-names></name><name><surname>Suzuka</surname><given-names>SM</given-names></name><name><surname>von Bonsdorff</surname><given-names>L</given-names></name><name><surname>Breuer</surname><given-names>W</given-names></name><name><surname>Hall</surname><given-names>CB</given-names></name><name><surname>Cabantchik</surname><given-names>ZI</given-names></name><name><surname>Bouhassira</surname><given-names>EE</given-names></name><name><surname>Fabry</surname><given-names>ME</given-names></name><name><surname>Ginzburg</surname><given-names>YZ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Transferrin therapy ameliorates disease in beta-thalassemic mice</article-title><source>Nature Medicine</source><volume>16</volume><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1038/nm.2073</pub-id><pub-id pub-id-type="pmid">20098432</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Hale</surname><given-names>J</given-names></name><name><surname>Bhagia</surname><given-names>P</given-names></name><name><surname>Xue</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Jaffray</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Lane</surname><given-names>J</given-names></name><name><surname>Gallagher</surname><given-names>PG</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>An</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Isolation and transcriptome analyses of human erythroid progenitors: BFU-E and CFU-E</article-title><source>Blood</source><volume>124</volume><fpage>3636</fpage><lpage>3645</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-07-588806</pub-id><pub-id pub-id-type="pmid">25339359</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Gallagher</surname><given-names>PG</given-names></name><name><surname>Mendelson</surname><given-names>A</given-names></name><name><surname>Yazdanbakhsh</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>An</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification and transcriptome analysis of erythroblastic island macrophages</article-title><source>Blood</source><volume>134</volume><fpage>480</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1182/blood.2019000430</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libani</surname><given-names>IV</given-names></name><name><surname>Guy</surname><given-names>EC</given-names></name><name><surname>Melchiori</surname><given-names>L</given-names></name><name><surname>Schiro</surname><given-names>R</given-names></name><name><surname>Ramos</surname><given-names>P</given-names></name><name><surname>Breda</surname><given-names>L</given-names></name><name><surname>Scholzen</surname><given-names>T</given-names></name><name><surname>Chadburn</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Kernbach</surname><given-names>M</given-names></name><name><surname>Baron-Lühr</surname><given-names>B</given-names></name><name><surname>Porotto</surname><given-names>M</given-names></name><name><surname>de Sousa</surname><given-names>M</given-names></name><name><surname>Rachmilewitz</surname><given-names>EA</given-names></name><name><surname>Hood</surname><given-names>JD</given-names></name><name><surname>Cappellini</surname><given-names>MD</given-names></name><name><surname>Giardina</surname><given-names>PJ</given-names></name><name><surname>Grady</surname><given-names>RW</given-names></name><name><surname>Gerdes</surname><given-names>J</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia</article-title><source>Blood</source><volume>112</volume><fpage>875</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-12-126938</pub-id><pub-id pub-id-type="pmid">18480424</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name><name><surname>Chasis</surname><given-names>JA</given-names></name><name><surname>An</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Membrane remodeling during reticulocyte maturation</article-title><source>Blood</source><volume>115</volume><fpage>2021</fpage><lpage>2027</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-08-241182</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name><name><surname>An</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Membrane assembly during erythropoiesis</article-title><source>Current Opinion in Hematology</source><volume>18</volume><fpage>133</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1097/MOH.0b013e32834521f3</pub-id><pub-id pub-id-type="pmid">21372707</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ginzburg</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Xue</surname><given-names>F</given-names></name><name><surname>De Franceschi</surname><given-names>L</given-names></name><name><surname>Chasis</surname><given-names>JA</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name><name><surname>An</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis</article-title><source>Blood</source><volume>121</volume><fpage>e43</fpage><lpage>e49</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-09-456079</pub-id><pub-id pub-id-type="pmid">23287863</pub-id></element-citation></ref><ref id="bib149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Mei</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Korobova</surname><given-names>FV</given-names></name><name><surname>Prado</surname><given-names>MA</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>Z</given-names></name><name><surname>Paulo</surname><given-names>JA</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Finley</surname><given-names>D</given-names></name><name><surname>Ji</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Membrane skeleton modulates erythroid proteome remodeling and organelle clearance</article-title><source>Blood</source><volume>137</volume><fpage>398</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1182/blood.2020006673</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Yrigoyen</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>C-T</given-names></name><name><surname>Fidanza</surname><given-names>A</given-names></name><name><surname>Cassetta</surname><given-names>L</given-names></name><name><surname>Taylor</surname><given-names>AH</given-names></name><name><surname>McCahill</surname><given-names>A</given-names></name><name><surname>Sellink</surname><given-names>E</given-names></name><name><surname>von Lindern</surname><given-names>M</given-names></name><name><surname>van den Akker</surname><given-names>E</given-names></name><name><surname>Mountford</surname><given-names>JC</given-names></name><name><surname>Pollard</surname><given-names>JW</given-names></name><name><surname>Forrester</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Genetic programming of macrophages generates an in vitro model for the human erythroid island niche</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>881</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-08705-0</pub-id><pub-id pub-id-type="pmid">30787325</pub-id></element-citation></ref><ref id="bib151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>LJ-S</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F</article-title><source>The Journal of Biological Chemistry</source><volume>283</volume><fpage>5258</fpage><lpage>5266</lpage><pub-id pub-id-type="doi">10.1074/jbc.M707125200</pub-id><pub-id pub-id-type="pmid">18158285</pub-id></element-citation></ref><ref id="bib152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luck</surname><given-names>AN</given-names></name><name><surname>Mason</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Transferrin-mediated cellular iron delivery</article-title><source>Current Topics in Membranes</source><volume>69</volume><fpage>3</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-394390-3.00001-X</pub-id><pub-id pub-id-type="pmid">23046645</pub-id></element-citation></ref><ref id="bib153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malcovati</surname><given-names>Luca</given-names></name><name><surname>Porta</surname><given-names>MGD</given-names></name><name><surname>Pascutto</surname><given-names>C</given-names></name><name><surname>Invernizzi</surname><given-names>R</given-names></name><name><surname>Boni</surname><given-names>M</given-names></name><name><surname>Travaglino</surname><given-names>E</given-names></name><name><surname>Passamonti</surname><given-names>F</given-names></name><name><surname>Arcaini</surname><given-names>L</given-names></name><name><surname>Maffioli</surname><given-names>M</given-names></name><name><surname>Bernasconi</surname><given-names>P</given-names></name><name><surname>Lazzarino</surname><given-names>M</given-names></name><name><surname>Cazzola</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making</article-title><source>Journal of Clinical Oncology</source><volume>23</volume><fpage>7594</fpage><lpage>7603</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.01.7038</pub-id></element-citation></ref><ref id="bib154"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malcovati</surname><given-names>L</given-names></name><name><surname>Della Porta</surname><given-names>MG</given-names></name><name><surname>Cazzola</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Predicting survival and leukemic evolution in patients with myelodysplastic syndrome</article-title><source>Haematologica</source><volume>91</volume><fpage>1588</fpage><lpage>1590</lpage><pub-id pub-id-type="pmid">17145593</pub-id></element-citation></ref><ref id="bib155"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malcovati</surname><given-names>L.</given-names></name><name><surname>Della Porta</surname><given-names>MG</given-names></name><name><surname>Strupp</surname><given-names>C</given-names></name><name><surname>Ambaglio</surname><given-names>I</given-names></name><name><surname>Kuendgen</surname><given-names>A</given-names></name><name><surname>Nachtkamp</surname><given-names>K</given-names></name><name><surname>Travaglino</surname><given-names>E</given-names></name><name><surname>Invernizzi</surname><given-names>R</given-names></name><name><surname>Pascutto</surname><given-names>C</given-names></name><name><surname>Lazzarino</surname><given-names>M</given-names></name><name><surname>Germing</surname><given-names>U</given-names></name><name><surname>Cazzola</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)</article-title><source>Haematologica</source><volume>96</volume><fpage>1433</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.3324/haematol.2011.044602</pub-id></element-citation></ref><ref id="bib156"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>J</given-names></name><name><surname>Lillis</surname><given-names>JA</given-names></name><name><surname>Couch</surname><given-names>T</given-names></name><name><surname>Getman</surname><given-names>M</given-names></name><name><surname>Steiner</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The methyltransferase setd8 is essential for erythroblast survival and maturation</article-title><source>Cell Reports</source><volume>21</volume><fpage>2376</fpage><lpage>2383</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.11.011</pub-id><pub-id pub-id-type="pmid">29186677</pub-id></element-citation></ref><ref id="bib157"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancias</surname><given-names>JD</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Harper</surname><given-names>JW</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy</article-title><source>Nature</source><volume>509</volume><fpage>105</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1038/nature13148</pub-id><pub-id pub-id-type="pmid">24695223</pub-id></element-citation></ref><ref id="bib158"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancias</surname><given-names>JD</given-names></name><name><surname>Pontano Vaites</surname><given-names>L</given-names></name><name><surname>Nissim</surname><given-names>S</given-names></name><name><surname>Biancur</surname><given-names>DE</given-names></name><name><surname>Kim</surname><given-names>AJ</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Goessling</surname><given-names>W</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name><name><surname>Harper</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis</article-title><source>eLife</source><volume>4</volume><elocation-id>e10308</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.10308</pub-id><pub-id pub-id-type="pmid">26436293</pub-id></element-citation></ref><ref id="bib159"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mankelow</surname><given-names>TJ</given-names></name><name><surname>Spring</surname><given-names>FA</given-names></name><name><surname>Parsons</surname><given-names>SF</given-names></name><name><surname>Brady</surname><given-names>RL</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name><name><surname>Chasis</surname><given-names>JA</given-names></name><name><surname>Anstee</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Identification of critical amino-acid residues on the erythroid intercellular adhesion molecule-4 (ICAM-4) mediating adhesion to alpha V integrins</article-title><source>Blood</source><volume>103</volume><fpage>1503</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-08-2792</pub-id><pub-id pub-id-type="pmid">14551135</pub-id></element-citation></ref><ref id="bib160"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchioli</surname><given-names>R</given-names></name><name><surname>Finazzi</surname><given-names>G</given-names></name><name><surname>Specchia</surname><given-names>G</given-names></name><name><surname>Cacciola</surname><given-names>R</given-names></name><name><surname>Cavazzina</surname><given-names>R</given-names></name><name><surname>Cilloni</surname><given-names>D</given-names></name><name><surname>De Stefano</surname><given-names>V</given-names></name><name><surname>Elli</surname><given-names>E</given-names></name><name><surname>Iurlo</surname><given-names>A</given-names></name><name><surname>Latagliata</surname><given-names>R</given-names></name><name><surname>Lunghi</surname><given-names>F</given-names></name><name><surname>Lunghi</surname><given-names>M</given-names></name><name><surname>Marfisi</surname><given-names>RM</given-names></name><name><surname>Musto</surname><given-names>P</given-names></name><name><surname>Masciulli</surname><given-names>A</given-names></name><name><surname>Musolino</surname><given-names>C</given-names></name><name><surname>Cascavilla</surname><given-names>N</given-names></name><name><surname>Quarta</surname><given-names>G</given-names></name><name><surname>Randi</surname><given-names>ML</given-names></name><name><surname>Rapezzi</surname><given-names>D</given-names></name><name><surname>Ruggeri</surname><given-names>M</given-names></name><name><surname>Rumi</surname><given-names>E</given-names></name><name><surname>Scortechini</surname><given-names>AR</given-names></name><name><surname>Santini</surname><given-names>S</given-names></name><name><surname>Scarano</surname><given-names>M</given-names></name><name><surname>Siragusa</surname><given-names>S</given-names></name><name><surname>Spadea</surname><given-names>A</given-names></name><name><surname>Tieghi</surname><given-names>A</given-names></name><name><surname>Angelucci</surname><given-names>E</given-names></name><name><surname>Visani</surname><given-names>G</given-names></name><name><surname>Vannucchi</surname><given-names>AM</given-names></name><name><surname>Barbui</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cardiovascular events and intensity of treatment in polycythemia vera</article-title><source>New England Journal of Medicine</source><volume>368</volume><fpage>22</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1208500</pub-id></element-citation></ref><ref id="bib161"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marro</surname><given-names>S</given-names></name><name><surname>Chiabrando</surname><given-names>D</given-names></name><name><surname>Messana</surname><given-names>E</given-names></name><name><surname>Stolte</surname><given-names>J</given-names></name><name><surname>Turco</surname><given-names>E</given-names></name><name><surname>Tolosano</surname><given-names>E</given-names></name><name><surname>Muckenthaler</surname><given-names>MU</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2 and a MARE/ARE sequence motif at position -7007 of the FPN1 promoter</article-title><source>Haematologica</source><volume>95</volume><fpage>1261</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.3324/haematol.2009.020123</pub-id></element-citation></ref><ref id="bib162"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKie</surname><given-names>AT</given-names></name><name><surname>Barrow</surname><given-names>D</given-names></name><name><surname>Latunde-Dada</surname><given-names>GO</given-names></name><name><surname>Rolfs</surname><given-names>A</given-names></name><name><surname>Sager</surname><given-names>G</given-names></name><name><surname>Mudaly</surname><given-names>E</given-names></name><name><surname>Mudaly</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>C</given-names></name><name><surname>Barlow</surname><given-names>D</given-names></name><name><surname>Bomford</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>TJ</given-names></name><name><surname>Raja</surname><given-names>KB</given-names></name><name><surname>Shirali</surname><given-names>S</given-names></name><name><surname>Hediger</surname><given-names>MA</given-names></name><name><surname>Farzaneh</surname><given-names>F</given-names></name><name><surname>Simpson</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>An iron-regulated ferric reductase associated with the absorption of dietary iron</article-title><source>Science</source><volume>291</volume><fpage>1755</fpage><lpage>1759</lpage><pub-id pub-id-type="doi">10.1126/science.1057206</pub-id><pub-id pub-id-type="pmid">11230685</pub-id></element-citation></ref><ref id="bib163"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaren</surname><given-names>CE</given-names></name><name><surname>Barton</surname><given-names>JC</given-names></name><name><surname>Gordeuk</surname><given-names>VR</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Adams</surname><given-names>PC</given-names></name><name><surname>Reboussin</surname><given-names>DM</given-names></name><name><surname>Speechley</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>H</given-names></name><name><surname>Acton</surname><given-names>RT</given-names></name><name><surname>Harris</surname><given-names>EL</given-names></name><name><surname>Ruggiero</surname><given-names>AM</given-names></name><name><surname>Castro</surname><given-names>O</given-names></name><collab>Hemochromatosis and Iron Overload Screening Study Research Investigators</collab></person-group><year iso-8601-date="2007">2007</year><article-title>Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in white HFE C282Y homozygotes in the hemochromatosis and iron overload screening study</article-title><source>American Journal of Hematology</source><volume>82</volume><fpage>898</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1002/ajh.20937</pub-id><pub-id pub-id-type="pmid">17597476</pub-id></element-citation></ref><ref id="bib164"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melis</surname><given-names>MA</given-names></name><name><surname>Cau</surname><given-names>M</given-names></name><name><surname>Congiu</surname><given-names>R</given-names></name><name><surname>Sole</surname><given-names>G</given-names></name><name><surname>Barella</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>A</given-names></name><name><surname>Westerman</surname><given-names>M</given-names></name><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Galanello</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A mutation in the TMPRSS6 gene, encoding A transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron</article-title><source>Haematologica</source><volume>93</volume><fpage>1473</fpage><lpage>1479</lpage><pub-id pub-id-type="doi">10.3324/haematol.13342</pub-id></element-citation></ref><ref id="bib165"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohandas</surname><given-names>N</given-names></name><name><surname>Prenant</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Three-dimensional model of bone marrow</article-title><source>Blood</source><volume>51</volume><fpage>633</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">630113</pub-id></element-citation></ref><ref id="bib166"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>K</given-names></name><name><surname>Xue</surname><given-names>L</given-names></name><name><surname>Planutis</surname><given-names>A</given-names></name><name><surname>Gnanapragasam</surname><given-names>MN</given-names></name><name><surname>Chess</surname><given-names>A</given-names></name><name><surname>Bieker</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>EKLF/KLF1 expression defines a unique macrophage subset during mouse erythropoiesis</article-title><source>eLife</source><volume>10</volume><elocation-id>e61070</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.61070</pub-id><pub-id pub-id-type="pmid">33570494</pub-id></element-citation></ref><ref id="bib167"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musallam</surname><given-names>KM</given-names></name><name><surname>Cappellini</surname><given-names>MD</given-names></name><name><surname>Viprakasit</surname><given-names>V</given-names></name><name><surname>Kattamis</surname><given-names>A</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name><name><surname>Taher</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Revisiting the non-transfusion-dependent (NTDT) vs. transfusion-dependent (TDT) thalassemia classification 10 years later</article-title><source>American Journal of Hematology</source><volume>96</volume><fpage>E54</fpage><lpage>E56</lpage><pub-id pub-id-type="doi">10.1002/ajh.26056</pub-id><pub-id pub-id-type="pmid">33219703</pub-id></element-citation></ref><ref id="bib168"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nai</surname><given-names>A</given-names></name><name><surname>Lidonnici</surname><given-names>MR</given-names></name><name><surname>Rausa</surname><given-names>M</given-names></name><name><surname>Mandelli</surname><given-names>G</given-names></name><name><surname>Pagani</surname><given-names>A</given-names></name><name><surname>Silvestri</surname><given-names>L</given-names></name><name><surname>Ferrari</surname><given-names>G</given-names></name><name><surname>Camaschella</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The second transferrin receptor regulates red blood cell production in mice</article-title><source>Blood</source><volume>125</volume><fpage>1170</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-08-596254</pub-id></element-citation></ref><ref id="bib169"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nearman</surname><given-names>ZP</given-names></name><name><surname>Szpurka</surname><given-names>H</given-names></name><name><surname>Serio</surname><given-names>B</given-names></name><name><surname>Warshawksy</surname><given-names>I</given-names></name><name><surname>Theil</surname><given-names>K</given-names></name><name><surname>Lichtin</surname><given-names>A</given-names></name><name><surname>Sekeres</surname><given-names>MA</given-names></name><name><surname>Maciejewski</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts</article-title><source>American Journal of Hematology</source><volume>82</volume><fpage>1076</fpage><lpage>1079</lpage><pub-id pub-id-type="doi">10.1002/ajh.20995</pub-id><pub-id pub-id-type="pmid">17654685</pub-id></element-citation></ref><ref id="bib170"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemeth</surname><given-names>E</given-names></name><name><surname>Tuttle</surname><given-names>MS</given-names></name><name><surname>Powelson</surname><given-names>J</given-names></name><name><surname>Vaughn</surname><given-names>MB</given-names></name><name><surname>Donovan</surname><given-names>A</given-names></name><name><surname>Ward</surname><given-names>DM</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>Kaplan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization</article-title><source>Science</source><volume>306</volume><fpage>2090</fpage><lpage>2093</lpage><pub-id pub-id-type="doi">10.1126/science.1104742</pub-id></element-citation></ref><ref id="bib171"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemeth</surname><given-names>E</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Anemia of inflammation</article-title><source>Hematology/Oncology Clinics of North America</source><volume>28</volume><fpage>671</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1016/j.hoc.2014.04.005</pub-id><pub-id pub-id-type="pmid">25064707</pub-id></element-citation></ref><ref id="bib172"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemeth</surname><given-names>E</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Hepcidin and iron in health and disease</article-title><source>Annual Review of Medicine</source><volume>74</volume><fpage>261</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-043021-032816</pub-id><pub-id pub-id-type="pmid">35905974</pub-id></element-citation></ref><ref id="bib173"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemkov</surname><given-names>T</given-names></name><name><surname>Kingsley</surname><given-names>PD</given-names></name><name><surname>Dzieciatkowska</surname><given-names>M</given-names></name><name><surname>Malik</surname><given-names>J</given-names></name><name><surname>McGrath</surname><given-names>KE</given-names></name><name><surname>Hansen</surname><given-names>KC</given-names></name><name><surname>D’Alessandro</surname><given-names>A</given-names></name><name><surname>Palis</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Circulating primitive murine erythroblasts undergo complex proteomic and metabolomic changes during terminal maturation</article-title><source>Blood Advances</source><volume>6</volume><fpage>3072</fpage><lpage>3089</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2021005975</pub-id></element-citation></ref><ref id="bib174"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolas</surname><given-names>G</given-names></name><name><surname>Chauvet</surname><given-names>C</given-names></name><name><surname>Viatte</surname><given-names>L</given-names></name><name><surname>Danan</surname><given-names>JL</given-names></name><name><surname>Bigard</surname><given-names>X</given-names></name><name><surname>Devaux</surname><given-names>I</given-names></name><name><surname>Beaumont</surname><given-names>C</given-names></name><name><surname>Kahn</surname><given-names>A</given-names></name><name><surname>Vaulont</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002a</year><article-title>The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation</article-title><source>Journal of Clinical Investigation</source><volume>110</volume><fpage>1037</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1172/JCI0215686</pub-id></element-citation></ref><ref id="bib175"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolas</surname><given-names>G</given-names></name><name><surname>Viatte</surname><given-names>L</given-names></name><name><surname>Bennoun</surname><given-names>M</given-names></name><name><surname>Beaumont</surname><given-names>C</given-names></name><name><surname>Kahn</surname><given-names>A</given-names></name><name><surname>Vaulont</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002b</year><article-title>Hepcidin, a new iron regulatory peptide</article-title><source>Blood Cells, Molecules &amp; Diseases</source><volume>29</volume><fpage>327</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1006/bcmd.2002.0573</pub-id><pub-id pub-id-type="pmid">12547223</pub-id></element-citation></ref><ref id="bib176"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowak</surname><given-names>RB</given-names></name><name><surname>Papoin</surname><given-names>J</given-names></name><name><surname>Gokhin</surname><given-names>DS</given-names></name><name><surname>Casu</surname><given-names>C</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name><name><surname>Lipton</surname><given-names>JM</given-names></name><name><surname>Blanc</surname><given-names>L</given-names></name><name><surname>Fowler</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tropomodulin 1 controls erythroblast enucleation via regulation of F-actin in the enucleosome</article-title><source>Blood</source><volume>130</volume><fpage>1144</fpage><lpage>1155</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-05-787051</pub-id></element-citation></ref><ref id="bib177"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nyffenegger</surname><given-names>N</given-names></name><name><surname>Zennadi</surname><given-names>R</given-names></name><name><surname>Kalleda</surname><given-names>N</given-names></name><name><surname>Flace</surname><given-names>A</given-names></name><name><surname>Ingoglia</surname><given-names>G</given-names></name><name><surname>Buzzi</surname><given-names>RM</given-names></name><name><surname>Doucerain</surname><given-names>C</given-names></name><name><surname>Buehler</surname><given-names>PW</given-names></name><name><surname>Schaer</surname><given-names>DJ</given-names></name><name><surname>Dürrenberger</surname><given-names>F</given-names></name><name><surname>Manolova</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease</article-title><source>Blood</source><volume>140</volume><fpage>769</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1182/blood.2021014716</pub-id></element-citation></ref><ref id="bib178"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliva</surname><given-names>EN</given-names></name><name><surname>Ronco</surname><given-names>F</given-names></name><name><surname>Marino</surname><given-names>A</given-names></name><name><surname>Alati</surname><given-names>C</given-names></name><name><surname>Praticò</surname><given-names>G</given-names></name><name><surname>Nobile</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients</article-title><source>Transfusion</source><volume>50</volume><fpage>1568</fpage><lpage>1570</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2010.02617.x</pub-id><pub-id pub-id-type="pmid">20230535</pub-id></element-citation></ref><ref id="bib179"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagani</surname><given-names>A</given-names></name><name><surname>Nai</surname><given-names>A</given-names></name><name><surname>Silvestri</surname><given-names>L</given-names></name><name><surname>Camaschella</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hepcidin and anemia: A tight relationship</article-title><source>Frontiers in Physiology</source><volume>10</volume><elocation-id>1294</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2019.01294</pub-id><pub-id pub-id-type="pmid">31649559</pub-id></element-citation></ref><ref id="bib180"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pak</surname><given-names>M</given-names></name><name><surname>Lopez</surname><given-names>MA</given-names></name><name><surname>Gabayan</surname><given-names>V</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>Rivera</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Suppression of hepcidin during anemia requires erythropoietic activity</article-title><source>Blood</source><volume>108</volume><fpage>3730</fpage><lpage>3735</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-06-028787</pub-id></element-citation></ref><ref id="bib181"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palis</surname><given-names>J</given-names></name><name><surname>Robertson</surname><given-names>S</given-names></name><name><surname>Kennedy</surname><given-names>M</given-names></name><name><surname>Wall</surname><given-names>C</given-names></name><name><surname>Keller</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Development of erythroid and myeloid progenitors in the yolk sac and embryo proper of the mouse</article-title><source>Development</source><volume>126</volume><fpage>5073</fpage><lpage>5084</lpage><pub-id pub-id-type="doi">10.1242/dev.126.22.5073</pub-id></element-citation></ref><ref id="bib182"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palis</surname><given-names>J</given-names></name><name><surname>Yoder</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Yolk-sac hematopoiesis: the first blood cells of mouse and man</article-title><source>Experimental Hematology</source><volume>29</volume><fpage>927</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1016/s0301-472x(01)00669-5</pub-id><pub-id pub-id-type="pmid">11495698</pub-id></element-citation></ref><ref id="bib183"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palis</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Ontogeny of erythropoiesis</article-title><source>Current Opinion in Hematology</source><volume>15</volume><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1097/MOH.0b013e3282f97ae1</pub-id></element-citation></ref><ref id="bib184"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Z</given-names></name><name><surname>Voehringer</surname><given-names>DW</given-names></name><name><surname>Meyn</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Analysis of redox regulation of cytochrome c-induced apoptosis in a cell-free system</article-title><source>Cell Death and Differentiation</source><volume>6</volume><fpage>683</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4400544</pub-id><pub-id pub-id-type="pmid">10453079</pub-id></element-citation></ref><ref id="bib185"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardanani</surname><given-names>A</given-names></name><name><surname>Lasho</surname><given-names>TL</given-names></name><name><surname>Finke</surname><given-names>C</given-names></name><name><surname>Hanson</surname><given-names>CA</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera</article-title><source>Leukemia</source><volume>21</volume><fpage>1960</fpage><lpage>1963</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2404810</pub-id></element-citation></ref><ref id="bib186"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>CH</given-names></name><name><surname>Valore</surname><given-names>EV</given-names></name><name><surname>Waring</surname><given-names>AJ</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Hepcidin, a urinary antimicrobial peptide synthesized in the liver</article-title><source>Journal of Biological Chemistry</source><volume>276</volume><fpage>7806</fpage><lpage>7810</lpage><pub-id pub-id-type="doi">10.1074/jbc.M008922200</pub-id></element-citation></ref><ref id="bib187"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrow</surname><given-names>NL</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Feola</surname><given-names>M</given-names></name><name><surname>Guerra</surname><given-names>A</given-names></name><name><surname>Casu</surname><given-names>C</given-names></name><name><surname>Prasad</surname><given-names>P</given-names></name><name><surname>Mammen</surname><given-names>L</given-names></name><name><surname>Ali</surname><given-names>F</given-names></name><name><surname>Vaicikauskas</surname><given-names>E</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name><name><surname>Ginzburg</surname><given-names>YZ</given-names></name><name><surname>Fleming</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Lobe specificity of iron binding to transferrin modulates murine erythropoiesis and iron homeostasis</article-title><source>Blood</source><volume>134</volume><fpage>1373</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1182/blood.2018893099</pub-id><pub-id pub-id-type="pmid">31434707</pub-id></element-citation></ref><ref id="bib188"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>HA</given-names></name><name><surname>Lukens</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Ferrokinetics in the syndrome of familial hypoferremic microcytic anemia with iron malabsorption</article-title><source>Journal of Pediatric Hematology/Oncology</source><volume>21</volume><fpage>412</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1097/00043426-199909000-00014</pub-id></element-citation></ref><ref id="bib189"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perron-Deshaies</surname><given-names>G</given-names></name><name><surname>St-Louis</surname><given-names>P</given-names></name><name><surname>Romero</surname><given-names>H</given-names></name><name><surname>Scorza</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Impact of erythropoietin production by erythroblastic island macrophages on homeostatic murine erythropoiesis</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>23</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21238930</pub-id><pub-id pub-id-type="pmid">33255601</pub-id></element-citation></ref><ref id="bib190"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>JM</given-names></name><name><surname>Harandi</surname><given-names>OF</given-names></name><name><surname>Paulson</surname><given-names>RF</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>BMP4, SCF, and hypoxia cooperatively regulate the expansion of murine stress erythroid progenitors</article-title><source>Blood</source><volume>109</volume><fpage>4494</fpage><lpage>4502</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-04-016154</pub-id></element-citation></ref><ref id="bib191"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pevny</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>CS</given-names></name><name><surname>D’Agati</surname><given-names>V</given-names></name><name><surname>Simon</surname><given-names>MC</given-names></name><name><surname>Orkin</surname><given-names>SH</given-names></name><name><surname>Costantini</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Development of hematopoietic cells lacking transcription factor GATA-1</article-title><source>Development</source><volume>1</volume><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1242/dev.121.1.163</pub-id><pub-id pub-id-type="pmid">7867497</pub-id></element-citation></ref><ref id="bib192"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platzbecker</surname><given-names>U</given-names></name><name><surname>Germing</surname><given-names>U</given-names></name><name><surname>Götze</surname><given-names>KS</given-names></name><name><surname>Kiewe</surname><given-names>P</given-names></name><name><surname>Mayer</surname><given-names>K</given-names></name><name><surname>Chromik</surname><given-names>J</given-names></name><name><surname>Radsak</surname><given-names>M</given-names></name><name><surname>Wolff</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Laadem</surname><given-names>A</given-names></name><name><surname>Sherman</surname><given-names>ML</given-names></name><name><surname>Attie</surname><given-names>KM</given-names></name><name><surname>Giagounidis</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study</article-title><source>The Lancet. Oncology</source><volume>18</volume><fpage>1338</fpage><lpage>1347</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(17)30615-0</pub-id><pub-id pub-id-type="pmid">28870615</pub-id></element-citation></ref><ref id="bib193"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porcu</surname><given-names>S</given-names></name><name><surname>Manchinu</surname><given-names>MF</given-names></name><name><surname>Marongiu</surname><given-names>MF</given-names></name><name><surname>Sogos</surname><given-names>V</given-names></name><name><surname>Poddie</surname><given-names>D</given-names></name><name><surname>Asunis</surname><given-names>I</given-names></name><name><surname>Porcu</surname><given-names>L</given-names></name><name><surname>Marini</surname><given-names>MG</given-names></name><name><surname>Moi</surname><given-names>P</given-names></name><name><surname>Cao</surname><given-names>A</given-names></name><name><surname>Grosveld</surname><given-names>F</given-names></name><name><surname>Ristaldi</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Klf1 affects DNase II-Alpha expression in the central macrophage of a fetal liver Erythroblastic Island: a non-cell-autonomous role in definitive Erythropoiesis</article-title><source>Molecular and Cellular Biology</source><volume>31</volume><fpage>4144</fpage><lpage>4154</lpage><pub-id pub-id-type="doi">10.1128/MCB.05532-11</pub-id></element-citation></ref><ref id="bib194"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Iron through the prism of haematology</article-title><source>British Journal of Haematology</source><volume>191</volume><fpage>587</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1111/bjh.17164</pub-id><pub-id pub-id-type="pmid">33190267</pub-id></element-citation></ref><ref id="bib195"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pratt</surname><given-names>JJ</given-names></name><name><surname>Khan</surname><given-names>KS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Non-anaemic iron deficiency - a disease looking for recognition of diagnosis: a systematic review</article-title><source>European Journal of Haematology</source><volume>96</volume><fpage>618</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1111/ejh.12645</pub-id><pub-id pub-id-type="pmid">26256281</pub-id></element-citation></ref><ref id="bib196"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preza</surname><given-names>GC</given-names></name><name><surname>Ruchala</surname><given-names>P</given-names></name><name><surname>Pinon</surname><given-names>R</given-names></name><name><surname>Ramos</surname><given-names>E</given-names></name><name><surname>Qiao</surname><given-names>B</given-names></name><name><surname>Peralta</surname><given-names>MA</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Waring</surname><given-names>A</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>Nemeth</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload</article-title><source>Journal of Clinical Investigation</source><volume>121</volume><fpage>4880</fpage><lpage>4888</lpage><pub-id pub-id-type="doi">10.1172/JCI57693</pub-id></element-citation></ref><ref id="bib197"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>B</given-names></name><name><surname>Sugianto</surname><given-names>P</given-names></name><name><surname>Fung</surname><given-names>E</given-names></name><name><surname>Del-Castillo-Rueda</surname><given-names>A</given-names></name><name><surname>Moran-Jimenez</surname><given-names>M-J</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>Nemeth</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination</article-title><source>Cell Metabolism</source><volume>15</volume><fpage>918</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2012.03.018</pub-id><pub-id pub-id-type="pmid">22682227</pub-id></element-citation></ref><ref id="bib198"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>DSC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Role of interleukin-6 in the anemia of chronic disease</article-title><source>Seminars in Arthritis and Rheumatism</source><volume>38</volume><fpage>382</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/j.semarthrit.2008.01.006</pub-id><pub-id pub-id-type="pmid">18336871</pub-id></element-citation></ref><ref id="bib199"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname><given-names>P</given-names></name><name><surname>Casu</surname><given-names>C</given-names></name><name><surname>Gardenghi</surname><given-names>S</given-names></name><name><surname>Breda</surname><given-names>L</given-names></name><name><surname>Crielaard</surname><given-names>BJ</given-names></name><name><surname>Guy</surname><given-names>E</given-names></name><name><surname>Marongiu</surname><given-names>MF</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Van Rooijen</surname><given-names>N</given-names></name><name><surname>Ghaffari</surname><given-names>S</given-names></name><name><surname>Grady</surname><given-names>RW</given-names></name><name><surname>Giardina</surname><given-names>PJ</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia</article-title><source>Nature Medicine</source><volume>19</volume><fpage>437</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1038/nm.3126</pub-id><pub-id pub-id-type="pmid">23502961</pub-id></element-citation></ref><ref id="bib200"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rampal</surname><given-names>R</given-names></name><name><surname>Al-Shahrour</surname><given-names>F</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Patel</surname><given-names>JP</given-names></name><name><surname>Brunel</surname><given-names>J-P</given-names></name><name><surname>Mermel</surname><given-names>CH</given-names></name><name><surname>Bass</surname><given-names>AJ</given-names></name><name><surname>Pretz</surname><given-names>J</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name><name><surname>Hricik</surname><given-names>T</given-names></name><name><surname>Kilpivaara</surname><given-names>O</given-names></name><name><surname>Wadleigh</surname><given-names>M</given-names></name><name><surname>Busque</surname><given-names>L</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis</article-title><source>Blood</source><volume>123</volume><fpage>e123</fpage><lpage>e133</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-02-554634</pub-id></element-citation></ref><ref id="bib201"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsay</surname><given-names>AJ</given-names></name><name><surname>Reid</surname><given-names>JC</given-names></name><name><surname>Velasco</surname><given-names>G</given-names></name><name><surname>Quigley</surname><given-names>JP</given-names></name><name><surname>Hooper</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The type II transmembrane serine protease matriptase-2--identification, structural features, enzymology, expression pattern and potential roles</article-title><source>Frontiers in Bioscience</source><volume>13</volume><fpage>569</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.2741/2702</pub-id><pub-id pub-id-type="pmid">17981570</pub-id></element-citation></ref><ref id="bib202"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>MM</given-names></name><name><surname>Kopsombut</surname><given-names>P</given-names></name><name><surname>Bondurant</surname><given-names>MC</given-names></name><name><surname>Price</surname><given-names>JO</given-names></name><name><surname>Koury</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Adherence to macrophages in erythroblastic islands enhances erythroblast proliferation and increases erythrocyte production by a different mechanism than erythropoietin</article-title><source>Blood</source><volume>111</volume><fpage>1700</fpage><lpage>1708</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-06-098178</pub-id></element-citation></ref><ref id="bib203"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>CL</given-names></name><name><surname>Delehanty</surname><given-names>LL</given-names></name><name><surname>Bullock</surname><given-names>GC</given-names></name><name><surname>Rival</surname><given-names>CM</given-names></name><name><surname>Tung</surname><given-names>KS</given-names></name><name><surname>Kimpel</surname><given-names>DL</given-names></name><name><surname>Gardenghi</surname><given-names>S</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name><name><surname>Goldfarb</surname><given-names>AN</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Isocitrate ameliorates anemia by suppressing the erythroid iron restriction response</article-title><source>Journal of Clinical Investigation</source><volume>123</volume><fpage>3614</fpage><lpage>3623</lpage><pub-id pub-id-type="doi">10.1172/JCI68487</pub-id></element-citation></ref><ref id="bib204"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rishi</surname><given-names>G</given-names></name><name><surname>Secondes</surname><given-names>ES</given-names></name><name><surname>Wallace</surname><given-names>DF</given-names></name><name><surname>Subramaniam</surname><given-names>VN</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hematopoietic deletion of transferrin receptor 2 in mice leads to a block in erythroid differentiation during iron-deficient anemia</article-title><source>American Journal of Hematology</source><volume>91</volume><fpage>812</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1002/ajh.24417</pub-id></element-citation></ref><ref id="bib205"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robb</surname><given-names>A</given-names></name><name><surname>Wessling-Resnick</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Regulation of transferrin receptor 2 protein levels by transferrin</article-title><source>Blood</source><volume>104</volume><fpage>4294</fpage><lpage>4299</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-06-2481</pub-id></element-citation></ref><ref id="bib206"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>L</given-names></name><name><surname>Seu</surname><given-names>KG</given-names></name><name><surname>Papoin</surname><given-names>J</given-names></name><name><surname>Muench</surname><given-names>DE</given-names></name><name><surname>Konstantinidis</surname><given-names>D</given-names></name><name><surname>Olsson</surname><given-names>A</given-names></name><name><surname>Schlum</surname><given-names>K</given-names></name><name><surname>Chetal</surname><given-names>K</given-names></name><name><surname>Chasis</surname><given-names>JA</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name><name><surname>Barnes</surname><given-names>BJ</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Grimes</surname><given-names>HL</given-names></name><name><surname>Salomonis</surname><given-names>N</given-names></name><name><surname>Blanc</surname><given-names>L</given-names></name><name><surname>Kalfa</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Erythroblastic islands foster granulopoiesis in parallel to terminal erythropoiesis</article-title><source>Blood</source><volume>140</volume><fpage>1621</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1182/blood.2022015724</pub-id><pub-id pub-id-type="pmid">35862735</pub-id></element-citation></ref><ref id="bib207"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>M-S</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Protchenko</surname><given-names>O</given-names></name><name><surname>Shakoury-Elizeh</surname><given-names>M</given-names></name><name><surname>Philpott</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>PCBP1 and NCOA4 regulate erythroid iron storage and heme biosynthesis</article-title><source>Journal of Clinical Investigation</source><volume>127</volume><fpage>1786</fpage><lpage>1797</lpage><pub-id pub-id-type="doi">10.1172/JCI90519</pub-id></element-citation></ref><ref id="bib208"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadahira</surname><given-names>Y</given-names></name><name><surname>Yoshino</surname><given-names>T</given-names></name><name><surname>Monobe</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Very late activation antigen 4-vascular cell adhesion molecule 1 interaction is involved in the formation of erythroblastic islands</article-title><source>The Journal of Experimental Medicine</source><volume>181</volume><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1084/jem.181.1.411</pub-id></element-citation></ref><ref id="bib209"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santini</surname><given-names>V</given-names></name><name><surname>Girelli</surname><given-names>D</given-names></name><name><surname>Sanna</surname><given-names>A</given-names></name><name><surname>Martinelli</surname><given-names>N</given-names></name><name><surname>Duca</surname><given-names>L</given-names></name><name><surname>Campostrini</surname><given-names>N</given-names></name><name><surname>Cortelezzi</surname><given-names>A</given-names></name><name><surname>Corbella</surname><given-names>M</given-names></name><name><surname>Bosi</surname><given-names>A</given-names></name><name><surname>Reda</surname><given-names>G</given-names></name><name><surname>Olivieri</surname><given-names>O</given-names></name><name><surname>Cappellini</surname><given-names>MD</given-names></name><name><surname>Kaufman</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hepcidin levels and their determinants in different types of myelodysplastic syndromes</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e23109</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0023109</pub-id></element-citation></ref><ref id="bib210"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasu</surname><given-names>BJ</given-names></name><name><surname>Cooke</surname><given-names>KS</given-names></name><name><surname>Arvedson</surname><given-names>TL</given-names></name><name><surname>Plewa</surname><given-names>C</given-names></name><name><surname>Ellison</surname><given-names>AR</given-names></name><name><surname>Sheng</surname><given-names>J</given-names></name><name><surname>Winters</surname><given-names>A</given-names></name><name><surname>Juan</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Begley</surname><given-names>CG</given-names></name><name><surname>Molineux</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia</article-title><source>Blood</source><volume>115</volume><fpage>3616</fpage><lpage>3624</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-09-245977</pub-id><pub-id pub-id-type="pmid">20053755</pub-id></element-citation></ref><ref id="bib211"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>PJ</given-names></name><name><surname>Toran</surname><given-names>PT</given-names></name><name><surname>Giannetti</surname><given-names>AM</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Andrews</surname><given-names>NC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The transferrin receptor modulates hfe-dependent regulation of hepcidin expression</article-title><source>Cell Metabolism</source><volume>7</volume><fpage>205</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2007.11.016</pub-id></element-citation></ref><ref id="bib212"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>PJ</given-names></name><name><surname>Racie</surname><given-names>T</given-names></name><name><surname>Westerman</surname><given-names>M</given-names></name><name><surname>Fitzgerald</surname><given-names>K</given-names></name><name><surname>Butler</surname><given-names>JS</given-names></name><name><surname>Fleming</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia</article-title><source>American Journal of Hematology</source><volume>90</volume><fpage>310</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1002/ajh.23934</pub-id><pub-id pub-id-type="pmid">25557851</pub-id></element-citation></ref><ref id="bib213"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>RK</given-names></name><name><surname>Schenone</surname><given-names>M</given-names></name><name><surname>Ferreira</surname><given-names>MV</given-names></name><name><surname>Kramann</surname><given-names>R</given-names></name><name><surname>Joyce</surname><given-names>CE</given-names></name><name><surname>Hartigan</surname><given-names>C</given-names></name><name><surname>Beier</surname><given-names>F</given-names></name><name><surname>Brümmendorf</surname><given-names>TH</given-names></name><name><surname>Germing</surname><given-names>U</given-names></name><name><surname>Platzbecker</surname><given-names>U</given-names></name><name><surname>Büsche</surname><given-names>G</given-names></name><name><surname>Knüchel</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>MC</given-names></name><name><surname>Waters</surname><given-names>CS</given-names></name><name><surname>Chen</surname><given-names>E</given-names></name><name><surname>Chu</surname><given-names>LP</given-names></name><name><surname>Novina</surname><given-names>CD</given-names></name><name><surname>Lindsley</surname><given-names>RC</given-names></name><name><surname>Carr</surname><given-names>SA</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9</article-title><source>Nature Medicine</source><volume>22</volume><fpage>288</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1038/nm.4047</pub-id></element-citation></ref><ref id="bib214"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>VP</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Lezon-Geyda</surname><given-names>K</given-names></name><name><surname>An</surname><given-names>X</given-names></name><name><surname>Hale</surname><given-names>J</given-names></name><name><surname>Hillyer</surname><given-names>CD</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name><name><surname>Gallagher</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A unique epigenomic landscape defines human erythropoiesis</article-title><source>Cell Reports</source><volume>28</volume><fpage>2996</fpage><lpage>3009</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.08.020</pub-id></element-citation></ref><ref id="bib215"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>AJ</given-names></name><name><surname>Das</surname><given-names>NK</given-names></name><name><surname>Ramakrishnan</surname><given-names>SK</given-names></name><name><surname>Jain</surname><given-names>C</given-names></name><name><surname>Jurkovic</surname><given-names>MT</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Nemeth</surname><given-names>E</given-names></name><name><surname>Lakhal-Littleton</surname><given-names>S</given-names></name><name><surname>Colacino</surname><given-names>JA</given-names></name><name><surname>Shah</surname><given-names>YM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hepatic hepcidin/intestinal HIF-2α axis maintains iron absorption during iron deficiency and overload</article-title><source>Journal of Clinical Investigation</source><volume>129</volume><fpage>336</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1172/JCI122359</pub-id></element-citation></ref><ref id="bib216"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>LM</given-names></name><name><surname>Tong</surname><given-names>W</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Scott</surname><given-names>MA</given-names></name><name><surname>Beer</surname><given-names>PA</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Erber</surname><given-names>WN</given-names></name><name><surname>McMullin</surname><given-names>MF</given-names></name><name><surname>Harrison</surname><given-names>CN</given-names></name><name><surname>Warren</surname><given-names>AJ</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis</article-title><source>The New England Journal of Medicine</source><volume>356</volume><fpage>459</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa065202</pub-id><pub-id pub-id-type="pmid">17267906</pub-id></element-citation></ref><ref id="bib217"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>YM</given-names></name><name><surname>Matsubara</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Yim</surname><given-names>S-H</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency</article-title><source>Cell Metabolism</source><volume>9</volume><fpage>152</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2008.12.012</pub-id><pub-id pub-id-type="pmid">19147412</pub-id></element-citation></ref><ref id="bib218"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiozawa</surname><given-names>Y</given-names></name><name><surname>Malcovati</surname><given-names>L</given-names></name><name><surname>Gallì</surname><given-names>A</given-names></name><name><surname>Sato-Otsubo</surname><given-names>A</given-names></name><name><surname>Kataoka</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Watatani</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Yoshizato</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Sanada</surname><given-names>M</given-names></name><name><surname>Makishima</surname><given-names>H</given-names></name><name><surname>Shiraishi</surname><given-names>Y</given-names></name><name><surname>Chiba</surname><given-names>K</given-names></name><name><surname>Hellström-Lindberg</surname><given-names>E</given-names></name><name><surname>Miyano</surname><given-names>S</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name><name><surname>Cazzola</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>3649</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-06063-x</pub-id><pub-id pub-id-type="pmid">30194306</pub-id></element-citation></ref><ref id="bib219"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siatecka</surname><given-names>M</given-names></name><name><surname>Bieker</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The multifunctional role of EKLF/KLF1 during erythropoiesis</article-title><source>Blood</source><volume>118</volume><fpage>2044</fpage><lpage>2054</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-03-331371</pub-id><pub-id pub-id-type="pmid">21613252</pub-id></element-citation></ref><ref id="bib220"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvestri</surname><given-names>L</given-names></name><name><surname>Pagani</surname><given-names>A</given-names></name><name><surname>Nai</surname><given-names>A</given-names></name><name><surname>De Domenico</surname><given-names>I</given-names></name><name><surname>Kaplan</surname><given-names>J</given-names></name><name><surname>Camaschella</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin</article-title><source>Cell Metabolism</source><volume>8</volume><fpage>502</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2008.09.012</pub-id><pub-id pub-id-type="pmid">18976966</pub-id></element-citation></ref><ref id="bib221"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sohn</surname><given-names>Y-S</given-names></name><name><surname>Breuer</surname><given-names>W</given-names></name><name><surname>Munnich</surname><given-names>A</given-names></name><name><surname>Cabantchik</surname><given-names>ZI</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications</article-title><source>Blood</source><volume>111</volume><fpage>1690</fpage><lpage>1699</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-07-102335</pub-id><pub-id pub-id-type="pmid">17975016</pub-id></element-citation></ref><ref id="bib222"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soni</surname><given-names>S</given-names></name><name><surname>Bala</surname><given-names>S</given-names></name><name><surname>Gwynn</surname><given-names>B</given-names></name><name><surname>Sahr</surname><given-names>KE</given-names></name><name><surname>Peters</surname><given-names>LL</given-names></name><name><surname>Hanspal</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Absence of erythroblast macrophage protein (Emp) leads to failure of erythroblast nuclear extrusion</article-title><source>Journal of Biological Chemistry</source><volume>281</volume><fpage>20181</fpage><lpage>20189</lpage><pub-id pub-id-type="doi">10.1074/jbc.M603226200</pub-id></element-citation></ref><ref id="bib223"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonnweber</surname><given-names>T</given-names></name><name><surname>Nachbaur</surname><given-names>D</given-names></name><name><surname>Schroll</surname><given-names>A</given-names></name><name><surname>Nairz</surname><given-names>M</given-names></name><name><surname>Seifert</surname><given-names>M</given-names></name><name><surname>Demetz</surname><given-names>E</given-names></name><name><surname>Haschka</surname><given-names>D</given-names></name><name><surname>Mitterstiller</surname><given-names>A-M</given-names></name><name><surname>Kleinsasser</surname><given-names>A</given-names></name><name><surname>Burtscher</surname><given-names>M</given-names></name><name><surname>Trübsbach</surname><given-names>S</given-names></name><name><surname>Murphy</surname><given-names>AT</given-names></name><name><surname>Wroblewski</surname><given-names>V</given-names></name><name><surname>Witcher</surname><given-names>DR</given-names></name><name><surname>Mleczko-Sanecka</surname><given-names>K</given-names></name><name><surname>Vecchi</surname><given-names>C</given-names></name><name><surname>Muckenthaler</surname><given-names>MU</given-names></name><name><surname>Pietrangelo</surname><given-names>A</given-names></name><name><surname>Theurl</surname><given-names>I</given-names></name><name><surname>Weiss</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB</article-title><source>Gut</source><volume>63</volume><fpage>1951</fpage><lpage>1959</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2013-305317</pub-id><pub-id pub-id-type="pmid">24598129</pub-id></element-citation></ref><ref id="bib224"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonoda</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Wong</surname><given-names>G</given-names></name><name><surname>Clark</surname><given-names>S</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Erythroid burst-promoting activity of purified recombinant human GM-CSF and interleukin-3: studies with anti-GM-CSF and anti-IL-3 sera and studies in serum-free cultures</article-title><source>Blood</source><volume>72</volume><fpage>1381</fpage><lpage>1386</lpage><pub-id pub-id-type="doi">10.1182/blood.V72.4.1381.1381</pub-id></element-citation></ref><ref id="bib225"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonoda</surname><given-names>Y</given-names></name><name><surname>Sakabe</surname><given-names>H</given-names></name><name><surname>Ohmisono</surname><given-names>Y</given-names></name><name><surname>Tanimukai</surname><given-names>S</given-names></name><name><surname>Yokota</surname><given-names>S</given-names></name><name><surname>Nakagawa</surname><given-names>S</given-names></name><name><surname>Clark</surname><given-names>S</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Synergistic actions of stem cell factor and other burst-promoting activities on proliferation of CD34+ highly purified blood progenitors expressing HLA-DR or different levels of c-kit protein</article-title><source>Blood</source><volume>84</volume><fpage>4099</fpage><lpage>4106</lpage><pub-id pub-id-type="doi">10.1182/blood.V84.12.4099.bloodjournal84124099</pub-id></element-citation></ref><ref id="bib226"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soranzo</surname><given-names>N</given-names></name><name><surname>Spector</surname><given-names>TD</given-names></name><name><surname>Mangino</surname><given-names>M</given-names></name><name><surname>Kühnel</surname><given-names>B</given-names></name><name><surname>Rendon</surname><given-names>A</given-names></name><name><surname>Teumer</surname><given-names>A</given-names></name><name><surname>Willenborg</surname><given-names>C</given-names></name><name><surname>Wright</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Salo</surname><given-names>P</given-names></name><name><surname>Voight</surname><given-names>BF</given-names></name><name><surname>Burns</surname><given-names>P</given-names></name><name><surname>Laskowski</surname><given-names>RA</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Menzel</surname><given-names>S</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Bradley</surname><given-names>JR</given-names></name><name><surname>Bumpstead</surname><given-names>S</given-names></name><name><surname>Burnett</surname><given-names>M-S</given-names></name><name><surname>Devaney</surname><given-names>J</given-names></name><name><surname>Döring</surname><given-names>A</given-names></name><name><surname>Elosua</surname><given-names>R</given-names></name><name><surname>Epstein</surname><given-names>SE</given-names></name><name><surname>Erber</surname><given-names>W</given-names></name><name><surname>Falchi</surname><given-names>M</given-names></name><name><surname>Garner</surname><given-names>SF</given-names></name><name><surname>Ghori</surname><given-names>MJR</given-names></name><name><surname>Goodall</surname><given-names>AH</given-names></name><name><surname>Gwilliam</surname><given-names>R</given-names></name><name><surname>Hakonarson</surname><given-names>HH</given-names></name><name><surname>Hall</surname><given-names>AS</given-names></name><name><surname>Hammond</surname><given-names>N</given-names></name><name><surname>Hengstenberg</surname><given-names>C</given-names></name><name><surname>Illig</surname><given-names>T</given-names></name><name><surname>König</surname><given-names>IR</given-names></name><name><surname>Knouff</surname><given-names>CW</given-names></name><name><surname>McPherson</surname><given-names>R</given-names></name><name><surname>Melander</surname><given-names>O</given-names></name><name><surname>Mooser</surname><given-names>V</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Nieminen</surname><given-names>MS</given-names></name><name><surname>O’Donnell</surname><given-names>CJ</given-names></name><name><surname>Peltonen</surname><given-names>L</given-names></name><name><surname>Potter</surname><given-names>SC</given-names></name><name><surname>Prokisch</surname><given-names>H</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name><name><surname>Salomaa</surname><given-names>V</given-names></name><name><surname>Sambrook</surname><given-names>J</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name><name><surname>Schunkert</surname><given-names>H</given-names></name><name><surname>Schwartz</surname><given-names>SM</given-names></name><name><surname>Serbanovic-Canic</surname><given-names>J</given-names></name><name><surname>Sinisalo</surname><given-names>J</given-names></name><name><surname>Siscovick</surname><given-names>DS</given-names></name><name><surname>Stark</surname><given-names>K</given-names></name><name><surname>Surakka</surname><given-names>I</given-names></name><name><surname>Stephens</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>JR</given-names></name><name><surname>Völker</surname><given-names>U</given-names></name><name><surname>Völzke</surname><given-names>H</given-names></name><name><surname>Watkins</surname><given-names>NA</given-names></name><name><surname>Wells</surname><given-names>GA</given-names></name><name><surname>Wichmann</surname><given-names>H-E</given-names></name><name><surname>Van Heel</surname><given-names>DA</given-names></name><name><surname>Tyler-Smith</surname><given-names>C</given-names></name><name><surname>Thein</surname><given-names>SL</given-names></name><name><surname>Kathiresan</surname><given-names>S</given-names></name><name><surname>Perola</surname><given-names>M</given-names></name><name><surname>Reilly</surname><given-names>MP</given-names></name><name><surname>Stewart</surname><given-names>AFR</given-names></name><name><surname>Erdmann</surname><given-names>J</given-names></name><name><surname>Samani</surname><given-names>NJ</given-names></name><name><surname>Meisinger</surname><given-names>C</given-names></name><name><surname>Greinacher</surname><given-names>A</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Ouwehand</surname><given-names>WH</given-names></name><name><surname>Gieger</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium</article-title><source>Nature Genetics</source><volume>41</volume><fpage>1182</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1038/ng.467</pub-id></element-citation></ref><ref id="bib227"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steensma</surname><given-names>DP</given-names></name><name><surname>Wermke</surname><given-names>M</given-names></name><name><surname>Klimek</surname><given-names>VM</given-names></name><name><surname>Greenberg</surname><given-names>PL</given-names></name><name><surname>Font</surname><given-names>P</given-names></name><name><surname>Komrokji</surname><given-names>RS</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Brunner</surname><given-names>AM</given-names></name><name><surname>Carraway</surname><given-names>HE</given-names></name><name><surname>Ades</surname><given-names>L</given-names></name><name><surname>Al-Kali</surname><given-names>A</given-names></name><name><surname>Alonso-Dominguez</surname><given-names>JM</given-names></name><name><surname>Alfonso-Piérola</surname><given-names>A</given-names></name><name><surname>Coombs</surname><given-names>CC</given-names></name><name><surname>Deeg</surname><given-names>HJ</given-names></name><name><surname>Flinn</surname><given-names>I</given-names></name><name><surname>Foran</surname><given-names>JM</given-names></name><name><surname>Garcia-Manero</surname><given-names>G</given-names></name><name><surname>Maris</surname><given-names>MB</given-names></name><name><surname>McMasters</surname><given-names>M</given-names></name><name><surname>Micol</surname><given-names>J-B</given-names></name><name><surname>De Oteyza</surname><given-names>JP</given-names></name><name><surname>Thol</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>ES</given-names></name><name><surname>Watts</surname><given-names>JM</given-names></name><name><surname>Taylor</surname><given-names>J</given-names></name><name><surname>Stone</surname><given-names>R</given-names></name><name><surname>Gourineni</surname><given-names>V</given-names></name><name><surname>Marino</surname><given-names>AJ</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Destenaves</surname><given-names>B</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Dar</surname><given-names>S</given-names></name><name><surname>Ohanjanian</surname><given-names>L</given-names></name><name><surname>Kuida</surname><given-names>K</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Scholz</surname><given-names>C</given-names></name><name><surname>Gualberto</surname><given-names>A</given-names></name><name><surname>Platzbecker</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms</article-title><source>Leukemia</source><volume>35</volume><fpage>3542</fpage><lpage>3550</lpage><pub-id pub-id-type="doi">10.1038/s41375-021-01328-9</pub-id><pub-id pub-id-type="pmid">34172893</pub-id></element-citation></ref><ref id="bib228"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stetka</surname><given-names>J</given-names></name><name><surname>Usart</surname><given-names>M</given-names></name><name><surname>Kubovcakova</surname><given-names>L</given-names></name><name><surname>Rai</surname><given-names>S</given-names></name><name><surname>Rao</surname><given-names>TN</given-names></name><name><surname>Sutter</surname><given-names>J</given-names></name><name><surname>Hao-Shen</surname><given-names>H</given-names></name><name><surname>Dirnhofer</surname><given-names>S</given-names></name><name><surname>Geier</surname><given-names>F</given-names></name><name><surname>Bader</surname><given-names>MS</given-names></name><name><surname>Passweg</surname><given-names>JR</given-names></name><name><surname>Manolova</surname><given-names>V</given-names></name><name><surname>Dürrenberger</surname><given-names>F</given-names></name><name><surname>Ahmed</surname><given-names>N</given-names></name><name><surname>Schroeder</surname><given-names>T</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>Nemeth</surname><given-names>E</given-names></name><name><surname>Silvestri</surname><given-names>L</given-names></name><name><surname>Nai</surname><given-names>A</given-names></name><name><surname>Camaschella</surname><given-names>C</given-names></name><name><surname>Skoda</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms</article-title><source>Blood</source><volume>141</volume><fpage>2127</fpage><lpage>2140</lpage><pub-id pub-id-type="doi">10.1182/blood.2022017976</pub-id><pub-id pub-id-type="pmid">36758212</pub-id></element-citation></ref><ref id="bib229"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>Z</given-names></name><name><surname>Nowak</surname><given-names>RB</given-names></name><name><surname>Bacconi</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>NE</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wickrema</surname><given-names>A</given-names></name><name><surname>An</surname><given-names>X</given-names></name><name><surname>Fowler</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Tropomodulin3-null mice are embryonic lethal with anemia due to impaired erythroid terminal differentiation in the fetal liver</article-title><source>Blood</source><volume>123</volume><fpage>758</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-03-492710</pub-id><pub-id pub-id-type="pmid">24159174</pub-id></element-citation></ref><ref id="bib230"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swann</surname><given-names>JW</given-names></name><name><surname>Koneva</surname><given-names>LA</given-names></name><name><surname>Regan-Komito</surname><given-names>D</given-names></name><name><surname>Sansom</surname><given-names>SN</given-names></name><name><surname>Powrie</surname><given-names>F</given-names></name><name><surname>Griseri</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>IL-33 promotes anemia during chronic inflammation by inhibiting differentiation of erythroid progenitors</article-title><source>The Journal of Experimental Medicine</source><volume>217</volume><elocation-id>e20200164</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20200164</pub-id><pub-id pub-id-type="pmid">32520308</pub-id></element-citation></ref><ref id="bib231"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taher</surname><given-names>AT</given-names></name><name><surname>Karakas</surname><given-names>Z</given-names></name><name><surname>Cassinerio</surname><given-names>E</given-names></name><name><surname>Siritanaratkul</surname><given-names>N</given-names></name><name><surname>Kattamis</surname><given-names>A</given-names></name><name><surname>Maggio</surname><given-names>A</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name><name><surname>Hollaender</surname><given-names>N</given-names></name><name><surname>Mahuzier</surname><given-names>B</given-names></name><name><surname>Gadbaw</surname><given-names>B</given-names></name><name><surname>Aydinok</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study</article-title><source>Blood</source><volume>131</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-06-790121</pub-id><pub-id pub-id-type="pmid">29097381</pub-id></element-citation></ref><ref id="bib232"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takano-Ohmuro</surname><given-names>H</given-names></name><name><surname>Mukaida</surname><given-names>M</given-names></name><name><surname>Morioka</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Distribution of actin, myosin, and spectrin during enucleation in erythroid cells of hamster embryo</article-title><source>Cell Motility and the Cytoskeleton</source><volume>34</volume><fpage>95</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0169(1996)34:2&lt;95::AID-CM2&gt;3.0.CO;2-H</pub-id><pub-id pub-id-type="pmid">8769722</pub-id></element-citation></ref><ref id="bib233"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talbot</surname><given-names>A-L</given-names></name><name><surname>Bullock</surname><given-names>GC</given-names></name><name><surname>Delehanty</surname><given-names>LL</given-names></name><name><surname>Sattler</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>ZJ</given-names></name><name><surname>Goldfarb</surname><given-names>AN</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Aconitase regulation of erythropoiesis correlates with a novel licensing function in erythropoietin-induced ERK signaling</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e23850</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0023850</pub-id><pub-id pub-id-type="pmid">21887333</pub-id></element-citation></ref><ref id="bib234"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>R</given-names></name><name><surname>Kato</surname><given-names>HE</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><name><surname>Deshpande</surname><given-names>CN</given-names></name><name><surname>Wada</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Ishitani</surname><given-names>R</given-names></name><name><surname>Jormakka</surname><given-names>M</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Outward- and inward-facing structures of a putative bacterial transition-metal transporter with homology to ferroportin</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>8545</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms9545</pub-id><pub-id pub-id-type="pmid">26461048</pub-id></element-citation></ref><ref id="bib235"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanno</surname><given-names>T</given-names></name><name><surname>Bhanu</surname><given-names>NV</given-names></name><name><surname>Oneal</surname><given-names>PA</given-names></name><name><surname>Goh</surname><given-names>S-H</given-names></name><name><surname>Staker</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>YT</given-names></name><name><surname>Moroney</surname><given-names>JW</given-names></name><name><surname>Reed</surname><given-names>CH</given-names></name><name><surname>Luban</surname><given-names>NLC</given-names></name><name><surname>Wang</surname><given-names>R-H</given-names></name><name><surname>Eling</surname><given-names>TE</given-names></name><name><surname>Childs</surname><given-names>R</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>Leitman</surname><given-names>SF</given-names></name><name><surname>Fucharoen</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin</article-title><source>Nature Medicine</source><volume>13</volume><fpage>1096</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1038/nm1629</pub-id><pub-id pub-id-type="pmid">17721544</pub-id></element-citation></ref><ref id="bib236"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taoka</surname><given-names>K</given-names></name><name><surname>Kumano</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>F</given-names></name><name><surname>Hosoi</surname><given-names>M</given-names></name><name><surname>Goyama</surname><given-names>S</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Hangaishi</surname><given-names>A</given-names></name><name><surname>Kurokawa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The effect of iron overload and chelation on erythroid differentiation</article-title><source>International Journal of Hematology</source><volume>95</volume><fpage>149</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1007/s12185-011-0988-3</pub-id><pub-id pub-id-type="pmid">22193844</pub-id></element-citation></ref><ref id="bib237"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taranath</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Vengalam</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Dion</surname><given-names>C</given-names></name><name><surname>Su</surname><given-names>A</given-names></name><name><surname>Tovera</surname><given-names>J</given-names></name><name><surname>Bhandari</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Mattheakis</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>DY</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Regulation of iron homeostasis and efficacy of rusfertide analog peptide in a mouse model for polycythemia vera</article-title><source>Blood</source><volume>138</volume><elocation-id>2006</elocation-id><pub-id pub-id-type="doi">10.1182/blood-2021-154118</pub-id></element-citation></ref><ref id="bib238"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiele</surname><given-names>J</given-names></name><name><surname>Kvasnicka</surname><given-names>HM</given-names></name><name><surname>Muehlhausen</surname><given-names>K</given-names></name><name><surname>Walter</surname><given-names>S</given-names></name><name><surname>Zankovich</surname><given-names>R</given-names></name><name><surname>Diehl</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients</article-title><source>Pathology, Research and Practice</source><volume>197</volume><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1078/0344-0338-5710013</pub-id><pub-id pub-id-type="pmid">11261821</pub-id></element-citation></ref><ref id="bib239"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toda</surname><given-names>S</given-names></name><name><surname>Segawa</surname><given-names>K</given-names></name><name><surname>Nagata</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>MerTK-mediated engulfment of pyrenocytes by central macrophages in erythroblastic islands</article-title><source>Blood</source><volume>123</volume><fpage>3963</fpage><lpage>3971</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-01-547976</pub-id><pub-id pub-id-type="pmid">24659633</pub-id></element-citation></ref><ref id="bib240"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Truksa</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Beutler</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6</article-title><source>PNAS</source><volume>103</volume><fpage>10289</fpage><lpage>10293</lpage><pub-id pub-id-type="doi">10.1073/pnas.0603124103</pub-id><pub-id pub-id-type="pmid">16801541</pub-id></element-citation></ref><ref id="bib241"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ubukawa</surname><given-names>K</given-names></name><name><surname>Guo</surname><given-names>Y-M</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Hirokawa</surname><given-names>M</given-names></name><name><surname>Michishita</surname><given-names>Y</given-names></name><name><surname>Nara</surname><given-names>M</given-names></name><name><surname>Tagawa</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Komatsuda</surname><given-names>A</given-names></name><name><surname>Nunomura</surname><given-names>W</given-names></name><name><surname>Takakuwa</surname><given-names>Y</given-names></name><name><surname>Sawada</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Enucleation of human erythroblasts involves non-muscle myosin IIB</article-title><source>Blood</source><volume>119</volume><fpage>1036</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-06-361907</pub-id><pub-id pub-id-type="pmid">22049517</pub-id></element-citation></ref><ref id="bib242"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ubukawa</surname><given-names>K</given-names></name><name><surname>Goto</surname><given-names>T</given-names></name><name><surname>Asanuma</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Y-M</given-names></name><name><surname>Kobayashi</surname><given-names>I</given-names></name><name><surname>Sawada</surname><given-names>K</given-names></name><name><surname>Wakui</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cdc42 regulates cell polarization and contractile actomyosin rings during terminal differentiation of human erythroblasts</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>11806</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-68799-1</pub-id><pub-id pub-id-type="pmid">32678227</pub-id></element-citation></ref><ref id="bib243"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valent</surname><given-names>P</given-names></name><name><surname>Krieger</surname><given-names>O</given-names></name><name><surname>Stauder</surname><given-names>R</given-names></name><name><surname>Wimazal</surname><given-names>F</given-names></name><name><surname>Nösslinger</surname><given-names>T</given-names></name><name><surname>Sperr</surname><given-names>WR</given-names></name><name><surname>Sill</surname><given-names>H</given-names></name><name><surname>Bettelheim</surname><given-names>P</given-names></name><name><surname>Pfeilstöcker</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform</article-title><source>European Journal of Clinical Investigation</source><volume>38</volume><fpage>143</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2362.2007.01915.x</pub-id><pub-id pub-id-type="pmid">18218040</pub-id></element-citation></ref><ref id="bib244"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Renswoude</surname><given-names>J</given-names></name><name><surname>Bridges</surname><given-names>KR</given-names></name><name><surname>Harford</surname><given-names>JB</given-names></name><name><surname>Klausner</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Receptor-mediated endocytosis of transferrin and the uptake of fe in K562 cells: identification of a nonlysosomal acidic compartment</article-title><source>PNAS</source><volume>79</volume><fpage>6186</fpage><lpage>6190</lpage><pub-id pub-id-type="doi">10.1073/pnas.79.20.6186</pub-id><pub-id pub-id-type="pmid">6292894</pub-id></element-citation></ref><ref id="bib245"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verstovsek</surname><given-names>S</given-names></name><name><surname>Harrison</surname><given-names>CN</given-names></name><name><surname>Kiladjian</surname><given-names>J-J</given-names></name><name><surname>Miller</surname><given-names>C</given-names></name><name><surname>Naim</surname><given-names>AB</given-names></name><name><surname>Paranagama</surname><given-names>DC</given-names></name><name><surname>Habr</surname><given-names>D</given-names></name><name><surname>Vannucchi</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy</article-title><source>Leukemia Research</source><volume>56</volume><fpage>52</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2017.01.032</pub-id></element-citation></ref><ref id="bib246"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verstovsek</surname><given-names>S</given-names></name><name><surname>Kuykendall</surname><given-names>AT</given-names></name><name><surname>Hoffman</surname><given-names>R</given-names></name><name><surname>Ginzburg</surname><given-names>Y</given-names></name><name><surname>Pemmaraju</surname><given-names>N</given-names></name><name><surname>Valone</surname><given-names>F</given-names></name><name><surname>Modi</surname><given-names>NB</given-names></name><name><surname>Khanna</surname><given-names>S</given-names></name><name><surname>O’Connor</surname><given-names>PG</given-names></name><name><surname>Gupta</surname><given-names>SK</given-names></name><name><surname>Kiladjian</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A Phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera</article-title><source>Blood</source><volume>138</volume><elocation-id>1504</elocation-id><pub-id pub-id-type="doi">10.1182/blood-2021-149219</pub-id></element-citation></ref><ref id="bib247"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visconte</surname><given-names>V</given-names></name><name><surname>Avishai</surname><given-names>N</given-names></name><name><surname>Mahfouz</surname><given-names>R</given-names></name><name><surname>Tabarroki</surname><given-names>A</given-names></name><name><surname>Cowen</surname><given-names>J</given-names></name><name><surname>Sharghi-Moshtaghin</surname><given-names>R</given-names></name><name><surname>Hitomi</surname><given-names>M</given-names></name><name><surname>Rogers</surname><given-names>HJ</given-names></name><name><surname>Hasrouni</surname><given-names>E</given-names></name><name><surname>Phillips</surname><given-names>J</given-names></name><name><surname>Sekeres</surname><given-names>MA</given-names></name><name><surname>Heuer</surname><given-names>AH</given-names></name><name><surname>Saunthararajah</surname><given-names>Y</given-names></name><name><surname>Barnard</surname><given-names>J</given-names></name><name><surname>Tiu</surname><given-names>RV</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron</article-title><source>Leukemia</source><volume>29</volume><fpage>188</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1038/leu.2014.170</pub-id><pub-id pub-id-type="pmid">24854990</pub-id></element-citation></ref><ref id="bib248"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vokurka</surname><given-names>M</given-names></name><name><surname>Krijt</surname><given-names>J</given-names></name><name><surname>Sulc</surname><given-names>K</given-names></name><name><surname>Necas</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis</article-title><source>Physiological Research</source><volume>55</volume><fpage>667</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.33549/physiolres.930841</pub-id><pub-id pub-id-type="pmid">16497104</pub-id></element-citation></ref><ref id="bib249"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vulpe</surname><given-names>CD</given-names></name><name><surname>Kuo</surname><given-names>YM</given-names></name><name><surname>Murphy</surname><given-names>TL</given-names></name><name><surname>Cowley</surname><given-names>L</given-names></name><name><surname>Askwith</surname><given-names>C</given-names></name><name><surname>Libina</surname><given-names>N</given-names></name><name><surname>Gitschier</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse</article-title><source>Nature Genetics</source><volume>21</volume><fpage>195</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1038/5979</pub-id><pub-id pub-id-type="pmid">9988272</pub-id></element-citation></ref><ref id="bib250"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ramirez</surname><given-names>T</given-names></name><name><surname>Ji</surname><given-names>P</given-names></name><name><surname>Jayapal</surname><given-names>SR</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name><name><surname>Murata-Hori</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mammalian erythroblast enucleation requires PI3K-dependent cell polarization</article-title><source>Journal of Cell Science</source><volume>125</volume><fpage>340</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1242/jcs.088286</pub-id><pub-id pub-id-type="pmid">22331356</pub-id></element-citation></ref><ref id="bib251"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C-Y</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Traeger</surname><given-names>L</given-names></name><name><surname>Dogan</surname><given-names>DY</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Steinbicker</surname><given-names>AU</given-names></name><name><surname>Babitt</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Erythroferrone lowers hepcidin by sequestering BMP2/6 heterodimer from binding to the BMP type I receptor ALK3</article-title><source>Blood</source><volume>135</volume><fpage>453</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1182/blood.2019002620</pub-id></element-citation></ref><ref id="bib252"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Schulz</surname><given-names>VP</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Qu</surname><given-names>X</given-names></name><name><surname>Qi</surname><given-names>Q</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Yazdanbakhsh</surname><given-names>K</given-names></name><name><surname>Hillyer</surname><given-names>CD</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Gallagher</surname><given-names>PG</given-names></name><name><surname>An</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Impairment of human terminal erythroid differentiation by histone deacetylase 5 deficiency</article-title><source>Blood</source><volume>138</volume><fpage>1615</fpage><lpage>1627</lpage><pub-id pub-id-type="doi">10.1182/blood.2020007401</pub-id><pub-id pub-id-type="pmid">34036344</pub-id></element-citation></ref><ref id="bib253"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>De Zan</surname><given-names>T</given-names></name><name><surname>Ishizaki</surname><given-names>T</given-names></name><name><surname>Yasuda</surname><given-names>S</given-names></name><name><surname>Kamijo</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>D</given-names></name><name><surname>Aoki</surname><given-names>T</given-names></name><name><surname>Kiyonari</surname><given-names>H</given-names></name><name><surname>Kaneko</surname><given-names>H</given-names></name><name><surname>Shimizu</surname><given-names>R</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Goshima</surname><given-names>G</given-names></name><name><surname>Narumiya</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Loss of a Rho-regulated actin nucleator, mDia2, impairs cytokinesis during mouse fetal erythropoiesis</article-title><source>Cell Reports</source><volume>5</volume><fpage>926</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.10.021</pub-id><pub-id pub-id-type="pmid">24239357</pub-id></element-citation></ref><ref id="bib254"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waugh</surname><given-names>RE</given-names></name><name><surname>McKenney</surname><given-names>JB</given-names></name><name><surname>Bauserman</surname><given-names>RG</given-names></name><name><surname>Brooks</surname><given-names>DM</given-names></name><name><surname>Valeri</surname><given-names>CR</given-names></name><name><surname>Snyder</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Surface area and volume changes during maturation of reticulocytes in the circulation of the baboon</article-title><source>The Journal of Laboratory and Clinical Medicine</source><volume>129</volume><fpage>527</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1016/s0022-2143(97)90007-x</pub-id><pub-id pub-id-type="pmid">9142049</pub-id></element-citation></ref><ref id="bib255"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Boulais</surname><given-names>PE</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Pinho</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Frenette</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Maea expressed by macrophages, but not erythroblasts, maintains postnatal murine bone marrow erythroblastic islands</article-title><source>Blood</source><volume>133</volume><fpage>1222</fpage><lpage>1232</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-11-888180</pub-id><pub-id pub-id-type="pmid">30674470</pub-id></element-citation></ref><ref id="bib256"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>G</given-names></name><name><surname>Goodnough</surname><given-names>LT</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Anemia of chronic disease</article-title><source>The New England Journal of Medicine</source><volume>352</volume><fpage>1011</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1056/NEJMra041809</pub-id><pub-id pub-id-type="pmid">15758012</pub-id></element-citation></ref><ref id="bib257"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Welch</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1992">1992</year><source>Transferrin: The Iron Carrier</source><publisher-loc>Boca Raton</publisher-loc><publisher-name>CRC Press</publisher-name></element-citation></ref><ref id="bib258"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witthuhn</surname><given-names>BA</given-names></name><name><surname>Quelle</surname><given-names>FW</given-names></name><name><surname>Silvennoinen</surname><given-names>O</given-names></name><name><surname>Yi</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>B</given-names></name><name><surname>Miura</surname><given-names>O</given-names></name><name><surname>Ihle</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin</article-title><source>Cell</source><volume>74</volume><fpage>227</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)90414-l</pub-id><pub-id pub-id-type="pmid">8343951</pub-id></element-citation></ref><ref id="bib259"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor</article-title><source>Cell</source><volume>83</volume><fpage>59</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90234-1</pub-id><pub-id pub-id-type="pmid">7553874</pub-id></element-citation></ref><ref id="bib260"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Moschetta</surname><given-names>GA</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Fisher</surname><given-names>AL</given-names></name><name><surname>Alfaro-Magallanes</surname><given-names>VM</given-names></name><name><surname>Dev</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>C-Y</given-names></name><name><surname>Babitt</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Regulation of iron homeostasis by hepatocyte TfR1 requires HFE and contributes to hepcidin suppression in β-thalassemia</article-title><source>Blood</source><volume>141</volume><fpage>422</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1182/blood.2022017811</pub-id><pub-id pub-id-type="pmid">36322932</pub-id></element-citation></ref><ref id="bib261"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Blanc</surname><given-names>L</given-names></name><name><surname>Narla</surname><given-names>A</given-names></name><name><surname>Lane</surname><given-names>JM</given-names></name><name><surname>Gao</surname><given-names>E</given-names></name><name><surname>Papoin</surname><given-names>J</given-names></name><name><surname>Hale</surname><given-names>J</given-names></name><name><surname>Hillyer</surname><given-names>CD</given-names></name><name><surname>Taylor</surname><given-names>N</given-names></name><name><surname>Gallagher</surname><given-names>PG</given-names></name><name><surname>Raza</surname><given-names>A</given-names></name><name><surname>Kinet</surname><given-names>S</given-names></name><name><surname>Mohandas</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Comprehensive phenotyping of erythropoiesis in human bone marrow: evaluation of normal and ineffective erythropoiesis</article-title><source>American Journal of Hematology</source><volume>96</volume><fpage>1064</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1002/ajh.26247</pub-id><pub-id pub-id-type="pmid">34021930</pub-id></element-citation></ref><ref id="bib262"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Kawane</surname><given-names>K</given-names></name><name><surname>Koike</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Uchiyama</surname><given-names>Y</given-names></name><name><surname>Nagata</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Phosphatidylserine-dependent engulfment by macrophages of nuclei from erythroid precursor cells</article-title><source>Nature</source><volume>437</volume><fpage>754</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1038/nature03964</pub-id><pub-id pub-id-type="pmid">16193055</pub-id></element-citation></ref><ref id="bib263"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Socolovsky</surname><given-names>M</given-names></name><name><surname>Gross</surname><given-names>AW</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry–based novel culture system</article-title><source>Blood</source><volume>102</volume><fpage>3938</fpage><lpage>3946</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-05-1479</pub-id></element-citation></ref><ref id="bib264"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D-L</given-names></name><name><surname>Hughes</surname><given-names>RM</given-names></name><name><surname>Ollivierre-Wilson</surname><given-names>H</given-names></name><name><surname>Ghosh</surname><given-names>MC</given-names></name><name><surname>Rouault</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2009">2009a</year><article-title>A ferroportin transcript that lacks an iron-responsive element enables duodenal and erythroid precursor cells to evade translational repression</article-title><source>Cell Metabolism</source><volume>9</volume><fpage>461</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2009.03.006</pub-id><pub-id pub-id-type="pmid">19416716</pub-id></element-citation></ref><ref id="bib265"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Randall</surname><given-names>MS</given-names></name><name><surname>Loyd</surname><given-names>MR</given-names></name><name><surname>Dorsey</surname><given-names>FC</given-names></name><name><surname>Kundu</surname><given-names>M</given-names></name><name><surname>Cleveland</surname><given-names>JL</given-names></name><name><surname>Ney</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2009">2009b</year><article-title>Mitochondrial clearance is regulated by Atg7-dependent and -independent mechanisms during reticulocyte maturation</article-title><source>Blood</source><volume>114</volume><fpage>157</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-04-151639</pub-id><pub-id pub-id-type="pmid">19417210</pub-id></element-citation></ref><ref id="bib266"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D-L</given-names></name><name><surname>Ghosh</surname><given-names>MC</given-names></name><name><surname>Ollivierre</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Rouault</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Ferroportin deficiency in erythroid cells causes serum iron deficiency and promotes hemolysis due to oxidative stress</article-title><source>Blood</source><volume>132</volume><fpage>2078</fpage><lpage>2087</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-04-842997</pub-id><pub-id pub-id-type="pmid">30213870</pub-id></element-citation></ref><ref id="bib267"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Qu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Geng</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Mendelson</surname><given-names>A</given-names></name><name><surname>Yazdanbakhsh</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>An</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>EpoR-tdTomato-Cre mice enable identification of EpoR expression in subsets of tissue macrophages and hematopoietic cells</article-title><source>Blood</source><volume>138</volume><fpage>1986</fpage><lpage>1997</lpage><pub-id pub-id-type="doi">10.1182/blood.2021011410</pub-id><pub-id pub-id-type="pmid">34098576</pub-id></element-citation></ref><ref id="bib268"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Mei</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wickrema</surname><given-names>A</given-names></name><name><surname>Ji</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Disruption of erythroid nuclear opening and histone release in myelodysplastic syndromes</article-title><source>Cancer Medicine</source><volume>8</volume><fpage>1169</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1002/cam4.1969</pub-id><pub-id pub-id-type="pmid">30701702</pub-id></element-citation></ref></ref-list></back></article>